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Chapter 1 reviews the synthesis and applications of [60]fullerene amino acids and 
peptides, in material science and biological activities reported so far. We segregated the 
type of [60]fullerene amino acids based on their connectivity, such as, fullerenyl 
substituents directly substituted to the amino acid α-carbon, [60]fullerenyl N-capped 
peptides and amino acids, [60]fullerenyl C-capped peptides and amino acids and 
fullerenyl amino acids that could potentially be incorporated within peptide chains.  
Chapter 2 demonstrated the synthesis of the novel [60]fullerene monopeptide 201 and 
dipeptide 204. [60]Fullerenoproline acid  198 was coupled to lysine amine 200 to yield 
the monopeptide 201 in 62% yield, which was separately deprotected to its amine salt 
202 using TFA and to its acid derivative 203 with Sn(CH3)3OH. An amide coupling 
reaction of the amine 202 and the acid 203 resulted in the dipeptide 204 (57%). 
Attempts to synthesise the tetrapeptide 207 using the same approach were not 
successful because of its poor solubility. Monopeptide 201 and the dipeptide 204 have 
been studied experimentally using spectroelectrochemical measurements by Prof. 
Timothy Clark and Prof. Dirk M. Guldi at the University of Erlangen-Nuremberg, 
Germany. The bis-fullerene-substituted peptide 204 provided experimental support for 
density-functional theory (DFT) calculations which indicate that van der Waals 
fullerene dimers can form between adjacent fullerenes in semiconductor layers resulting 
in interstitial electron traps. 
An alternative synthesis of the tetrapeptide 207 was examined. The lysine tetrapeptide 
216 (70% yield) and its tetramine 217 (100%) were successfully synthesised. Attempts 
to couple 217 with [60]fullerenoproline acid 198 to produce the tetrapeptide 207 were 
also unsuccessful, possibly due to steric hindrance problems because of the sterically 
v 
 
demanding fullerene groups. Accordingly, we thought that the cyclic peptide 
tetrapeptide 220 might help to solve these steric hindrance problems. Tetrapeptide 216 
was successfully converted to the novel cyclic peptide 220 in three synthetic steps. 
However we did not pursue this route any further because of the poor chemical yields 
and the difficulties in purifying 220. 
Chapter 3 reported an extension of [60]fullerenyl oligomers with the incorporation of 
spacers between the fullerenyl groups. Two types of amino acid spacers (L-lysine and 
L-phenylalanine) were introduced in to the oligomers (hexapeptide 227 and hexapeptide 
238). The synthesis of tripeptides with L-lysine spacers 224 in 62%, and L-
phenylalanine spacers 235 (in 60%) were achieved by coupling the acid 203 with the 
amine 213 and the amine 202 with the acid 234, respectively. The previously used ester 
and N-Boc cleavage reaction conditions were adopted to synthesise the corresponding 
acids (225 and 236) and amines (226 and 237) of 224 and 235. Their amide coupling 
reaction provided the hexapeptides of 227 (44%) and 238 (40%) respectively. Currently, 
these molecules are under studies to form supramolecular complexes between these 
[60]fullerene peptides and porphyrin and photoinduced charge separation in Prof. 
Fukuzumi’s laboratory at Osaka University, Japan. 
Chapter 4 reported the synthesis and antibacterial screening of mono substituted 
[60]fullerenyl peptides (243, 245, 247, 272-279) and bis-[60]fullerenyl peptide (285). A 
range of tri, tetra and pentapeptides having an oxazole or isopentyl ester terminal group 
were synthesised. These peptides were then deprotected to form their HCl and TFA 
salts 247, 276-279. Antibacterial screening of these peptides (243, 245, 247, 272-279 
and 285) was performed at the University of Western Australia in Prof. Thomas Riley’s 
laboratory; unfortunately, none of these compounds showed significant activity.   
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[60]Fullerenyl Amino Acid 
Derivatives: Synthesis and Their 
Applications 
 A large portion of synthetic [60]fullerene chemistry is directed towards its 
functionalization providing biologically active derivatives and molecules with 
applications also in material science.
1-6
 The impetus for such work was to exploit the 
physical properties of [60]fullerene (such as sensitization of singlet oxygen and electron 
acceptor characteristics) and combine this with the properties of biomolecules (water 
solubility and precise secondary and tertiary structure).
5,7-10
 For example, [60]fullerene 
derivatives covalently linked to peptides and proteins has been the goal of a number of 
research groups concerned with the application of [60]fullerene-peptide conjugates to 
biological problems.
11-16
 It was anticipated that the addition of biologically active 
compounds to [60]fullerene in a strict regioselective fashion would aid the activity and 
specificity of future therapies. In recent times, the field has matured significantly such 
that there are different types of fullerenyl amino acids that can be categorised according 
to properties of the amino acid itself, allowing for a broader perspective of how they 
could be incorporated into different research programs. In this chapter we report on the 
current progress in the synthesis of fullerenyl amino acids and related derivatives and 
attempt to categorise the molecules into functional types for different uses: these include 
directly attached fullerenyl amino acids, fullerenyl N- and C-capping amino acids, and 
those amino acids in which the [60]fullerene group is attached to the amino acid side 
chain. These first and last mentioned derivatives have the potential to be incorporated 
into non-terminal positions of peptides. The applications of these substrates by 





integration into different biological and materials chemistry programs are then 
highlighted. 
1.1 Synthesis of Fullerenyl Amino Acids 
 From a material science and medicinal chemistry perspective, fullerenyl amino 
acids are important targets potentially serving as central hubs in architecturally defined 
nanostructures or 3D-templates in drug design.
17-24
 To date fullerenyl amino acids and 
peptide derivatives have been prepared by the initial attachment of a handle to the 
fullerene followed by coupling to a protected amino acid or peptide.
25-27
 
1.2 Synthesis of Derivatives with Fullerenyl Substituents Directly 
Substituted to the Amino Acid α-Carbon 
There are surprisingly few examples of fullerenyl amino acids that are direct 
analogues of α-amino acids, i.e. the α-carbon is bonded directly to a C60 carbon atom. 
There are two examples of this type of molecule, the well-established fullerenoprolines, 
and there are reports of protected versions of amino acids whereby the fullerenyl 
substituent is directly coupled to the α-carbon. 
1.2.1 Fullerenoproline derivatives 
 The first synthesis of α-substituted fullerenyl amino acids, the fullerenoprolines 
(Fpr) (4), was achieved by the addition of azomethine ylides to [60]fullerene.
28-30
 The 
azomethine ylide intermediate can be generated in two different ways, either via a 
thermal ring-opening of aziridines 1 or via tautomerisation of iminium salts formed by 
the condensation of α-amino esters 2 with aldehydes 3 (Scheme 1.1). These reactions 





allow for a significant number of Fpr derivatives to be generated by using different 
combinations of aldehydes and amino esters. 
 
Scheme 1.1: The synthesis of fulleroprolines 4 can be achieved by thermal addition of aziridines or 
iminium salts to [60]fullerene. 
 Fpr analogues can be prepared with the pyrrolidine nitrogen protected (Scheme 
1.2) or unprotected (Scheme 1.3).
31
 Addition of the aziridine 5 to [60]fullerene under 
thermal conditions formed the N-protected Fpr 6. Subsequent treatment with TFA 
provided the secondary amine salt 7, which could then be acylated with acetic anhydride 




Scheme 1.2: Synthesis of the protected fulleroproline 8 was achieved through thermal addition of 
aziridine 5 to [60]fullerene. 
 





To obtain more useful Fpr derivatives for peptide synthesis, the azomethine ylides, 
which are generated in situ from the reaction of glycinate esters 9 and 10 with 
paraformaldehyde, can be added to [60]fullerene to produce the free Fprs 11 and 12, 
respectively. These were relatively unstable and had to be kept as dilute solutions in the 
dark.
31
 However, the amine group was readily functionalized using standard acylation 
procedures with acid anhydrides and acid chlorides (Scheme 1.3), to deliver racemic N-
protected Fpr ester of the type 13. Alternatively the amine 11 was protected as the N-
Fmoc derivative 14, and then the tert-butyl ester converted to the acid 15 by treatment 
with TFA. Subsequent coupling with ethyl L-alaninate under EDCI/HOAt conditions 
afforded the diastereomers 16 and 17. The diastereomeric ratio of 13 was determined by 
formation of the dioxopiperazines 18 and 19, thus eliminating the additional complexity 
in characterization imposed by amide rotamers.
31
 
A second type of fullerenyl amino acid was initially envisaged as a 
methanofullerene of the type 21 (Scheme 1.4). Strategies towards such molecules 
include the addition of diphenyliminoglycinates to [60]fullerene under Bingel 
cyclopropanation reaction conditions which was originally reported to furnish the 
corresponding methano[60]fullerene derivatives 21 (Scheme 1.4).
32,33
 However 
subsequent extensive NMR studies revealed that the structure of the products was that 
of the dihydrofullerenoproline derivatives
33
 22, and not the more strained three-
membered (cyclopropane) ring products 21. The dihydrofullerenoproline derivative 23 
was hydrolysed to its carboxylic acid using TFA to yield 24 in 90% yield.  






Scheme 1.3: Synthesis of Fpr peptide derivatives 16-19. 






Scheme 1.4: The addition of iminoglycinate to fullerene under Bingel cyclopropanation conditions 
provides the analogous [60]fullerenyldihydropyrrole 22 not the previously reported methano[60]fullerene 
21. 
BF3.Et2O and NaCNBH3 mediated reductive ring-opening of 
dihydrofullerenoproline derivative
33
 22 yielded the ethyl N-
benzhydrylfullerenyl[60]glycinate 25, which was N-deprotected to give ethyl 
fullerenylglycinate 26
34
 a true fullerenyl α-amino ester which was fully characterised as 
its more stable N-acetyl derivative 27. Therefore, the original structure 22 could be 
considered as a protected version of 26. The free amine of 26 reacted with a variety of 
aldehydes and ketones in a Mannich-type process to produce 5-substituted and 5,5-
disubstituted Fprs 28-38. This process represents a versatile and general strategy to 
synthesise Fprs. 






Scheme 1.5: Synthesis of 5-substituted and 5,5-disubstituted fulleroprolines 28-38. 
The reactions of amino acid ester hydrochlorides and CS2 with [60]fullerene in 
the presence of Et3N yields novel [60]fullerene derivatives 40 (major) and 41 (minor) 
containing biologically active amino acids,
35
 thioamide, and thiourea units. The 
thiolactam groups in compounds 40 are sensitive to moisture and can easily be 
hydrolyzed to the corresponding lactams. 
 
Scheme 1.6: Reactions of [60]fullerene with amino acid esters and CS2. 





1.3 Synthesis of [60]fullerenyl N-Capped Peptides and Amino Acids 
The thermal addition of the diazomethane derivative 42 to [60]fullerene and 
subsequent deprotection of the ester of the resulting methano[60]fullerene 43 provided 
the acid 44.
36
 This represented the first synthesis of a fullerenyl compound which had a 
synthetic handle to readily allow for peptide functionalization (Scheme 1.7). The acid 
44 was converted to the reactive acid chloride 45 which underwent amide coupling with 





Scheme 1.7: Synthesis of 46 through a diazo-addition of 42 to [60]fullerene. 
This work was extended to alkyl diazoacetates of the type 47, which was added 
to [60]fullerene forming the methano[60]fullerene 48, which was deprotected to the 
carboxylic acid 49 and then coupled to amino acids under standard DCC coupling 
reaction conditions to form fullerenyl amino acid esters of the type 50.
37,38
 
Alternatively, a more efficient route was developed, that allowed the direct addition of 





diazoamides to [60]fullerene. For example, a solution of [60]fullerene in toluene was 
treated with the diazoacetamide 51 at reflux for 48 h providing the fullerenyl amino acid 




Scheme 1.8: Synthesis of 50 through a diazo-addition of 47 or 51 to [60]fullerene. 








diazoketones, provides a broad variety of methano[60]fullerenes, having handles for 
further functionalization. The methano[60]fullerene carboxylic acid 49 can be accessed 
from either the tert-butyl ester 52 (Scheme 1.9) or the O-glycolic ester 47 (Scheme 1.8), 
followed by ester deprotection of the fullerenyl adducts 53 and 48, respectively. The 
synthetic utility of the methano[60]fullerenyl carboxylic acid 49 was further 










Scheme 1.9: Synthesis of peptide 54 was achieved through addition of 52 to [60]fullerene. i) H-Thr-Thr-
Asn-Tyr-Thr-OH, DCC, HOBt, C6H5Br/DMSO (6:1). 
 The Bingel reaction conditions have been modified to work, in moderate to 
excellent yields, with ketones, esters and iminoglycinates. This modification has 
allowed for the generation of the analogous α-haloanion in situ rather than the previous 
isolation of the halogenated intermediate. This efficient and reliable one-pot reaction 





Scheme 1.10: Malonates add to [60]fullerene under Bingel cyclopropanation conditions to provide 
methanofullerenes 56. 
Thermolysis of sulfones 57 in the presence of [60]fullerene in 1,2,4-
trichlorobenzene at reflux under a nitrogen atmosphere afforded the fullerene 
derivatives 58 (via the corresponding pyrimidine o-quinodimethanes) (Scheme 1.11). A 










Scheme 1.11: Synthesis of [60]fullerene based tetrahydroquinazolines. 
 
Organic azides act as 1,3-dipoles and can undergo [3+2]-cycloaddition reactions 
(either photochemically or thermally) with [60]fullerene to yield fulleroaziridines 
(Scheme 1.12).
50,51
 Of these organic azides, photochemical or thermal reactions of 
[60]fullerene with perfluorophenylazide 62 produces the fulleroaziridine 63 with an 
activated N-hydroxysuccinamide ester. This active ester allows further 
functionalization, such as peptide coupling resulting in the formation of 64. 





Scheme 1.12: Synthesis of fulleroaziridine 
The reaction of [60]fullerene with organolithium and Grignard reagents have 
been exploited to incorporate a protected carboxylic acid functionality onto the C60 
sphere.
52
 The organolithium reagent made from the stable bicyclic orthoester 65, 
prepared by following the general procedure described by Corey,
53,54
 has been 
successfully added to [60]fullerene to give adduct 66. This was converted to the acid 68 
by two sequential hydrolysis steps and then coupled with L-alanine ethyl ester 
hydrochloride to give 69 (Scheme 1.13). 
Scheme 1.13: Synthesis of 1-hydro-2-[3ʹ-(L-Ala-OEt)propyl]-1,2-dihydro[60]fullerene 69.  





      Methano[60]fullerene carboxylic acid derivatives 49 and 70-72 were converted to 
their active esters of N-hydroxysuccinimide (NHS) 73-76 and pentafluorophenol 
(PFP)
55
 77-80 and coupled with amino acids and peptides. These active esters have been 
reacted selectively with the amino group of the amino acid or peptide, or the hydroxy 
group but only under DMAP catalysis. Analysis by MALDI-TOF-MS revealed the 
potential utility of these active esters for the preparation of fullerene-modified amino 
acids or peptides for applications in biological studies (Scheme 1.14). 
 
Scheme 1.14: Derivatization of carboxylic acids 49 and 70-72 with amino acids and peptides. 





1.4 Synthesis of [60]Fullerenyl C-Capped Peptides and Amino Acids             
       Alternative methods to generate methano[60]fullerene derivatives via 
addition/elimination mechanisms have employed sulfonium and phosphonium 
ylides.
56,57
 Deprotection of the ester moieties in these methano[60]fullerenes, as well as 
the malonate derivatives, has provided access to versatile handles, including the 
carboxylic acid 49 which was generated by the addition of the sulfonium ylide 85 to 
[60]fullerene, followed by cleavage of the tert-butyl ester 53 with p-TsOH (Scheme 
16).
58
 The acid 49 was then converted to its acid chloride 86, which was subsequently 
treated with tributyltin azide to deliver the acyl azide 87 in good yield. Exposure of 87 
to o-xylenes at reflux was expected to have afforded the isocyanate 88, which was not 
isolated but trapped as the tert-butyl carbamate derivative 89. Treatment of 89 with 
TfOH provided the amine salt 90, which was coupled to various acyl chlorides 91 to 




Scheme 1.15: Synthesis of amides 92 was achieved via the Curtius rearrangement. 





Thermal ring opening of methylenecyclopropanone ketal 93 in chlorobenzene in 
the presence of [60]fullerene followed by silica gel hydrolysis of the resulting ketene 
acetal gave a mixture of cycloadducts 94 and 95.
60
 The corresponding fullerenyl amino 





Scheme 1.16: Synthesis of fullerenyl amino ester derivatives via [3+2]-cycloaddition reactions. 
Protected bis-fulleropyrrolidine amino acids derivatives 101 and 102 have been 
synthesised and characterised from two successive [3+2]-cycloaddition reactions of 
azomethine ylides to [60]fullerene, prepared in situ from the reactions of N-glycine 
derivatives and formaldehyde (Prato reaction). These reactions resulted in two different 
fullereopyrrolidine couples having unsymmetrical, orthogonally protected amino and 
acid functional groups.
62
 These peptides could be used as models for fullerene-based 





peptidomimetics with the carbon sphere inserted into the peptide backbone (Scheme 
1.17). 
 
Scheme 1.17: Synthesis of mono-fulleropyrrolidines and unsymmetrical bis-fulleropyrrolidines. 
The 1,3-dipolar cycloaddition reaction of the N-substituted glycine derivative 
103 to [60]fullerene produced the fulleropyrrolidine 104 having a hydroxyl group at the 
terminus of the N-substituent (Scheme 1.18). Subsequent esterification of this alcohol 





with the C-terminus of the protected amino acids gave 105 and 106. Deprotection of 
106 to its TFA salt 107 and then coupling with a hexapeptide followed by final 





Scheme 1.18: Synthesis of [60]fulleropeptides. 
1.5 Synthesis of Fullerenyl Amino Acids That Could Potentially be 
Incorporated Within Peptide Chains 
 The synthesis of highly functionalized benzo-annulated indane-based α-amino 
acid (AAA) derivatives was reported via a [4+2]-cycloaddition strategy using the sultine 
derivative 109, containing an AAA ester moiety, as a reactive diene component. By 
adopting this strategy, a new α,α-dialkylatedindane-based [60]fullerene containing a 
rigid AAA unit 110 was realized (Scheme 1.19).
64
  






Scheme 1.19: Synthesis of α,α-dialkylatedindane-based [60]fullerene containing AAAs. 
 A Diels-Alder approach has been developed to prepare dicarba analogues of 
cystine. Treatment of diene 111 with [60]fullerene in toluene at reflux furnished the 




Scheme 1.20: [60]Fullerene-based dicarba analogue of cysteine 112. 
Ketone 115 has been used to synthesise [60]fullerene substituted D-
phenylalanine derivatives (Scheme 1.21).
14
 The para-amino substituted phenylalanine 
derivatives 113 and 114 readily undergo condensation reactions with 115 forming the 
analogous imines 116 and 117, which were converted to their corresponding amines 118 
and 119 by borane reduction. The N-Boc-glycine derivative 118 was coupled to ethyl 
glycinate under HBTU mediated coupling conditions to provide the peptide 120. 
Treatment of the methyl glycinate derivative 119 with BBr3 led to the isolation of the 
free glycine analogue 121. 






Scheme 1.21: Synthesis of [60]fullerenyl amino acids 120 and 121. 
A rhodium catalyzed reaction of [60]fullerene with the boronic acid derivative 
of phenylalanine 122 is shown in Scheme 1.22. This reaction gave the fullerene-tagged 




Scheme 1.22: Synthesis of 1-substituted 1,2-dihydro[60]fullerene derivatives. 





A direct route was developed to produce fullerenyl peptides 125 by prolonged 




Scheme 1.23: Thermal addition of diazoamide to [60]fullerene provides access to fullerenyl amino esters. 
[60]Fullerene functionalized amino acids with 4–6 methylene spacers from the 
α-carbon to the nitrogen atom of fulleropyrrolidine 126, and their corresponding N-
protected versions 128, have been synthesized from the reactions of N-glycine 





Scheme 1.24. Synthesis of [60]fullerene functionalized amino acids with 4-6 methylene spacers. 
The [4+2]-cycloaddition of the 2-trimethylsilyloxybutadiene 129 to 
[60]fullerene provided the ketone 115, after hydrolysis. Subsequent reduction with 
DIBAL-H afforded the racemic alcohol 130, a versatile synthon for the generation of 
fullerenyl amino acid derivatives (Scheme 1.25). For example, the DCC mediated 





esterification of 130 with alanine and glutamate derivatives provided the protected 




Scheme 1.25. Synthesis of [60]fullerenyl amino acids 131. 
[60]Fullerene pyrrolidine derivative (137), bearing two carboxylic acid 
functional groups has been reported (Scheme 1.26).
68
 The crucial glycine precursor 135, 
was synthesised from commercially available starting materials and reacted with 
[60]fullerene and formaldehyde under Prato’s reaction conditions to yield the diester 
136. The tert-butyl groups of 136 were deprotected under acidic conditions, which 
efficiently provided the stable bis-acid derivative 137. This diacid derivative was readily 
functionalized under solid phase conditions to yield the derivatives dipeptide 138 and 
PEG 139. In addition, the reaction of 136 with TFA and TFAA provide an anhydride 
intermediate, which was used to synthesise [60]fullerene derivatives bearing two 
different amide moieties 140. 






Scheme 1.26. Synthesis of bis-carboxylic acid group functionalized [60]fullerene derivatives. 
 
 The [60]fullerene derivative 141 was deprotected with TFA to give a free amino 
functional linker containing [60]fullerene derivative 142. This was then reacted with N-
Fmoc-L-glutamic acid α-tert-butyl ester to yield a [60]fullerene functionalized amino 
acid. The tert-butyl ester was deprotected under acidic conditions to give the carboxylic 
acid 143, which was subjected to solid-phase peptide synthesis with peptide 144. The 
product 145 was cleaved from the resin support and was found to be water soluble.
69
 






Scheme 1.27. Solid phase synthesis of fullereno peptide 145. 
1.6 Applications of [60]fullerene amino acids and peptides  
The potential uses of amino acid and peptide derivatives of fullerenes range 
from the biological to the material sciences. This section will outline the major areas of 
achievement. 
1.6.1 Biological Applications 
The fullereopeptide 108 (Scheme 1.18) was biologically active against sera from 
Mixed Connective Tissue Disease (MCTD) and Systemic Lupus Erythematosus (SLE) 
patients (ELISA experiments). 





The peptide 144 (Scheme 1.27) itself was not active against Staphylococcus 
aureus (S. aureus) and Escherichia coli (E. coli), whereas the analogous 




Table 1.1. Antimicrobial activity of peptides 144 and 145, Reported as MIC (Minimum 
Inhibitory Concentrations). Results are the mean of a minimum four independent evaluations run in 
duplicate (na = nonactive). 
Peptide 144 145 
S. aureus na 8 µM 
E. coli na 64 µM 
 
The antioxidant properties of the water soluble amino acid derivatives of the 
sodium salts of fullerenylaminobutyric acid (C60-γ-ABNa, 146) and 
fullerenylaminocaproic acid (C60-ω-ACNa, 147) as well as that of the hybrid structure 
based on a N-fullerenoproline and the natural oxidant carnosine  (C60-Pro-carnosine, 
148) have been studied. Their roles in the inhibition of herpes virus infection have also 
been described.
70
 The amino acid fullerene derivatives 146 and 147 of [60]fullerene 
were found to have significant antioxidant activities and were not cytotoxic (IC50 1000 
and 1200 μg mL
–1
 (mln. cells), for 149 and 146, respectively). These derivatives were 
also studied as inhibitors of cytomegalovirus (CMV) infection. The introduction of C60-
γ-ABNa 146, into infected human embryonic fibroblasts (HEF) reduced the 
concentration of virus proteins in the cells to values approaching that in non-infected 
cells (Table 1.2). The malonic dialdehyde (MDA) concentration in the infected HEF 
culture also decreased to the concentration in intact HEF. The drug ganciclovir also 
decreased the lipid peroxidation (LPO) level in the HEF culture but had significantly 
lower antioxidant and inhibitory effects than 146 (Table 1.2). These results indicated 
that the antioxidant activity of these fullerene derivatives played an important role in 





their antiviral effect against CMV infection. Compound 146 was considered as a 
potential drug against CMV infections. Its chemotherapeutical index (CTI) was found to 
be 5000, which fivefold exceeds that of ganciclovir. 
Table 1.2. Contents of the protein and MDA in the HEF cultures 
Sample  Protein content 











HEF                0.07±0.02 3.75±0.03 
HEF-CMV    0.284±0.03 6.8±0.01 
HEF-CMV- gancyclovir  0.22±0.04 5.4±0.03 
HEF-CMV-C60-γ-ABNa (146)      0.072±0.02 3.8±0.03 







. The average values of five measurements were presented. HEF (human embryonic fibroblasts), 
CMV (cytomegalovirus infection), MDA (malonicdialdehyde). 
 
Figure 1.1: [60]Fullerene based water soluble amino acids. 
The antioxidative/anti-inflammatory activities of the fullerene-polyamine (FUL-
PA) conjugates 149-156 have been described.
71
 Conjugation of [60]fullerene with 
spermine (SPM) or spermidine (SPD) resulted in a large improvement of both the anti-
lypoxygenase (LOX) and the anti-lipid peroxidation activity of the unconjugated 
molecules. An enhancement in the anti-inflammatory potency of [60]fullerene was 
observed only with the conjugate 150 (42%), which was comparable in activity to the 
reference compound indomethacin (47%). Most of the FUL-SPD conjugates, and 





especially compounds 150 and 152, were of comparable toxicity, even at the highest 





Figure 1.2: Biologically active novel fullerene-polyamine (FUL-PA) conjugates. 
The glycopeptide antibiotic derivative teicoplanin ψ-aglycone has been 
covalently attached to a fullerenopyrrolidine derivative using azide-alkyne “click 
chemistry”. The aggregation of the resulting antibiotic-fullerene conjugate 157 in 
aqueous solution has been studied resulting in nano-sized clusters.
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 The conjugate 














Table 1.3. Antibacterial activity of compound 157. 
                 Bacteria 
 
Teicoplanin        Compound 157 
 
MIC (µg/mL) 
Bacillus subtilis ATCC 6633 0.5 16 
S. aureus MSSA ATCC 29213 0.5 8 
S. aureus MRSA ATCC 33591 0.5 4 
S. epidermidis ATCC 35984 biofilm 4 2 
S. epidermidis mec A 16 1 
E. faecalis ATCC 29212 1 6 
E. faecalis 15376 VanA 256 16 
E. faecalis ATCC 51299 VanB 0.5 16 
Note. MIC: Minimum Inhibition Concentration, ATCC: American Typed Culture Collection, MRSA: 
Methicillin Resistant Staphylococcus aureus, vanA: vanA gene positive, vanB: vanB gene positive. 
 
Figure 1.3: Teicoplanin ψ-aglycon-fullerene conjugate 157. 
The water-soluble dendrofulleropyrrolidine 158 (synthesised from 102) and its 
bis-analogues 159 and 160 have been prepared (Figure 1.4).
73
 These cationic species 
can efficiently complex plasmid DNA as demonstrated by gel electrophoresis studies. 





These molecules showed excellent DNA binding efficiencies and were therefore 
considered to be potential candidates for DNA binding therapies.  
The fulleropyrrolidine peptides 162-172 containing only GABA (γ-
aminobutyric) residues, having zero or one glycine moiety were reported (Figure 1.5).
74
 
The authors claim that these may be used as nanobioparticles, however, no results 
related to these properties were reported. 
 
Figure 1.4. Monoadduct 158 and bisadducts 159 and 160 of highly water soluble polycationic 
[60]fullerenes. 






Figure 1.5. Fulleropeptides 162-172 synthesized from fulleropyrrolidinic acid 161. 
Mitsutoshi et al. reported the inhibitory effects of [60]fullerene derivatives 173 
and  [60]fullerene-ethylenediamine-N,Nʹ-diacetic acid 174 (Figure 1.6) on 
acetylcholine-induced (endogenous NO) relaxation in endothelium-intact rabbit thoracic 




 These [60]fullerene derivatives 173 
(10
-5
 M) and 174 (10
-5
 M) reduced the maximum amplitude of the acetylcholine-
induced relaxation without significantly changing the pD2 values obtained from the 
concentration response curves.  
 
Figure 1.6. [60]Fullerene derivatives 173 ([60]fullerene-proline-N-acetic acid) and 174 ([60]fullerene-
ethylenediamine-N,Nʹ-diacetic acid). 
Water soluble [60]fullerene derivatives 175-177 (WSFD), have been studied to 
show the potential to prevent NO-induced cytotoxicity without obvious toxicity (Figure 







 These fullerene derivatives apply protective activities by direct interaction with 
NO and neutralization of O2
-
. The folacin fullerene derivative 177 (FFD) self-assembles 
to form spherical aggregates because of hydrogen bonding, and the aggregate ion 
morphology impacts on the NO-scavenging activities of WSFD. Pretreatment of the 
cells with WSFD, prior to sodium nitroprusside (SNP) exposure blocks NO-induced 
cellular events including oxidation of membrane lipids, depolarization of mitochondrial 
membranes, reduction of superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidise (GSH-Px) activities and caspase-mediated apoptotic cell death. Apart from 
the biological studies, the authors have revealed the synthesis of novel fullerene 




Figure 1.7. The structures of  AFD (175), VFD (176) and  FFD (177).  
Oxidized [60]fullerene glutathione derivatives have been synthesized and 
characterized.
78
 The [60]fullerene glutathione derivative 178 (Figure 1.8) was soluble in 
dimethylsulfoxide, dimethylformamide and dimethylacetamide. Rat pheochromocytoma 
(PC12) cells were treated with hydrogen peroxide and then cytotoxicity and apoptotic 
death was estimated by a MTT assay, flow cytometry analysis, PI/Hoechst 33342 





staining and glutathione assay. These results indicated that the glutathione [60]fullerene 





Figure 1.8. Oxidized glutathione [60]fullerene derivative 178 
1.6.2 Materials Chemistry Applications 
A new class of peptide nanotubes from α,γ-cyclic peptides (CPs) 179 (Figure 
1.9) tethered to a methanofullerene moiety has been reported.
79
 These CPs are able to 
form nanotubes in which the fullerenes point outward from the nanotube on both sides 
(180° orientation). The fullerenes form two parallel wires separated by the insulating 
peptide nanotube. The authors suggest that these materials may have applications as 
nanowire components and/or in optical and electronic devices. 
 
Figure 1.9: Structure of tethered α,γ-cyclic peptide (CP) 179. 





Two molecules (180 and 181, Figure 1.10) having a pyrrolidino[60]fullerene 
tethered through an intramolecular hydrogen bonding peptide linker to a nitroxide 
radical have been synthesised.
80
 These peptide moieties have a rigid 310-helical 
structures that possess a strong molecular dipole. The direction of the molecular dipole 
moment can be reversed by switching the position of the fullerene and the nitroxide 
with respect to the peptide nitrogen and carbon terminus. The fullerene-peptide-radical 
systems 180 and 181 were compared to the behaviours of otherwise identical peptides 
but without either [60]fullerene or the free radical moiety with retention of the number 
of intramolecular hydrogen bonds.  
 
Figure 1.10: Structures of [60]fullerene based peptides with intramolecular hydrogen bonds showing 
their molecular dipoles.  
A strategy of photocurrent generation out of thin layers composed by the 
amphiphilic [60]fullerene and pyrene derivatives was investigated by Shunsaku’s 
group.
81,82
 Three different types of compounds, namely pyrene derivative 182 (R-Pyr) 
having diethylene glycol and a long alkyl chain, [60]fullerene-PEG conjugate 183 (C60-
PEG) without cyclic peptide scaffold and [60]fullerene-cyclic peptide-PEG conjugate 
184 (cyclo8-C60-PEG), were synthesised (Figure 1.11). The study of photoinduced 
electron transfer concluded that a bilayer structure with desired orientation of functional 





units is important for efficient photoinduced electron transfer and that the cyclic peptide 
scaffold is useful to locate hydrophobic functional groups in a thin layer. 
 
Figure 1.11. The structures of R-Pyr 182, C60-PEG 183 and cyclo8-C60-PEG 184. 
1.7 Background of this Project 
There is much current research interest in the synthesis and design of chemical systems 
for use in organic solar cells such as in organic photovoltaic applications as bulk 
heterojunction solar cells.
83-85
 Solladie et al. have been successful in synthesising such 
potential systems based on polypeptide-porphyrin structures (Scheme 1.28).
86-88
 
Porphyrins with their highly conjugated structures and light adsorption features are well 
suited materials to act as electron donors.
86
 Additionally, the design of suitable electron 
acceptor systems has focussed on the use of fullerenes which can reversibly accept up to 





six electrons (Figure 1.12).
89
 It has been shown that by interchelation of fullerenes to 
two porphyrin moieties in polypeptide-porphyrin structures, self-organized helical 
systems suitable for use in organic solar cells readily form.
86,87
 A schematic structure of 
one potential amino acid/fullerene-porphyrin composite system is shown in Figure 1.12.  
n
hn










The synthesis of the polypeptide-porphyrin structure 194 was realised from the starting 
material 185 (Scheme 1.28).
86-88
 A selective deprotection of allyl ester to the acid 186 
was performed under Pd(PPh3)4/dimethylacetamide/piperidine reaction conditions to 
give the acid 186 in 84% yield. The Boc group removal to the amine 187 was 
successfully performed using TMSCl and phenol in 1 M CH2Cl2 solution to give amine 
187 in 91% yield. An amide coupling reaction of acid 186 and amine 187 under DCC 
and HOBt conditions gave the dipeptide 188 in 88% yield (Scheme 1.28). By repeating 
the reaction conditions mentioned above for the synthesis of acid 186, amine 187 and 
dipeptide 188, the polypeptide-porphyrin structure 194 (Scheme 1.28) was achieved 






















1.8 Aims of this Project  
While the Solladie group are developing helical porphyrin oligomers to intercalate 
fullerene (Figure 1.12), we plan to build fullerenes into the peptide oligomer structure 
which may allow for the insertion of porphyrins as shown in Figure 1.13. We planned to 
prepare octapeptide
88
 and hexadecapeptide derivatives from L-lysine which are 
functionalized with fullerenes at their lysine amino termini. Beyond a certain degree of 
oligomerisation the development of a secondary structure, such as a 310 helix, may be 
observed (Figure 1.13). This would force the fullerenes to arrange in a defined spatial 
arrangement as shown in Figure 1.13. These fullerenyl peptides can be studied for the 
accommodation of guests like porphyrin rings in between two helices. Preparation of 
supramolecular complexes using these fullerene-peptide oligomers as hosts and 
porphyrins as guest molecules could be expected to be potentially useful as organic 
photovoltaic cells (as shown in Figure 1.13). 
 





Figure 1.13. Potential structure of a amino acid/porphyrinic-peptide system for use in organic solar cells. 
An additional object of this project was to investigate the [60]fullerene moiety as a 
hydrophobic anchor in the synthesis of dicationic peptoids as potential anti-biotic 
agents. A more comprehensive background to this part of the project is presented at the 
beginning of Chapter 4. 
 Therefore, the specific aims of this thesis were: 
 The design, synthesis, isolation and characterization of [60]fullerene based 
oligomers (ex. tetrapeptide, octapeptide, dodecapeptide and hexadecapeptide). 
 Supramolecular complexation with suitable electron acceptor-donor substrates, 
including; porphyrins for potential solar cell applications.  





 The design, synthesis, isolation and characterisation of [60]fullerene based peptides. 
 The synthesis of water soluble dicationic [60]fullerene peptide salts for anti-
bacterial studies. 
  







The Synthesis of [60]Fullerenyl Amino Acids Oligomers  
2.1 Applications as Solar Cells in Material Science 
The major aim to this project was to build fullerenyl-peptides which may allow the 
intercalation of porphyrins as shown in Figure 1.13 see page 39. Specifically, we 
planned to prepare octapeptide and hexadecapeptide derivatives from L-lysine which 
are functionalized with fullerenes at the lysine side chain amino termini. Beyond a 
certain degree of oligomerisation the development of a secondary structure, such as a 
310 helix, may be observed (Figure 1.13). This would force the fullerenes to arrange in a 
defined spatial arrangement as shown in Figure 1.13. These fullerenyl-peptides can be 
studied for the accommodation of guests, including porphyrins, in between two helices. 
Preparation of supramolecular complexes using these fullerene-peptide oligomers as 
hosts and porphyrins as guest molecules could be expected to be potentially useful as 
organic photovoltaic cells as discussed in the previous Chapter (as shown in Figure 
1.13). 





2.2 Strategy 1: Synthesis of [60]fullerenolysine monopeptide 201, 
dipeptide 204, tetrapeptide 207 and octapeptide 195 by sequential 
coupling  
2.2.0 Proposed synthetic strategy for the initial [60]fullerenolysine 
octapeptide 195.     
The retro-synthesis of the [60]fullerenolysine octapeptide 195, starting from the 
previously reported 5,5-diphenylfullerenedihydropyrrole-2-carboxylic acid
33
 198, is 
outlined in Scheme 2.1. A key step was the coupling of the fullerenyl acid 198 to the 
diprotected L-lysine 200 to give the crucial monopeptide 201. The coupling partner 
amine 200 could be readily prepared from the known triprotected L-lysine 199 (Scheme 
2.1). The monopeptide 201, could then be deprotected to its amine derivative 202 and 
acid derivative 203 and these could then be coupled under standard peptide coupling 
reaction conditions to yield the dipeptide 204. By repeating the deprotection and 










Scheme 2.1 Retrosynthetic analysis for the synthesis of [60]fullerenolysine octapeptide 195 from the tetrapeptide 207. 






Scheme 2.1 continued: Retrosynthetic analysis for the synthesis of [60]fullerenolysine tetrapeptide 207 from the known diprotected lysine 200, and known 
[60]fullerenoproline acid 198. 





2.2.1 Addition of tert-butyl 2-((diphenylmethylene)amino)acetate to 
[60]fullerene under Bingel conditions followed by acidolytic 
cleavage of the tert-butyl group 
Slightly modified literature synthetic procedures were adopted to synthesize the  
[60]fullerene adducts 197 and 198.
33,90
  To a solution of [60]fullerene, carbon 
tetrabromide and the imine 196 in toluene was added DBU dropwise. The reaction 
mixture was stirred at rt for 6 h before the crude material was subjected to flash silica 
gel chromatography. Elution with CH2Cl2/hexanes (1:1) led to the isolation of 
compound 197 in 60% yield, which was carried forward for the acidolytic cleavage of 
the tert-butyl group with TFA and CH2Cl2 (1:4 v/v) to form the acid 198 in 90% yield 
(Scheme 2.1).  The spectroscopic data of 198 were in agreement with that previously 
reported.
90 
Examination of the 
1
H NMR spectrum of 198 revealed the loss of the tert-
butyl resonance at δ 1.60 (s, 9H) when compared to that of 197, along with the 
appearance of a broad singlet, with a relative integration of 1H, at δ 8.63 attributed to 
the carboxylic acid proton. Analysis of the mass spectrum of 198 showed a base peak at 




Scheme 2.2: Synthesis of the fullerenyl amino acid 198. 




2.2.2 Base-promoted N-Fmoc removal for the triprotected L-lysine 199, 
followed by amide coupling to give the monopeptide 201 
The Fmoc protecting group is widely utilized in the synthesis of peptides 
91, 92
 as it can 
be cleaved from the desired amine by the use of a simple base – most commonly 
piperidine.
93
 Therefore, in a typical procedure
94
 a solution of triprotected L-lysine 199 
in piperidine/acetonitrile (1:9 v/v) was stirred overnight at rt to produce the free amine 
200, in 100% crude yield, which was carried forward to the successive reactions without 
additional purification (Scheme 2.3).  
The molecular structure of this salt was verified by the appearance of an ion at m/z 287 





Scheme 2.3: Reagents and conditions: (a) (a) piperidine, CH3CN, rt, 4 h; (b) EDCI, HOBt, Et3N, 
CH2Cl2, rt, 4 h, 62%. 
 
The increased lability of the Fmoc group is attributable to its aromatic fluorenyl 
structure and the presence of the sp
3
 methine carbon bridging the two benzene rings. As 
a result, this methine proton is susceptible to deprotonation by moderate bases (pKa 
~25) and this produces a delocalized 14-electron aromatic carbanion (Scheme 2.4).
95
 
The aromatic carbanion then rapidly decomposes to generate dibenzofulvene (DBF), 
CO2, and the desired free amine. The pKa of piperidine is much lower (pKa ~11)
35
 than 




that of the Fmoc methine proton and only a minute percentage of the molecules will 
ever be deprotonated at any one time. However, any aromatic carbanion that forms will 
immediately undergo an irreversible decomposition, the released CO2 gas escapes the 
reaction mixture and this continually pushes the reaction to the side of deprotection. 
 
Scheme 2.4: Mechanism of base-promoted Fmoc deprotection by piperidine with the dibenzofulvene 
scavenging pathway (red) shown. 
While high yielding, the piperidine-promoted reaction also produces copious quantities 
of an insoluble, white by-product, i.e. the dibenzofulvene (DBF)-piperidine adduct. This 
side reaction (Scheme 2.4 – red pathway) results from interaction of the piperidine base 
with DBF and it is known to occur with most amine bases.
92,93
 The excess piperidine 
thus functions as a scavenger as well as preventing the desired product amine from 
reacting with the dibenzofulvene.
92,93
 The DBF-piperidine adduct is soluble in DMF and 
hence, solid-phase peptide synthesis allows the adduct to be washed away via 
filtration.
93
 Since solution-phase synthesis was employed in this study, DMF was 
avoided as a reaction solvent due to its relatively high boiling point. The DBF-
piperidine adduct was found to be partially soluble in acetonitrile and therefore could 
not be removed by simple filtration. Thus, chromatography was necessary to isolate the 




pure amine 200, which was the most polar compound in the reaction product mixture. 
This problem could have been avoided by employing an amine base that produces an 
adduct with DBF that is soluble in aqueous phosphate buffer, such as 4-
(aminomethyl)piperidine or tris(2-aminoethyl)amine.
93
 Therefore, an aqueous extractive 
work-up could be utilized in the future and chromatography possibly avoided. 
Amide coupling 
The formation of amide bonds from carboxylic acids and amines (e.g. amino acids) was 
a key reaction in the synthesis of the target [60]fullerenolysine derivatives. The 
transformation was employed for coupling of C-terminal amino acid onto the N-
terminal amino acid for the synthesis of dipeptide scaffold. Previous syntheses of 
peptides have utilized the common EDCI (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride), HOBt (1-hydroxy-1H-
benzotriazole) peptide coupling reagent system in dichloromethane/chloroform to form 
the necessary peptide bonds.
94,96,97 
Therefore, a general procedure was developed and 
utilized in all subsequent amide coupling reactions (see Scheme 2.3). For example, the 
synthesis of the crucial monopeptide 201 (Scheme 2.3) was realized in 62% yield by 
stirring in dichloromethane, a solution of previously synthesised amine 200 and the 5,5-
diphenylfullerenedihydropyrrole-2-carboxylic acid
33
 198 with the coupling reagents 
EDCI and HOBt at rt for 4 h. Purification of the crude reaction product by flash column 
chromatography followed by simple trituration from diethyl ether yielded the desired 
monopeptide 201 in 62% yield (Scheme 2.3).  
 
The broad singlet at δ 8.55 (-COOH) in the 
1
H NMR spectrum of acid 198  (see 
Appendix) was no longer observed in the spectrum of 201 but two signals appeared at δ 




3.52-3.58 (m, 2H, CH2N (Lys)) and δ 7.88 (bs, 1H, NH), assigned to the methylene and 
a newly formed amidic proton of monopeptide 201. This evidence indicated that the 
methylene protons, adjacent to the primary amine in precursor 200, experienced a 
downfield shift as a result of the newly installed amide bond. Additionally, the 
13
C 
NMR spectrum showed resonance at δ 162.1, assigned to the new amide carbonyl 
group. The molecular structure of the product 201 was verified by the appearance of a 
peak at m/z 1248.2494 in the HRMS, that was assigned to the sodiated molecular 




The synthesis of the amide bond in 201, and the large number of amide bonds (i.e. 
iterative amide coupling) in later compounds in this study, were made feasible due to 
the reliable and mild conditions afforded by the amide coupling reagents EDCI and 
HOBt. The uncatalysed reaction between the carboxylic acid and amine components 
generates an ammonium carboxylate salt; their subsequent amide condensation would 
require intense heat, which would be incompatible with such multi-functionalized 
molecules.
98
 Therefore, peptide coupling reagents (or ‘activators’) are utilized to 
increase the electrophilicity of the acyl moiety, which allows amide bond formation via 
aminolysis of an activated acyl species under much milder conditions.
98-100
 
Carbodiimides (e.g. EDCI) are employed to generate an active O-acylisourea 
intermediate (Scheme 2.5) by reaction with the carboxylate anion. This intermediate can 
undergo aminolysis by the precursor amine to give the desired product amide.
98
 In a 
possible side reaction, the highly activated O-acylisourea intermediate can undergo 
intramolecular acyl transfer to give an inactive N-acylurea by-product (Scheme 2.5 – 
red pathway),
98,100
 thus consuming the precursor acid without formation of the desired 
amide product.  





Scheme 2.5 Mechanism of EDCI/HOBt promoted amide coupling: both the product pathway (blue) and 
the undesired side reaction (red) are displayed.  
 
To avoid this deleterious side reaction and the possibility of racemization, nucleophilic 
additive (e.g. HOBt) was added to the reaction.
98-100
 HOBt reacts with the active O-
acylisourea intermediate to generate an activated HOBt ester with the key acyl moiety 
(Scheme 2.5 – blue pathway). Crucially, this reaction occurs faster than the 
intramolecular acyl transfer, thus preventing the side reaction but still generating an 
activated acid derivative for subsequent aminolysis to the product amide.
98
 
Epimerization of the stereogenic α-carbon on the O-acylisourea intermediate is another 




possible side reaction and it can occur through two mechanisms – simple enolate 
formation by deprotonation of the α-hydrogen and then re-protonation (resulting in loss 
of chirality) or via formation of the planar 5(4H)-oxazolone intermediate, in which the 
α-hydrogen is readily deprotonated due the resonance stabilization of the resulting 
carbanion. HOBt helps to prevent racemization as the intermediate HOBt ester that is 
preferentially formed is less activated than the O-acylisourea, i.e. the -OBt functionality 
is less electron-withdrawing than the corresponding isourea substituent and therefore 
the adjacent α-hydrogen is less prone to enolization.
100
 Furthermore, the use of the 
Fmoc group (and other carbamates) for protection of the α-nitrogen during coupling is 
known to reduce the prevalence of 5(4H)-oxazolone mediated racemization by induced 
destabilization of the resultant oxazolone carbanion. The lack of epimerization observed 
during the performed amide coupling reactions in this study was a result of these 
combined factors (e.g. HOBt and carbamate protection). Such an epimerization process 
would result in the formation of diastereomeric products that could be detected by 
1
H 
NMR and/or TLC analysis. Based on such analyses, the isolated amide products were 
obtained as single diastereomers. Based on these findings and the analysis that dipeptide 
204 has a single diastereomer we conclude that product 201 is a single enantiomer. 
2.2.3 N-Boc and tert-butyl ester removal via acidolysis, allyl ester 
hydrolysis by using (CH3)3SnOH   
The acidolytic cleavage of the Boc and tert-butyl ester protecting groups in this study 
could be easily achieved with a variety of acids. However, trifluoroacetic acid (TFA) 
was used most often in this study.
91,101
 The ability of these groups to be cleaved 
separately or simultaneously under relatively mild acidic conditions was an essential 
feature of this general reaction. As such, a previously published general procedure
97
 was 




employed, with modifications, for the deprotection N-Boc alone and/or tert-butyl ester 
group at rt for 4 h. The N-Boc derivative 201 was dissolved in a mixture of TFA and 
CH2Cl2 (1:1 v/v) and stirred at rt for 4 h which gave a 90% yield of the TFA salt of the 
target amine 202 (Scheme 2.6).  
 
Scheme 2.6: Reagents and conditions: (a) TFA: CH2Cl2 (1:1), rt, 4 h, 90%. (b) 1,2-DCE, (CH3)3SnOH, 
80 
0




H NMR spectrum of compound 202 (see Appendix) was lacking the prominent 9H 
resonance at δ 1.44 that was present in the spectrum of carbamate 201 and was assigned 
to the tert-butyl methyl protons. ESIMS analysis of compound 202 showed a peak at 




In this chapter the Boc and tert-butyl ester protecting groups were cleaved using TFA. 
The cleavage mechanism is similar for both substituents (Schemes 2.7) and proceeds via 
protonation followed by heterolytic cleavage and release of a relatively stable tert-butyl 
carbocation. The tertiary nature of the tert-butyl cation stabilizes the positive charge by 
donating electron density onto the tertiary carbon (Scheme 2.7). Release of the cationic 
species from the N-protected substrate results in a carbamic acid (Schemes 2.7), which 
decomposed by the loss of CO2 and gave the product amine as the TFA salt. 
 




The simple acidolytic conditions required for removal of the N-Boc protecting group 
allowed for the isolation of the crude TFA salts by simple solvent removal. Due to the 
volatility of the Boc deprotection by-products, no resultant impurities were observed. 
Overall, it was the relative ease, speed, and resultant product purity of the acidolytic 
deprotection method that allowed for the efficient turn-over of TFA salt of the 
corresponding amine or free amine. 
 
 
Scheme 2.7. Mechanism of tert-butylcarbamate acidolysis by TFA to give the desired amine (blue) and 
by-products (red) 
 
Allyl ester cleavage 
 (CH3)3SnOH had been previously used by Mascaretti and co-workers
102-105
 to cleave 
phenacyl ester anchored amino acids and peptides from a polystyrene resin and to 
hydrolyze methyl phenylacetate (Figure 2.1). By utilizing this reagent, K. C. Nicolaou 
and co-workers developed a method to hydrolyse esters on highly epimerization 
sensitive systems
106
 (Figure 2.2). This method remarkably resulted in quantitative 
conversion of a dipeptide allyl ester to the corresponding acid with negligible erosion of 
the stereochemical integrity (Figure 2.2). 
 




Figure 2.1. Literature precedent for (CH3)3SnOH cleavage of esters. 
 
Figure 2.2. Mild and selective cleavage of an ester with (CH3)3SnOH. 
A probable mechanistic interpretation can be seen in Figure 2.3. The hydroxide moiety 
of the reagent engages the generic ester to create a polar tetracoordinated transition 








 which is easily hydrolysed upon aqueous workup to the 
desired acid. Additionally, the Sn atom most likely facilitates the reaction by 
participating as a weak Lewis acid and coordinating to the carbonyl oxygen of the ester 
starting material. 
 
Figure 2.3. A proposed mechanism of (CH3)3SnOH mediated hydrolysis of esters. 
The [60]fullerenolysine monopeptide 201 was treated with (CH3)3SnOH under the 
above mentioned reaction conditions to selectively hydrolyse the allyl ester to give the 
acid 203 in 88% yield (Scheme 2.6).  
The 
1
H NMR spectrum of compound 203 (see Appendix) was lacking the prominent 
allyl ester resonances at δ 4.58 (m, 2H), 5.28 (d, J = 10.0 Hz, 1H), 5.30 (d, J = 17.0 Hz, 
1H) and 5.84 (m, 1H), that were present in the spectrum of ester 201. HRMS analysis of 
compound 203 contained a peak at m/z 1208.2145 that was assigned to the sodiated 
molecular ion ([M + Na]
+
, C86H31N3O5Na). This compound was not sufficiently soluble 
to generate an adequate 
13
C NMR spectrum. 




2.2.4 Amide coupling to synthesize dipeptide 204, followed by 
deprotection reactions to obtain 205 and 206 
The synthesis of the dipeptide 204 (Scheme 2.8) was realized in 57% yield by stirring in 
dichloromethane, a solution of previously synthesised monopeptide amine 202 and the 
monopeptide acid 203 under the coupling conditions described in Section 2.2.2. 
Purification of the crude reaction product by flash column chromatography followed by 
simple trituration from diethyl ether yielded the desired dipeptide 204 in 57% yield 
(Scheme 2.8). Subsequent deprotection of dipeptide 204 yielded the dipeptide amine 
205 (in 90%), and the dipeptide acid 206 (in 86%), using the reaction conditions 
adopted from Section 2.2.3.  
 
Scheme 2.8: Synthesis of a dipeptide 204, dipeptide amine 205 and dipeptide acid 206. Reagents and 
conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 57%; (b) TFA: CH2Cl2 (1:1), rt, 4 h, 90%. (c) 1,2-
DCE, (CH3)3SnOH, 80 
0




H NMR spectrum of dipeptide 204 (see Appendix) showed the prominent allyl 
ester resonances [at δ 4.58 (m, 2H), 5.28 (d, J = 10.0 Hz, 1H), 5.30 (d, J = 17.0 Hz, 1H) 
and 5.84 (m, 1H)], that were present in the spectrum of amine 202 and the Boc methyl 




resonances (δ 1.45, s, 9H), that was present in the spectrum of acid 203. Additionally, 
an amidic proton was also present at δ 6.68 (bs, 1H, NH), due to the newly formed 
amide bond. Furthermore, the 
13
C NMR spectrum showed a resonance at δ 162.7, which 
was assigned to the newly formed amide carbonyl group. The molecular structure of the 
product 204 was verified by the appearance of the peak at m/z 2315.4114 in the HRMS, 
that was assigned to the sodiated molecular ion ([M+Na]
+ 
C170H56N6O7Na). 
The dipeptide amine 205 showed the disappearance of a prominent Boc group 
resonance at δ 1.45 (s, 9H), that was present in the 
1
H NMR spectrum of dipeptide 204. 
The molecular structure of the product 205 was verified by the appearance of the peak 




The deallylation of dipeptide 204 to its acid 206 was supported by the loss of 
resonances [at δ 4.58 (m, 2H), 5.28 (d, J = 10.0 Hz, 1H), 5.30 (d, J = 17.0 Hz, 1H) and 
5.84 (m, 1H)], in the 
1
H NMR spectrum, that were present in the dipeptide 204, which 
were assigned to the allyl protons. The molecular structure of the product 206 was 
verified by the appearance of the peak at m/z 2276 in the ESIMS, that was assigned to 
the sodiated molecular ion ([M+Na]
+ 
C167H51N6O7Na). 
2.2.5 Coupling of amine 205 and acid 206 to the tetrapeptide 207    
The general synthetic procedure was employed to synthesise tetrapeptide 207, was as 
described in section 2.2.2. The synthesis of the tetrapeptide 207 (Scheme 2.9) was 
realized by stirring in chloroform, a solution of previously synthesised dipeptide amine 
205 and the dipeptide acid 206 under the coupling conditions mentioned in Section 
2.2.2. TLC analysis of tetrapeptide 207 showed the presence of dipeptide acid 206 along 




with a new spot (Rf = 0.6), which was assumed to be the tetrapeptide 207. Further base 
(sat. NaHCO3) treatment did not completely remove the acid 206 from the crude 
mixture. Purification of the crude product by flash column chromatography followed by 
simple trituration from diethyl ether did not yield the desired tetrapeptide 207, in 
satisfactory purity. Further purification by preparative thin layer chromatography 
(PTLC) followed by trituration from dichloromethane/diethyl ether (1:1) resulted in 
51% yield of tetrapeptide 207 (Scheme 2.9), which we believe to have a small amount 
of acid 206 impurity remaining in it. In a subsequent reaction, a change of solvent from 
chloroform to chloroform/pyridine (1:1) for the coupling reaction of compounds 205 
and 206 yielded tetrapeptide 207 in 50% crude yield. Unfortunately subsequent base 
(sat. NaHCO3) wash, flash column chromatography and PTLC could not remove all the 
acid 206 impurity from the tetrapeptide 207.     
Scheme 2.9: Synthesis of the tetrapeptide 207. Reagents and conditions: (a) EDCI, HOBt, Et3N, CHCl3, 




H NMR spectrum of tetrapeptide 207 showed the prominent allyl ester resonances 
[at δ 4.56 (m, 2H), 5.25 (d, J = 9.0 Hz, 1H), 5.27 (d, J = 17.0 Hz, 1H) and 5.82 (m, 
1H)], that were present in the spectrum of amine 205 and the Boc methyl resonances (δ 
1.44, s, 9H), that was present in the spectrum of acid 206. Additionally, an amidic 




proton was also appeared at 7.80 (bs, 1H, NH), due to the newly formed amide bond. 
Unfortunately, the products from both coupling procedures were not sufficiently soluble 
in most of the organic solvents to generate an adequate 
13
C NMR spectrum and were not 
sufficiently soluble in MeOH to generate an adequate ESI-MS. Thus we could not 
verify if this reaction was successful. 
2.2.6 Optimization of coupling reaction to synthesise tetrapeptide 207  
To optimize the coupling reaction of dipeptide amine 205 and dipeptide acid 206 to 
provide the tetrapeptide 207 in purer form and perhaps better solubility, several 
different reaction conditions were tried. These included changes to the coupling reagent, 
solvent, base and the reaction temperatures. Unfortunately, none of these attempts could 
evolve as suitable conditions to synthesise tetrapeptide 207 in purer form, instead an 
inseparable mixture was the end result (Table 2.1). 
Table 2.1 Attempted optimisation reaction conditions: 









1 CH2Cl2 DCC, HOBt Et3N rt mixture 
2 CH2Cl2 EDCI, HOBt Et3N rt mixture 
3 CH2Cl2 HBTU Et3N /DIPEA rt-40 
0
C mixture 
4 CHCl3 DCC, HOBt Et3N /DIPEA rt mixture 
5 1,2-DCE DCC, HOBt Et3N rt-80 
0
C mixture 
6 1,2-DCE EDCI, HOBt Et3N /DIPEA rt-80 
0
C mixture 
7 1,2-DCE HBTU Et3N /DIPEA rt-80 
0
C mixture 
8 1,2-DCE HATU Et3N /DIPEA rt-80 
0
C mixture 
9 1,2-DCB EDCI, HOBt Et3N /DIPEA rt-80 
0
C mixture 
10 1,2-DCB HBTU Et3N /DIPEA rt-80 
0
C mixture 
11 1,2-DCB HATU Et3N /DIPEA rt-80 
0
C mixture 




(a). All the reactions were tried on 15 mg scale and verified by the TLC analysis. (b). Possible 
compounds in the mixture are tetrapeptide 207 along with dipeptide acid 206.  
2.2.7 Strategy 2: Synthesis of tetrapeptide 207, by synthesising a lysine 
tetramine 217 first and then coupling with acid 198.  
In an alternative strategy, the synthesis of the tetrapeptide 207 was proposed from the 
previously unknown lysine tetrapeptide tetramine 217 and the previously known 
[60]fullerenoproline acid 198. Compound 207 was proposed in seven synthetic steps 
(Scheme 2.10) starting from the known lysine acid 210 and amine 211. This strategy 
was adopted due to the relative ease of handling peptides in terms of solubility, 
purification and the size of the molecule. The previous attempts (Sections 2.2.5 and 
2.2.6) were unsuccessful in providing pure samples of 207, perhaps because of steric 
hinderance due to the steric bulk of the incoming dipeptides 205 and 206. This strategy 
could possibly overcome these adverse steric effects, with the reaction between the 
relatively smaller peptide 217 and [60]fullerenoproline acid 198.    





Scheme 2.10 Retrosynthetic analysis for the synthesis of [60]fullerenolysine tetrapeptide 207 from the 
unknown lysine tetrapeptide tetramine 217 and a known acid 198. 
2.2.8 Synthesis of lysine dipeptide 212 and its amine 213 
The synthesis of the lysine dipeptide 212 (Scheme 2.11) was realized in 85% yield by 
stirring a solution of commercially available acid 210 and the amine 211 in 




dichloromethane under the coupling conditions mentioned in section 2.2.2. Purification 
of the crude reaction product by flash column chromatography followed by simple 
trituration from diethyl ether yielded the desired dipeptide 212 in 85% yield (Scheme 
2.11). Subsequent Boc deprotection of dipeptide 212 with TFA realised the amine salt 
213 in 90%, by the conditions adopted from Section 2.2.3. 
 
Scheme 2.11: Reagents and conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 85%; (b) TFA: CH2Cl2 
(1:1), rt, 4 h, 90%. 
The broad singlet at δ 8.55 (CHNH3
+
) in the 
1
H NMR spectrum of 211 was no longer 
observed in the spectrum of 212 but two signals appeared at δ 4.12 (m, 1H) and δ 4.18 
(m, 1H), assigned to the two different lysine α-methine protons in 212. This evidence 
indicated that the α-proton, adjacent to the primary amine in precursor 211, experienced 
a downfield shift as a result of the newly installed amide bond. Additionally, the 
molecular structure of the product 212 was verified by the appearance of the peak at m/z 





NMR spectrum of compound 213 was lacking the prominent 9H resonance at δ 1.42 
that was present in the spectrum of carbamate 212 and was assigned to the tert-butyl 
methyl protons. ESIMS analysis of compound 213 indicated peak at m/z 759 that was 
assigned to the protonated molecular ion ([M + H]
+
, C45H50N4O7). 




2.2.9 Synthesis of lysine tripeptide 214 and its amine 215 
The synthesis of the lysine tripeptide 214 (Scheme 2.12) was realized in 83% yield by 
stirring in dichloromethane, a solution of previously synthesised dipeptide amine 213  
and the monopeptide acid 210 under the coupling conditions mentioned in section 2.2.2. 
Purification of the crude reaction product by flash column chromatography followed by 
simple trituration from diethyl ether yielded the desired dipeptide 214 in 83% yield 
(Scheme 2.12). Subsequent Boc deprotection of tripeptide 214 in TFA realised the 
amine salt 215 in 98%, by the conditions adopted from Section 2.2.3.  
 
Scheme 2.12: Synthesis of the lysine tripeptide 214 and amine 215. Reagents and conditions: (a) EDCI, 
HOBt, Et3N, CH2Cl2, rt, 4 h, 83%; (b) TFA: CH2Cl2 (1:1), rt, 4 h, 98%. 
Analysis of the 
1
H NMR spectrum of 214 showed a loss of the resonance attributable to 
the carboxylic acid proton in 210 and the presence of resonances for the characteristic 
protons of both the carboxylic acid 210 and amine 213. A multiplet at δ 3.43-3.44         
(-CHNH2) in the 
1
H NMR spectrum of 213 was no longer observed in the spectrum of 
214 but a multiplet at δ 4.14-4.15 with an integration of 6H was assigned to the three 
lysine α-methine protons and three Fmoc methine protons. This evidence indicated that 
the α-proton, adjacent to the primary amine in precursor 213, experienced a downfield 
shift as a result of the newly installed amide bond. This sample turned into a gum over a 
period of time, so without measuring the 
13
C NMR spectrum, the material was carried 
forward to the subsequent reaction. Additionally, the molecular structure of the product 
was verified by the appearance of the peak at m/z 1231 in the ESI MS, that was assigned 




to the sodiated molecular ion ([M + Na]
+
 C71H80N6O12Na). Compound 215 was 
characterised by the appearance of the peak at m/z 1109 in the ESI MS, that was 
assigned to the protonated molecular ion ([M + H]
+
 C66H73N6O10). 
2.2.10 Synthesis of lysine tetrapeptide 216 and its tetramine 217 
The synthesis of the lysine tetrapeptide 216 (Scheme 2.13) was achieved in 70% yield 
by stirring in dichloromethane, a solution of lysine tripeptide amine 215  and the 
monopeptide acid 210 under the coupling conditions described in section 2.2.2. 
Purification of the crude reaction product by flash column chromatography followed by 
simple trituration from diethyl ether yielded the desired tetrapeptide 216 (Scheme 2.13). 
To remove the Fmoc groups in 216 a solution of tetrapeptide 216 in 
piperidine/acetonitrile (1:9 v/v) was stirred overnight at rt to produce the lysine 
tetramine 217, which was carried forward to the next reaction. 
Scheme 2.13: Synthesis of the lysine tetrapeptide 216 and tetramine 217. Reagents and conditions: (a) 
EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 70%; (b) piperidine, CH3CN, rt, 4 h, 100%. 
The 
1
H NMR spectrum of tetrapeptide 216 showed the prominent allyl ester resonances 
[at δ 4.46 (bs, 2H), 5.11 (d, J = 10.5 Hz, 1H), 5.21 (d, J = 17.5 Hz, 1H) and 5.78 (m, 
1H)], that were present in the spectrum of amine 215 and Boc methyl resonances (δ 
1.29, s, 9H), that were present in the spectrum of acid 210. Additionally, an amidic 
proton was also appeared at δ 8.18 (bs, 1H, NH), this was due to the newly formed 
amide bond. Additionally, the 
13
C NMR spectrum of 216 showed resonances at δ 155.5, 
assigned to the Boc carbonyl and δ 172.3 that was assigned to the ester carbonyl. This 




indicated the presence of carbonyl signals from both the reactants. The molecular 
structure of the product 216 was verified by the appearance of the peak at m/z 
1581.7362 in the HRMS, that was assigned to the sodiated molecular ion ([M+Na]
+ 
C92H102N8O15Na). Compound 217 was characterised by the appearance of the peak at 




2.2.11 Coupling of lysine tetrapeptide tetramine 217 and acid 198 to 
synthesise tetrapeptide 207 
The general synthetic procedure was employed to synthesise tetrapeptide 207 using two 
different combinations of solvents (chloroform and 1:1 mixture of chloroform/pyridine) 
for better solubility. The attempted synthesis of the tetrapeptide 207 (Scheme 2.14) 
produced a mixture of products in both the cases; three significant compounds (10 mg, 
14 mg and 56 mg) were separated by column chromatography and the ESIMS showed 
molecular ions at m/z 1167, 1387 and 1417, respectively. Unfortunately, none of these 
MS data matched with the possible fullerene substituted peptides, including the mono-
fullerene, di-fullerene, tri-fullerene or the desired tetra-fullerene coupled tetrapeptide 
207. This could possibly be due to steric hindrance between the incoming 
[60]fullerenoproline acid 198 units. Therefore, a less sterically hindered cyclic peptide 
was considered. 





Scheme 2.14: Attempted synthesis of the tetrapeptide 207. Reagents and conditions: (a) EDCI, HOBt, 
Et3N, CHCl3, rt, 8 h, mixture of products; or EDCI, HOBt, Et3N, CHCl3/Pyridine (1:1), rt, 8 h, mixture of 
products. 
2.2.12 Strategy 3: Synthesis of [60]fullerenolysine cyclic tetrapeptide 
222, by synthesising a lysine cyclic tetrapeptide amine 221 first 
and then coupling with acid 198. 
The synthesis of the cyclic tetrapeptide 222 was proposed from the unknown cyclic 
tetrapeptide tetramine 221 and the [60]fullerenoproline acid 198. Compound 221 was 
proposed in four synthetic steps (Scheme 2.15) starting from previously synthesised 
lysine tetrapeptide 216. This strategy was adopted to reduce the steric hindrance 
between the incoming fullerenyl units on to the cyclic peptide. The unsuccessful results 
described in Sections 2.2.5, 2.2.6 and 2.2.11 were thought to arise from the steric bulk 
of the dipeptides 205 and 206, and therefore the less hindered cyclic peptide 221 might 




have a higher reactivity towards acid 198 due to less steric hindrance as shown for the 
proposed synthesis of the fullerenyl peptide 222 in Scheme 2.15. 
 
Scheme 2.15: Retrosynthetic analysis for the synthesis of [60]fullerenolysine cyclic tetrapeptide 222 
starting from the tetrapeptide 216. 




2.2.13 Synthesis of lysine tetrapeptide amine salt 218 and acrolyl 
coupled tetrapeptide 219 
The synthesis of the lysine tetrapeptide amine salt 218 (Scheme 2.16) was realized in 
98% by using TFA (1:1) in dichloromethane as solvent by following the procedure 
described in Section 2.2.3. This product was carried forward to the subsequent coupling 
reaction with acrylic acid under the coupling conditions mentioned in Section 2.2.2. 
Purification of the crude reaction product by flash column chromatography followed by 
simple trituration from diethyl ether yielded the desired product 219 in 75% yield 
(Scheme 2.16).  
 
Scheme 2.16: Synthesis of compound 218 and 219. Reagents and conditions: (a) TFA: CH2Cl2 (1:1), rt, 
4 h, 98%. (b) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 75%. 
Compound 218 was characterised by the appearance of the peak at m/z 1459 in the 
ESIMS, that was assigned to the protonated molecular ion ([M+H]
+
 C87H94N8O13). The 
1
H NMR spectrum of compound 219 showed the prominent allyl ester resonances [at δ 
4.56 (bs, 2H), 5.20-5.33 (m, 2H), and 5.63-5.65 (m, 1H)], and acrylyl group resonances 
[at δ 5.81-5.83 (m, 1H, NHCOCH=CHH), 6.06-6.20 (m, 1H, NHCOCH=CHH)]. 
Additionally, the molecular structure of the product 219 was verified by the appearance 
of the peak at m/z 1535 (100%) in the ESIMS, that was assigned to the sodiated 
molecular ion ([M+Na]
+
 C90H96N8O14Na).  




2.2.14 Synthesis of cyclic tetrapeptide 220 by ring closing metathesis 
(RCM) 
A solution of 219 in CH2Cl2 (100 mL) was heated at reflux then Grubbs’ II catalyst
107
 
was added in one portion. The colour became pink then purple and then darkened to 
orange. The reaction was heated at reflux for 4 h, after which TLC analysis showed 
complete consumption of 219. The crude reaction mixture was then subjected to flash 
silica chromatography, elution with MeOH/CH2Cl2 (1:25) provided the cyclic 
compound 220 as an off-white solid (Scheme 2.17).  
 
Scheme 2.17: Synthesis of compound 220. Reagents and conditions: (a) CH2Cl2, Grubb’s II catalyst, 
reflux, 4 h, 19%.  
The cyclic peptide 220 was characterised by the appearance of the peak at m/z 1486 
(80%) in the ESIMS, that was assigned to the protonated molecular ion ([M+H]
+
 





C NMR spectrum. 
This strategy was not pursued any further because of the difficulty of characterising 
compounds due to their poor solubilities and the low chemical yields. 
 




2.2.15 Material Science Applications of compounds 201 and 204 as 
Fullerene van der Walls Oligomers 
The results from this section were generated by collaborators in Germany (Prof. 
Timothy Clark and Prof Dirk M. Guldi, University of Erlangen-Nuremberg). 
[60]Fullerenes are used extensively as electron acceptors, for instance in phenyl-C60-
butyric acid methyl ester (PCBM) based organic solar cells and in devices based on 
polycrystalline fullerene films. In most cases, van der Waals interactions between 
fullerenes are present. An exciting possibility for low-voltage organic field-effect 
transistors (FETs) is to combine the dielectric and the semiconductor functionalities in a 
single molecule that can form a self-assembled monolayer (SAM).
108
 When the 
semiconductor moiety in such molecules is a substituted fullerene, an n-type 
semiconductor layer results that can become negatively charged under conductance 
conditions. This results in considerable hysteresis in the voltage-current characteristics 
of the device.
109
 When our collaborators in Erlangen were analyzing semiempirical 
molecular orbital calculations on such SAMs,
110
 they noticed that the local electron 
affinity
111,112
 indicated electron traps in the interstitial volumes between adjacent 
fullerenes in the semiconductor layer and that these traps were particularly deep when 
three fullerenes were involved.
110
 A literature survey revealed that several groups have 
studied covalently linked fullerenes, their radical anions and dianions,
113-123
 but that 
little attention has been paid to non-bonded van der Waals aggregates of fullerenes.
124
 
The covalently bonded C60-dimer radical anion/dianion, A
•/2 
can be considered to be 
the result of an addition to a Csp2-Csp2 bond in the fullerene cage, whereas a reduced van 
der Waals dimer, B can form one-electron bonds
125
 between fullerene “super atoms” 
(Figure 2.4).
126
 A third possibility is the dimer adduct formed by a formal [2+2] 
cycloaddition of two 5,6-bonds, C (Figure 2.4).
113 





Figure 2.4: Structures of fullerene dimers A, B and C. 
The “super atom” picture of fullerenes is interesting in this context because the lowest 
unoccupied molecular orbitals of C60 are triply degenerate. This means that additional 
electrons can occupy low-lying intermolecular molecular orbitals, leading to the 
possibility that larger van der Waals C60-oligomer dianions can form multi-center two-
electron bonds to give trimers (D) analogous to H3
+ 127
 and tetramers (E) analogous to 
the 1,3-dehydro-5,7-adamatanediyl dication.
128 
Figure 2.5: Structures of fullerene trimer D and tetramer E. 
Table 2.2 shows the results obtained by Prof. T. Clark et al. from density-functional 
theory (RI-BP86
129,130
/TZV) calculations on fullerene dimers, trimers and tetramers and 
one- and two-electron reduced forms. They used an empirical correction to account for 
dispersion,
131
 although the correctness of such treatments for fullerenes has recently 
been placed in doubt.
132
 They have investigated the three structures A-C in Figure 2.4 
for  60 2C




 . A has a long covalent bond of 1.6 to 1.7 Å, whereas B features a 
shortened van der Waals contact distance of approximately 2.6 Å between the fullerenes 




(the van der Waals radius of carbon is 1.7 Å). Surprisingly the non-bonded structure B 
is found to be more stable than the covalently bonded isomer A (by up to 11.3 kcal mol
–
1
 for the radical anion and 4.8 kcal mol
–1
 for the singlet dianions). The D3-dispersion 
correction lowers these values (stabilizes the dimers) by approximately 5 kcal mol
–1
. 
Table 2.2 Relative energies (ERel, kcal mol
–1
) of C60 oligomers 1-5, the corresponding anions and 
dianions, relevant Electron Affinities (EA, eV) and reaction energies (ER, kcal mol
–1
) calculated at 
the RI- BP86/TZV 









Because this result could easily be caused by the self-interaction error in DFT, Prof. T. 




 using increasing amounts (0 to 
50%) of Hartree-Fock exchange in a modified hybrid B3LYP functional
133,134 
and 
performed additional calculations using the long-range corrected CAM-B3LYP
135
 





Species ERel EA 
Dissociation 
Reaction ER 
C60  2.82   
B 0.0 (0.0) 3.24  2C60 +11.9 
C +1.2 (–5.4) 3.25  2C60 +17.3 
D  3.49  3C60 +34.2 




  –0.21   
A
–.




















  1.86  3C60+C60
–.
 +85.6 




Figure 2.6. Calculated potential energy diagrams for the dissociation of (C60)2
-•
.  
The data shown in Table 2.2 and Figure 2.6 demonstrate that the van der Waals dimer 
radical anion and dianion are probably more stable than the covalently bound isomer B 
investigated previously or comparable to the [2+2] adduct C in the same oxidation 
states. These values lie between those obtained at the RI-BP86-D3/TZV level (–15.8 






, respectively). All calculations find the deepest 
minimum to be 2 kcal mol
–1
, with a significantly shortened van der Waals contact 
(between 2.4 and 2.9 Å). Thus, the range of DFT functionals tested agrees that B
•
 is 
more stable than A
•
. HF-TPSS and HF-PBE calculations with the def2-SVP basis set 
also predict B
–•
 to be more stable than A
–•
 by 15 kcal mol
-1
, with a barrier of ca. 3 kcal 
mol
-1
 between them. 




(5,4) calculations on DFT-optimized 
geometries to verify the DFT and HF-DFT results (Figure 2.7). CASPT2(5,4) 




 are close in energy, with a barrier of 6.2 kcal 
mol
–1
 between them. Unfortunately, the size of the system limits calculations to the 
CASPT2(5,4)/ANO-L-VDZ level.
139,140 





Figure 2.7. CAS (5,4) formally singly occupied orbital of B
–•
. The calculated occupancy is given in 
parentheses. This orbital corresponds to a one-electron -bond between the two fullerenes. 




 can be distinguished 
easily. Structure 2
–•
 is characterized by very intense absorptions at 1430-1486 and 1600 
cm
1
 that are far weaker in the separated monomers and A
.
. Once again, the van der 
Waals dimer radical anion B
–•
 is clearly distinguished by a strong absorption in the 
infrared at 1760 nm (5672 cm
1
). This absorption is far more intense than that found at 
slightly longer wavelength (1848 nm) for A
–•
, which also exhibits a second weaker 
absorption at 1441 nm. Separated fullerene and its radical anion do not absorb in this 
region. 
To investigate the proposed effect experimentally, they performed cyclic voltammetry 
and spectroelectrochemical experiments on the fullerene-substituted peptides 201 and 
204. Both the monomer 201 and dimer 204 are soluble in chloroform, chlorobenzene 
and ortho dichlorobenzene. Monomer 201 is more soluble in these organic solvents than 
the dimer 204 possibly because of the absence of interactions between the fullerene 
balls, whereas this effect is more possible dimer 204. These two compounds offer the 
opportunity to observe and compare a system in which interactions between non-bonded 
fullerenes are possible (204) with one in which they are not (201). The redox properties 
of the mono- and dipeptides were studied by means of cyclic voltammetry (CV). The 
measurements were performed at room temperature in chlorobenzene with 




tetrabutylammonium hexafluorophosphate as supporting electrolyte.  Chlorobenzene, an 
aprotic solvent, was chosen to avoid protonation of the charged species.  Figure 2.8 
shows the reductive scans between -0.2 to -1.6 V of 201 and 204.  They compared the 
spectra obtained upon fast and slow scanning.  Both compounds show a reduction, 
which is assigned to the one-electron reduction of C60.  At fast scan rates (0.2 Vs
1
), the 
reduction appeared to be quasi-reversible and occured at nearly the same potential for 
both 201 and 204.  In contrast, slowing down the scan rate to 0.005 Vs
1
 lead to an 
irreversible reduction of 204, while 201 remains reversible.  Moreover, at slower scan 
rates 204 was more easily reduced than 201.  The change to an irreversible reduction of 
204 at slower scan rates is consistent with the formation of a van der Waals dimer of the 
fullerenes in 204. 
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Figure 2.8. Cyclic voltammograms of 201 and 204 with a scan rate of 0.0050 Vs
1
 and 0.200 Vs
1
. 
Measurements were performed in chlorobenzene containing 0.05 M TBAPF6 as supporting electrolyte 
with a glassy carbon working electrode, a platinum counter electrode, and a silver pseudo-reference 
electrode. Corrected for ferrocene as an internal standard. 
With this information in hand, they carried out spectroelectrochemical experiments to 
gather information about the absorption features of the reduced species.  A differential 
absorption spectra for 204 in chlorobenzene solution is shown in Figure 2.9. The 
corresponding spectrum for 201 shows the features known from the literature for N-
methylfulleropyrrolidine.
141 
In particular, a sharp peak with a 1028 nm maximum is 
observed for the one electron reduced C60.  In contrast, the differential spectrum of 204 
is characterized by a broad absorption between 700 and 1200 nm and with a local 
maximum at 860 nm.  These spectral attributes are assigned to a van der Waals dimer of 





Figure 2.9. Normalized differential absorption spectrum of 204 with an applied voltage of −0.85 V. 
Measurements were performed in chlorobenzene containing 0.05 M TBAPF6 as supporting electrolyte 
with a platinum gauze as working electrode, a platinum plate as counter electrode, and a silver wire as 
pseudoreference electrode. Calculated spectra for 204a•− and 204b•− (204a•− has separated fullerenes, 
whereas 204b•− has fullerenes in van der Waals contact) shown in red and blue, respectively. 





                             204a•−                                                                    204b•− 
The calculations presented are on a system for which it is difficult to obtain definitive 
results because of its size and the electronic characteristics. However, standard 
functionals with and without dispersion corrections, HF-DFT calculations, modified 
functionals with increasing amounts of HF-exchange and long-range corrected 
functionals all gave consistent results that indicate that fullerene can function as a 
“super-atom” that forms a one-electron intermolecular bond, resulting in an electron 
trap that is even more stable than the isolated fullerene, which is itself an unusually 
strong electron acceptor. 
These experimental results were all consistent with 204 existing as at least two 
conformations in solution, with a minority conformation having a van der Waals contact 
between the two fullerenes (e.g. 204b). At slow CV scan rates, 204b can be formed by 
rearrangement and stabilized by the inter-fullerene one-electron bond. At fast scan rates, 
only the majority conformations without inter-fullerene contact are observed. The 
observed spectrum of 204
.
 corresponds to a superposition of those of the majority non-
contact conformation and 204b
.
 or a similar conformation. 
Although definitive calculations are not yet possible, they used standard density-
functional theory to calculate the electron affinities of fullerene van der Waals 




oligomers. These results are shown in Figure 2.10. The first electron affinity increases 
from 2.7 eV for the monomer to 3.6 eV for the tetramer, which exhibits a second 
electron affinity of almost 2 eV. The tetramer is also calculated to just be able to bind a 
third electron. Van der Waals fullerene oligomers can thus exhibit first electron 
affinities as much as one electron volt more strongly binding than the isolated fullerene 
and second electron affinities up to approximately ~2 eV. These interstitial electron 
traps represent an unexpected feature of non-covalently bonded aggregates of fullerenes 
that can affect the performance of electronic devices strongly. Deep electron traps can 
be expected in amorphous and crystalline fullerene layers or in self-assembled 
monolayers of fullerene-substituted organic molecules, all of which are often used as n-




Figure 2.10. Calculated (RI-BP/TZV) electron affinities (eV) of (C60)n. 
2.2.16 Future directions and conclusions 
The synthesis of [60]fullerenoproline monopeptide 201, dipeptide 204 and a lysine 
tetrapeptide 216 were achieved for the first time and were successfully characterised. 




Unfortunately, the tetrapeptides 207 and 220 which were thought to be prepared, could 
not be fully characterised due to their poor solubilities.   
Because of steric hindrance problems in some of our peptide coupling reactions, it was 
thought that the inclusion of a spacer between two fullerenyl units could be better 
option. Hence, a new strategy was adopted towards the synthesis of a different hexa and 
dodecapeptide oligomer (Chapter 3). 
The [60]fullerene amino acid monomer 201 and the bis-fullerene 204 were studied 
experimentally using spectroelectrochemical measurements. The bis-fullerene-
substituted peptide 204 provided experimental support for density-functional theory 
(DFT) calculations which indicate that van der Waals fullerene dimers can form 
between adjacent fullerenes in semiconductor layers resulting in interstitial electron 
traps. The fullerenes behave like “super atoms” and the interstitial electron traps 
represent one-electron intermolecular σ-bonds. The proposed electron traps are relevant 
for all organic electronics applications in which non-covalently linked fullerenes in van 










The Synthesis of [60]Fullerenyl Amino Acids Oligomers 
With Spacers  
3.1 Material Science Applications as Solar Cells 
With the aim of resolving the identified steric hindrance problems in Chapter 2, it was 
thought that the inclusion of a spacer between two fullerenyl units could be a better 
option (Figure 3.1 and 3.2). Hence, a new strategy was adopted towards the synthesis of 
two different hexa and dodecapeptide oligomers (Scheme 3.1 and 3.4). 
The aim of this chapter was to synthesise two different combinations of [60]fullerenyl 
based oligomers 223 (Figure 3.1) and 230 (Figure 3.2) having spacers (e.g. lysine and 
phenylalanine) in between the fullerenyl units. The first target dodecapeptide 223, 
which could be prepared from the peptide coupling reaction of hexapeptide acid 228 
and hexapeptide amine 229 is shown in Scheme 3.1. Similarly, the second target 
dodecapeptide 230 (Figure 3.2) could be prepared from the acid and amine precursors of 
the hexapeptide 239 and 240 under peptide coupling conditions mentioned in section 
2.2.2.  
These targeted dodecapeptides 223 and 230 showing every fourth lysine unit bearing 
[60]fullerene on the peptide. Beyond a certain degree of oligomerisation the 
development of a secondary structure, such as a 310 helix, may be observed (Figure 3.1 
and 3.2). This would force the fullerenes to arrange in a defined spatial arrangement as 
shown in Figure 3.1 and 3.2. These fullerenyl peptides can be studied for the 
accommodation of guests like porphyrin rings in between two helices. Preparation of 




supramolecular complexes using these fullerene-peptide oligomers as hosts and 
porphyrins as guest molecules could be potentially useful as organic photovoltaic cells 
(as shown in Figure 3.1 and 3.2). 
 
Figure 3.1. Potential structure of a fullerene-peptide system for use in organic solar cells. 




3.2 Target 1: Synthesis of [60]fullerenolysine dodecapeptide 223, by the 
multiplication of coupling reactions.  
3.2.1 Proposed synthetic strategy for the [60]fullerenolysine   
dodecapeptide 223.     
The retro-synthesis of the [60]fullerenolysine dodecapeptide 223, starting from the 
previously synthesised [60]fullerenomonopeptide acid 203, is outlined in Scheme 3.1. A 
key step was the coupling of the acid 203 to the lysine dipeptide amine 213, to give the 
crucial tripeptide 224. The tripeptide 224, could then be deprotected to its acid 
derivative 225 and amine derivative 226 and these could then be coupled under standard 
peptide coupling reactions to yield the hexapeptide 227. By repeating the deprotection 
and coupling reaction protocol the targeted dodecapeptide 223 could then be potentially 
realised (Scheme 3.1).  
 
 






Scheme 3.1 Retrosynthetic analysis for the synthesis of [60]fullerenolysine dodecapeptide 223 from the hexapeptide 227.






Scheme 3.1 continued. Retrosynthetic analysis for the synthesis of [60]fullerenolysine hexapeptide 227 
from the previously synthesised lysine dipeptide amine 213, and [60]fullerenomonopeptide acid 203. 




3.2.2 Synthesis of tripeptide 224 from acid 203 and amine 213, followed 
by deprotection to its acid 225 and the amine salt 226 
The synthesis of the tripeptide 224 (Scheme 3.2) was realized in 62% yield by stirring 
in dichloromethane, a solution of previously synthesised lysine dipeptide amine 213 and 
the [60]fullerenomonopeptide acid 203 under standard coupling conditions described in 
Section 2.2.2. Purification of the crude reaction product by flash column 
chromatography followed by simple trituration from diethyl ether yielded the desired 
tripeptide 224 in 62% yield (Scheme 3.2). Subsequent deprotection reactions of 
tripeptide 224 yielded the tripeptide acid 225 (in 77%), and the tripeptide amine 226 (in 
89%), using the reaction conditions adopted from Section 2.2.3 (Scheme 3.2). 




Scheme 3.2: Synthesis of a tripeptide 224, tripeptide acid 225 and tripeptide amine 226. Reagents and 
conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 62%; (b) 1,2-DCE, (CH3)3SnOH, 80 
0
C, 6 h, 77%; (c) 
TFA: CH2Cl2 (1:1), rt, 4 h, 89%.  
The 
1
H NMR spectrum of tripeptide 224 showed the prominent allyl ester resonances at 
δ 4.37-4.43 (m, 2H), 5.22-5.26 (m, 2H), and 5.82-5.88 (m, 1H), that were present in the 
spectrum of amine 213 and the Boc methyl resonance (δ 1.40, s, 9H), which was present 
in the spectrum of acid 203. Additionally, an amidic proton resonance also appeared at δ  
6.74-6.82 (m, 1H, NH) which was associated with the newly formed amide bond. 
Furthermore, the molecular formula of product 224 was verified by the appearance of 








The deallylation of tripeptide 224 to its acid 225 was supported by the loss of 
resonances at δ 4.37-4.43 (m, 2H), 5.22-5.26 (m, 2H), and 5.82-5.88 (m, 1H), in the 
1
H 
NMR spectrum, that were present in the tripeptide 224, which were assigned to the allyl 
protons. The molecular formula of product 225 was verified by the appearance of the 




Tripeptide amine salt 226 showed the disappearance of a prominent Boc group 
resonance (δ 1.40, s, 9H) that was present in the 
1
H NMR spectrum of tripeptide 224. 
The molecular formula of product 226 was verified by the appearance of the peak at m/z 
1826.5789 in the HRMS, that was assigned to the protonated molecular ion ([M+H]
+ 
C126H71N7O9). 
3.2.3 Coupling of acid 225 and amine 226 to the hexapeptide 227    
The general synthetic procedure stated in Section 2.2.2 was employed to synthesise the 
hexapeptide 227. The synthesis of the hexapeptide 227 (Scheme 3.3) was realized from 
the coupling reaction of tripeptide acid 225 and the tripeptide amine 226. Purification of 
the crude reaction product by flash column chromatography followed by simple 
trituration from diethyl ether yielded the desired hexapeptide 227 in 44% yield (Scheme 
3.3).  





Scheme 3.3: Synthesis of a hexapeptide 227. Reagents and conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, 
rt, 4 h, 44%. 
The 
1
H NMR spectrum of the hexapeptide 227 showed the prominent allyl ester 
resonances [at δ 4.50-4.62 (m, 2H), 5.20-5.22 (m, 2H), and 5.81-5.86 (m, 1H)], that 
were present in the 
1
H NMR spectrum of amine 226 and the Boc resonance (δ 1.39, s, 
9H), that was present in the 
1
H NMR spectrum of acid 225. Additionally, an amidic 
proton resonance also appeared at δ 6.83-6.84 (m, 1H, NH) which was associated with 
the newly formed amide bond. This compound was not sufficiently soluble to generate 
an adequate 
13
C NMR spectrum and not sufficiently soluble in MeOH to generate an 
adequate ESI-MS. 
This strategy was not pursued any further because of the difficulty of characterising 
compounds due to their poor solubilities and the relatively low chemical yields.  




3.3 Target 2: Synthesis of [60]fullerenolysine phenylalanine 
dodecapeptide 230, by the multiplication of coupling reactions.  
3.3.1 Proposed synthetic strategy for the [60]fullerenolysine 
phenylalanine dodecapeptide 230.     
The retro-synthesis of the [60]fullerenolysine dodecapeptide 230, starting from the 
previously synthesised [60]fullerenomonopeptide amine 202, is outlined in Scheme 3.4. 
A key step was the coupling of the amine 202 to the L-phenylalanine dipeptide acid 
234, to give the crucial tripeptide 235. The tripeptide 235, could then be deprotected to 
its acid derivative 236 and amine derivative 237 and these could then be coupled under 
standard peptide coupling reactions to yield the hexapeptide 238. By repeating the 
deprotection and coupling reaction protocol the targeted dodecapeptide 230 could then 








 Figure 3.2. Potential structure of a amino acid/porphyrinic-peptide system for use in organic solar cells.






Scheme 3.4 Retrosynthetic analysis for the synthesis of [60]fullerenolysine phenylalanine dodecapeptide 230 from the hexapeptide 238. 





Scheme 3.4 continued. Retrosynthetic analysis for the synthesis of [60]fullerenolysine phenylalanine 
hexapeptide 238 from previously synthesised dipehnylalanine dipeptide acid 234, and [60]fullerenomonopeptide 
amine 202. 
. 




3.3.2 Amide coupling of acid 231 and amine 232 to synthesize a dipeptide 
233, followed by ester hydrolysis to its acid 234 
The synthesis of the phenylalanine dipeptide
143
 233 (Scheme 3.5) was realized from the 
peptide coupling reaction of commercially available phenylalanine acid 231 and the amine 
232. Purification of the crude reaction product by flash column chromatography followed by 
simple trituration from diethyl ether yielded the desired tripeptide 233 in 92% yield (Scheme 
3.5). Subsequent removal of tert-butyl group of dipeptide 233 yielded the dipeptide acid 234 
(in 90%) using the reaction conditions adopted from Section 2.2.3. 
 
Scheme 3.5: Reagents and conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 62%; (b) TFA: CH2Cl2 (1:1), rt, 
4 h, 90%.  
The 
1
H NMR spectrum of dipeptide 233 showed the prominent tert-butyl ester resonance at δ 
1.36 (s, 9H), that was present in the 
1
H NMR spectrum of amine 232 and the Fmoc protecting 
group methine and methylene resonances at δ 4.28 (bs, 1H, CH), 4.40-4.43 (m, 2H, CH2), 
that were present in the 
1
H NMR spectrum of acid 231. Additionally, an amidic proton 
resonance was evident at δ 6.31 (bs, 1H, NH) that was associated with the newly formed 
amide bond. Additionally, the 
13
C NMR spectrum of 233 showed resonances at δ 155.9, 
assigned to the Fmoc carbonyl, and δ 170.2, that was assigned to the ester carbonyl. This 
indicated the presence of carbonyl resonances from both the reactants. Furthermore, the 
molecular structure of the product 233 was verified by the appearance of the peak at m/z 




591.2865 in the HRMS, that was assigned to the protonated molecular ion ([M+H]
+ 
C37H38N2O5). 
The ester hydrolysis of dipeptide 233 to its acid 234 was supported by the loss of the tert-
butyl 
1
H NMR resonance at δ 1.36 (s, 9H) that were present in the dipeptide 233. The 
molecular structure of the product 234 was verified by the appearance of the peak at m/z 
535.2238 in the HRMS, that was assigned to the protonated molecular ion ([M+H]
+ 
C33H30N2O5). 
3.3.3 Amide coupling of acid 234 and amine 202 to synthesize a tripeptide 
235, followed by ester hydrolysis to its acid 236 and Fmoc removal to 
the amine 237 
The synthesis of the [60]fullerenyl tripeptide 235 (Scheme 3.6) was realized from the peptide 
coupling reaction of the previously synthesised phenylalanine dipeptide acid 234 and the 
monopeptide amine 202. Purification of the crude reaction product by flash column 
chromatography followed by simple trituration from diethyl ether yielded the desired 
tripeptide 235 in 60% yield (Scheme 3.6). Subsequent allyl ester hydrolysis of tripeptide 235 
yielded the tripeptide acid 236 (in 75% yield) using the reaction conditions adopted from 
Section 2.2.3, and the tripeptide amine 237 (in 99% yield), using the reaction conditions 
adopted from Section 2.2.2. 
 





Scheme 3.6: Synthesis of a tripeptide 235, tripeptide acid 236 and tripeptide amine 237. Reagents and 
conditions: (a) EDCI, HOBt, Et3N, CH2Cl2, rt, 4 h, 60%; (b) 1,2-DCE, (CH3)3SnOH, 80 
0
C, 6 h, 75%; 
(c) piperidine, CH3CN, rt, 4 h, 99%. 
The 
1
H NMR spectrum of tripeptide 235 showed the prominent allyl ester resonances at δ 
4.39-4.59 (m, 2H), 5.19-5.25 (m, 2H) and 5.84-5.90 (m, 1H), that were present in the 
1
H 
NMR spectrum of the monopeptide amine 202 and the Fmoc protecting group methine and 
methylene resonances [at δ 4.06-4.11 (m, 1H, CH), 4.39-4.59 (m, 2H, CH2)], that were 
present in the 
1
H NMR spectrum of acid 234. Additionally, an amidic proton resonance was 
observed at δ 6.57 (bs, 1H, NH), that was associated to the newly formed amide bond. 
Furthermore, the 
13
C NMR spectrum showed a resonance at δ 162.4, which was assigned to 
the newly formed amide carbonyl group. The molecular formula of the product 235 was 
verified by the appearance of the peak at m/z 1641.4235 in the HRMS, that was assigned to 
the protonated molecular ion ([M+H]
+ 
C117H55N5O7). 




The deallylation of tripeptide 235 to its acid 236 was carried forward to the subsequent 
reaction without any spectroscopic analysis, because of its poor solubility.  
The molecular formula of the amine product 237, from removal of the Fmoc protecting group 
from 235 was verified by the appearance of the peak at m/z 1419.3529 in the HRMS, that was 
assigned to the protonated molecular ion ([M+H]
+ 
C102H45N5O5). 
3.3.4 Amide coupling between tripeptide acid 236 and amine 237 to 
synthesize a hexapeptide 238   
The synthesis of the [60]fullerenyl hexapeptide 238 (Scheme 3.7) was realized from the 
peptide coupling reaction of the previously synthesised tripeptide acid 236 and the tripeptide 
amine 237. Purification of the crude reaction product by flash column chromatography 
followed by simple trituration from diethyl ether yielded the desired hexapeptide 238 in 40% 
yield (Scheme 3.7).  
 




H NMR spectrum of hexapeptide 238 showed the prominent allyl ester resonances [at δ 
4.37-4.61 (m, 2H), 5.17-5.25 (m, 2H) and 5.86-5.92 (m, 1H)], that were present in the 
1
H 
NMR spectrum of the tripeptide amine 237 and the Fmoc protecting group methine and 




methylene resonances [at δ 4.04-4.15 (m, 1H, CH), 4.37-4.61 (m, 2H, CH2)], that were 
present in the 
1
H NMR spectrum of acid 236. Additionally, an amidic proton was also 
appeared at δ 6.65 (bs, 1H, NH), that was associated with the newly formed amide bond. This 
compound was not sufficiently soluble to generate an adequate 
13
C NMR spectrum and not 
sufficiently soluble in MeOH to generate an adequate ESIMS. 
3.3.5 Future directions and conclusions 
The synthesis of [60]fullerenolysine/phenylalanine tripeptides  224 and 235, and their 
amine/acid derivatives 225, 226 and 236, 237 respectively, were achieved for the first time 
and characterised. Attempts were made to prepare the hexapeptides 227 and 238 from the 
coupling reactions of 225 and 226, and 236 and 237, respectively. The products of these 
reactions, however, could not be fully characterised due to their poor solubilities.   
Currently, some of these molecules (224, 227, 235 and 238) are under study to form 
supramolecular complexes between the [60]fullerenes and porphyrin, and photoinduced 
charge separation experiments in Prof. Fukuzumi’s laboratory at Osaka University, Japan. 
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Synthesis of Mono and Bis[60]fullerene 
Based Di-Cationic Peptoids as Potential Anti-
Bacterial Agents  
4.1 Introduction                                                                                                          
There are significant health care issues posed by multidrug resistant human pathogenic 
bacteria.
144-147
 Of particular concern is the emergence of Gram-positive bacteria, e.g. 
Staphylococcus aureus and Enterococcus faecium, resistant to the glycopeptide 
antibiotic, vancomycin.
148,149
 Recent work undertaken within our research laboratories 
has revealed a new peptide class of antibiotics, exemplified by binaphthyl-anchored 
peptide (Figure 4.1)
96
. These dicationic binaphthyl-templated linear peptides possess 
some similarity to structural aspects of vancomycin (Fig. 4.1) and could potentially act 
in a similar way but have added flexibility for interacting strongly with the changed 
peptido-glycan cell wall moiety
150
 in vancomycin-resistant bacteria.
151
 Also, the 
significant antimicrobial activity in some biaryl-based cyclic β–hairpin cationic 
peptidomimetics is noteworthy.
152
 While medicinal chemistry investigations of 
binaphthyl-anchored peptide as antibacterial agents made significant progress, with the 
evolution of the amino acids required
94,97,153
 and the better termini,
96
 early 
investigations into alternatives to the binaphthyl unit were restricted to macrocycles 











 Within these studies, 
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acyclic versions of the hydrophobic anchored peptide derivatives were tested with little 
success. Considering that all of these approaches investigated reducing the size of the 
hydrophobic anchoring unit, we thought that alternative hydrophobic units could match 
the space occupied by the binaphthyl unit. Given the diameter of [60]fullerenes is 6.8 Å 
and the distance from distal points of the binaphthyl moiety is 8.3 Å, we considered the 
possibility of replacing the binaphthyl unit with a [60]fullerene. Structure Activity 
Relationships (SAR) will be compared with the replacement of hydrophobic binaphthyl 
moiety with [60]fullerene unit. This chapter describes the synthesis of the [60]fullerene 
based peptoids, 243, 245, 247, 272-279 and 285 and their antibacterial activities. 
 
Figure 4.1. Binaphthyl-anchored peptide anti-biotic agents, Vancomycin and [60]Fullerene dicationic 
peptides. 
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4.2 Strategy 1: Coupling of a [60]fullerenoglycine derivative with a 
dipeptide followed by standard peptide couplings. 
4.2.1 Proposed synthetic strategy for the initial peptoid 247.   
The retro synthesis of the initial [60]fullerene based peptoid target 247, starting from 
the previously reported 5,5-diphenylfullerenedihydropyrrole acid
33
 198, is outlined in 
Scheme 4.1. A key step was the coupling of the fullerenyl acid 242 to the peptide 213 to 
give the tripeptide 243. 
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Scheme 4.1 Retrosynthetic analysis for the synthesis of [60]fullereno tetrapeptoid 247 from 
diphenylfullerenyldihydropyrrole acid 198 and amine 213.  
4.2.2 N-Boc, N-Pmc/Pbf and tert-butyl ester removal via acidolysis and 
HCl salt formation  
A general procedure
97
 mentioned in Section 2.2.3 (Scheme 2.7) was employed, with 
modifications, for the deprotection of N-Boc alone and/or tert-butyl ester group at rt for 
4 h, and for all N-Boc and N-Pmc/Pbf containing intermediates at rt overnight. To form 
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the HCl salt, the residue was resuspended in a minimal volume of CH2Cl2 and the 
solution was then treated with an excess amount of 2 M HCl/ether (2 mL/0.01 mmol) 
solution and the solvent then evaporated. The product was purified by precipitation 
from CH2Cl2, with hexane and diethyl ether.  
 
In this thesis the Boc, tert-butyl and Pbf/Pmc protecting groups were cleaved using 
TFA. The cleavage mechanism is similar for both substituents (Schemes 2.7 and 4.2) 
and proceeds via protonation followed by heterolytic cleavage and release of a stable 
carbocation. The acid-labile nature of the Boc and Pbf/Pmc groups lies in their ability to 
stabilize the resultant cationic species – for Boc it is a result of the tert-butyl 
carbocation and for Pbf/Pmc it is the 2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran and 
2,2,5,7,8-pentamethylchromane respectively.
101,159
 The tertiary nature of the tert-butyl 
cation stabilizes the positive charge by donating electron density onto the tertiary carbon 
(Scheme 2.7). Release of the cationic species from the N-protected substrate results in a 
carbamic acid for the Boc mechanism and the deprotected guanidine product in the 
Pbf/Pmc mechanism (Schemes 2.7 and 4.2). In the Boc mechanism, proton transfer 
followed by decomposition of the deprotonated carbamic acid gives CO2 and the 
product amine as the TFA salt. In the Pbf/Pmc cleavage mechanism, the generated 
(alkylamino)(sulfonylamino)methaniminium undergoes decomposition to generate SO2 
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Scheme 4.2: Proposed mechanism for the acidolysis of an N-Pbf/Pmc group to give the product 
guanidine and by-products 
The simple acidolytic conditions required for removal of both the N-Boc and N-Pbf 
groups allowed for the isolation of the crude TFA salts by simple solvent removal. 
Solvent-aided anion-exchange with anhydrous HCl allowed for the simple isolation of 
the final compounds as the mono- or di-hydrochloride salts by precipitation from 
diethyl ether. The general procedure that was developed allowed for at least a full 14 h 
reaction time, even though the Boc protecting groups have been observed to be fully 
deprotected in as little as 15 min. The longer reaction time was implemented to ensure 
complete deprotection of the Pbf/Pmc group, as shorter reaction times have been 
observed to give incomplete acidolysis. Due to the volatility of the Boc deprotection by-
products, no resultant impurities were observed. The precipitation and repeated 
trituration of the final di-hydrochloride salt removes the majority of the 
benzofuran/chromene by-product. In the event of inefficient trituration, three small but 
distinctive peaks were noted in the 
1
H NMR spectrum between δ 2.00 – 2.20 that were 
assigned to the benzofuran/chromene by-product (3 x CH3). Overall, it was the relative 
ease, speed, and resultant product purity of the acidolytic deprotection method that 
allowed for the efficient turn-over of multiple derivatives. 
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4.2.3 From fullerenyldihydropyrrole derivatives towards fullerenyl 
peptides  
4.2.4 Amide coupling of carboxylic acid 198, followed by ester 
deprotection yielding carboxylic acid 242 
[60]Fullerenyl peptide 242 was prepared as shown in Scheme 4.3, from the fullerenyl 
carboxylic acid 198. 
 
Scheme 4.3: Synthesis of the fullerenyl amino acid 242. 
Under EDCI/HOBt amide coupling reaction conditions the fullerenyl carboxylic acid 
198 was found to readily couple to tert-butyl glycinate in CH2Cl2 at rt in 5 h. The 
solution was washed with water then the solvent was reduced in volume to 
approximately half before being applied directly to the top of a silica gel column. 
Elution with CH2Cl2 provided the fullerenyl peptide 241 in 48% yield, which was 
converted to the acid 242 by treatment of a solution of 241 in CH2Cl2 with TFA at rt for 
3 h (Scheme 4.3). Hexanes were then added and the precipitate was collected providing 
the acid 242 in 90% yield.  
Evidence for the successful coupling was provided by analysis of the 
1
H NMR spectrum 
of 241 which indicated loss of the resonance attributable to the carboxylic acid proton 
and the presence of a singlet, with a relative integration of 9H at  1.42, assigned to the 
tert-butyl protons. The presence of another singlet with an integration of 2H at δ 3.85 
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also provided strong evidence of the α-methylene protons of the tert-butyl glycine 
moiety. Analysis of the ESI-MS revealed an ion at m/z 1093 assigned as the sodiated 
molecular ion [(M+Na)
+ 
C81H22N2O3Na]. Successful deprotection of the tert-butyl 
group was provided by analysis of the 
1
H NMR spectrum of 242, which indicated loss 
of the resonance attributable to the tert-butyl group ( 1.42 (9H, s)) along with the 
appearance of a broad singlet, with a relative integration of 1H, at 8.56 attributed to 
the carboxylic acid proton. Analysis of the ESI-MS, which showed a base peak at m/z 
1015 assigned as the protonated molecular ion [(M+H)
+ 
C77H15N2O3]. 
4.2.5 Synthesis of the [60]fullereno tripeptide 243 
The crucial [60]fullerenyl tripeptide 243 was prepared as shown in Scheme 4.4, starting 
with the coupling reaction of the fullerenyl carboxylic acid compound 242 and the 
dipeptide 213.  
 
Scheme 4.4: Synthesis of [60]fullereno tripeptide.  
Under EDCI/HOBt amide coupling reaction conditions the fullerenyl acid 242 was 
found to readily couple to a TFA salt of dipeptide 213 in CH2Cl2 at rt in 5 h in 45% 
yield. However, optimisation of the yield of this peptide coupling reaction under HBTU 
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rather than EDCI/HOBt, resulted in better yield of 67% for compound 243, after 
purification by silica gel column chromatography. Analysis of the 
1
H NMR spectrum of 
243 showed a loss of the resonance attributable to the carboxylic acid proton and the 
presence of resonances for the characteristic protons of both the carboxylic acid 242 and 
amine 213. A multiplet at δ 3.43-3.44 (-CHNH2) in the 
1
H NMR spectrum of 213 was 
no longer observed in the spectrum of 243 but a broad singlet at δ 4.51 with an 
integration of 2H was assigned to the two lysine α-methine protons. This evidence 
indicated that the α-proton, adjacent to the primary amine in precursor 213, experienced 
a downfield shift as a result of the newly installed amide bond. Additionally, the 
13
C 
NMR spectrum showed a resonance at δ 171.7, assigned to the new amide carbonyl 
group. The molecular structure of the product was verified by the appearance of the 
peak at m/z 1778.4565 in the HRMS, that was assigned to the sodiated molecular 
formula ([M + Na]
+
 C122H62N6O9Na). 
4.2.6 Selective deallylation of tripeptide 243 using (CH3)3SnOH to 
provide carboxylic acid 244 
The [60]fullereno tripeptide 243 was treated with (CH3)3SnOH under the above 
mentioned reaction conditions to selectively hydrolyse the allyl ester to give the acid 
244 in 84% yield (Scheme 4.5) without any noticeable cleavage of the Fmoc carbamate 
protecting group. The acid 244 was then carried in to the subsequent reaction without 
any further characterisation, because of its poor solubility. 
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Scheme 4.5: Synthesis of the [60]fullereno tripeptide acid 244. 
4.2.7 Synthesis of novel tetrapeptide 245 from acid 244 under amide 
coupling conditions 
The synthesis of tetrapeptide  245 (Scheme 4.6) was realized in 62% yield after stirring 
a CH2Cl2 solution of the commercially available amine, (S)-isopentyl 2-amino-4-
methylpentanoate, and the acid derivative 244 with the coupling reagents EDCI and 
HOBt at rt for 4 h. Flash column chromatography followed by simple trituration from 
diethyl ether yielded the desired novel tetrapeptide product 245. 
 
Scheme 4.6: Synthesis of [60]fullereno tetrapeptide 245. Reagents and conditions: (a) isopentyl L-
leucinate hydrochloride, EDCI, HOBt, TEA, CH2Cl2, rt, 4 h. 
A broad singlet at δ 8.76 (-CHNH2) in the 
1
H NMR spectrum of (S)-isopentyl 2-amino-
4-methylpentanoate was no longer observed in the spectrum of 245 but a triplet 
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resonance for the isopentyl ester –OCH2  (δ 4.04 (2H, t, J = 6.5 Hz)) was observed. A 
multiplet at δ 4.11-4.17 for 4H was assigned to the leucine-α-methine proton including 
other protons, this evidence indicated that the α-proton, adjacent to the primary amine in 
precursor (S)-isopentyl 2-amino-4-methylpentanoate, experienced a downfield shift as a 
result of the newly installed amide bond. Additionally, the molecular structure of the 
product was verified by the appearance of a peak at m/z 1898.6011 in the HRMS, which 
was assigned to the protonated molecular formula ([M+H]
+
, C130H79N7O10). This 




4.2.8 Base-promoted N-Fmoc removal for the tetrapeptide 246, 
followed by HCl salt formation to give peptoid 247 
A solution of tetrapeptide 245 in piperidine/acetonitrile (1:9 v/v) was stirred overnight 
at rt to produce the free amine 246, which was carried forward to form the HCl salt by 
treatment with an excess amount of 1 M HCl/diethyl ether solution. The crude product 
was purified by precipitation from CH2Cl2, with hexane and diethyl ether (Scheme 4.7) 
to achieve a 70% yield of the hydrochloride salt 247. 
The molecular structure of this salt was verified by the appearance of a peak m/z 
1454.4750 in the HRMS, which was assigned to the protonated molecular formula 
([M+H]
+
, C100H59N7O6). Unfortunately, this compound was not sufficiently soluble to 




C NMR spectrum.  
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Scheme 4.7: Synthesis of [60]fullereno peptoid salt 247. Reagents and conditions: (a) piperidine, 
CH3CN, rt, 4 h; (g) 1 M HCl.Et2O, 0 °C-rt, 0.5 h. 
4.3 Strategy 2 
4.3.1 Proposed synthetic strategy for the synthesis of [60]fullereno 
peptoids 272-279.     
The synthesis of the second series of novel [60]fullereno peptoids 272-279 started from 
the previously mentioned 5,5-diphenylfullerenedihydropyrrole acid 198 and a variety of 
tri- and tetra-peptides was proposed in seven synthetic steps for the [60]fullereno 
pentapeptides, and six steps for the [60]fullereno tetrapeptides (Scheme 4.8). This 
strategy was adopted because of the relative ease of handling peptides in terms of 
solubility and purification without the fullerene moiety present, and additionally to 
minimise the exposure of the [60]fullerene containing peptide to acidic conditions, 
because of the possible cleavage of the [60]fullerene group especially under TFA 
reaction conditions.  
Chapter 4 
Synthesis of Mono and Bis[60]fullerene Based Di-Cationic Peptoids as 






Scheme 4.8 Retrosynthetic analysis for the synthesis of [60]fullereno tetra and pentapeptoids  from the 
known diphenylfullerenyldihydropyrrole acid 198, and amino acids 262, 269-271. 
4.3.2 Synthesis of the known dipeptides 250-253 and the Fmoc 
deprotected dipeptides 254-257 
The synthesis of the previously reported
94,96,97
 free amine containing dipeptides 254-257 
(Scheme 4.9) were achieved from commercially available starting materials 248 and 
249. Under EDCI/HOBt amide coupling reaction conditions the D/L-Arg-(Fmoc)-OH 
or D/L-Lys-(Boc)-OH acids were found to readily couple to free amines 248 and 249 in 
CH2Cl2 at rt in 5 h to produce dipeptides 250-253 in 65-75% yield. Fmoc deprotection 
of these compounds, then gave compounds 254-257, respectively. These compounds 
exhibited NMR spectroscopic data that closely matched with those previously 
reported.
94,96,97 
The yields for these individual reactions are summarised in Scheme 4.9. 
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Scheme 4.9: Reagents and conditions: (a) Fmoc-D-arg-(Pmc/Pbf)-OH, Fmoc-L-arg-(Pmc)-OH or 
Fmoc-D-lys(Boc)-OH, EDCI, HOBt, CH2Cl2, rt, 4 h; (b) piperidine, CH3CN, rt, 4 h. 
4.3.3 Synthesis of the tripeptides 258-261 and the Fmoc deprotected 
tripeptides 262-265 
Tripeptides 258-261 were prepared in 72-86% yields, by reacting 254-257 with Fmoc-D 
or L-Lys-(Boc)-OH under our standard amide coupling procedures (Section 2.2.2). 
Subsequent deprotection of the Fmoc group resulted in the compounds 262-265 in 
yields of 77-88%.  
 
Scheme 4.10: Reagents and conditions: (a) Fmoc-D or L-Lys-(Boc)-OH, EDCI, HOBt, CH2Cl2, rt, 4 h, 
79% for 258, 80% for 259, 86% for 260 and 72% for 261; (b) piperidine, CH3CN, rt, 4 h, 88% for 262, 
77% for 263, 84% for 264, and 85% for 265. 
A broad singlet at δ 8.62 (-CHNH2) in the 
1
H NMR spectrum of 254 was no longer 
observed in the spectrum of 258 but a signal appeared at δ 4.43-4.45 (m, 1H), that was 
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assigned to the arginine α-methine proton. This evidence indicated that the α-proton, 
adjacent to the primary amine in precursor 254, experienced a downfield shift as a result 
of the newly installed amide bond. Additionally, the 
1
H NMR singlet at δ 12.10 for the 
acid –OH in Fmoc-D-Lys-(Boc)-OH was absent in the 
1
H NMR spectrum of compound 
258.  Further analysis of the 
13
C NMR spectra showed a signal at δ 172.5, assigned to 
the new amide carbonyl. The molecular structure of the product was verified by the 
appearance of the peak at m/z 1074.0 in the ESI MS, that was assigned to the protonated 
molecular ion, [M + H]
+
.  
Analysis of the 
1
H NMR spectrum of amine 263 provided clear evidence for Fmoc 
deprotection as there was a notable absence of signals at approximately δ 4.10 (2H, m) 
and 4.32 (1H, t, J = 6.5 Hz) that were present in the spectrum of compound 259 and had 
been assigned to the three non-aromatic Fmoc protons (i.e. -OCH2-CH-Ar). 
Furthermore, two distinct multiplet resonances at δ 7.26-7.29 (2H, m) and δ 7.35-7.38 
(2H, m) in the spectrum of 259, assigned as aromatic Fmoc protons, were no longer 
observed. This indicated the successful removal of the fluorenyl moiety and its eight 
aromatic protons. Analysis of the 
13
C NMR data confirmed the absence of a deshielded 
methylene carbon signal at δ 67.4 and a methine carbon at δ 47.3 (assigned as the Fmoc 
CH2 and CH carbons, respectively), as well as four aromatic signals between δ 120.2-
144.1. The protonated molecular ion ([M + H]
+
) of 263 was assigned to the peak at m/z 
838.0 in the ESIMS.   
Chapter 4 
Synthesis of Mono and Bis[60]fullerene Based Di-Cationic Peptoids as 





4.3.4 Synthesis of the tetrapeptides 266-268 and the Fmoc deprotected 
tetrapeptides 269-271 
The tetrapeptides 266-268 were prepared in 71-82% yields, by the coupling reactions of 
263-265 with Fmoc-Gly-OH. Subsequent deprotection of their Fmoc groups resulted in 
the compounds 269-271, respectively in yields of 80-88% yield. 
 
Scheme 4.11: Reagents and conditions: (a) Fmoc-Gly-OH, EDCI, HOBt, CH2Cl2, rt, 4 h, 75% for 266, 
71% for 267 and 82% for 268; (b) piperidine, CH3CN, rt, 4 h, 80% for 269, 88% for 270, and 86% for 
271. 
A broad singlet at δ 6.29 (-CHNH2) in the 
1
H NMR spectrum of 263 was no longer 
observed in the spectrum of 266 but a signal appeared at δ 4.58 (1H, m), which was 
assigned to the lysine α-methine proton. This evidence indicated that the α-proton, 
adjacent to the primary amine in precursor 263, experienced a downfield shift as a result 
of the newly installed amide bond. Additionally, the 
1
H NMR signal at δ 12.50 for the 
acid –OH of Fmoc-Gly-OH had disappeared in the spectrum of compound 266.  Further 
to this the 
13
C NMR signal at δ 172.9 was assigned to the new amide carbonyl group. 
The molecular structure of the product was also supported by the appearance of the peak 




Analysis of the 
1
H NMR spectrum of amine 269 provided clear evidence for Fmoc 
deprotection as there was a notable absence of signals at δ 4.17 (t, J = 6.5 Hz, 1H) and 
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4.33 (d, J = 7.0 Hz, 2H) that were present in the spectrum of compound 266 and had 
been assigned to the three non-aromatic Fmoc protons (i.e. -OCH2-CH-Ar). 
Furthermore, a clear absence of two distinct doublet resonances at δ 7.57 (d, J = 6.5 Hz, 
2H) and δ 7.73 (d, J = 8.0 Hz, 2H) in the spectrum of 269, which were present in the 
spectrum of 266, and assigned as aromatic Fmoc protons.  This indicated the successful 
removal of the fluorenyl moiety and its eight aromatic protons. Analysis of the 
13
C 
NMR data of compound 269 was also conclusive by the absence of characteristic 
signals of deshielded methylene carbon at δ 67.4 and a methine carbon at δ 47.3 
(assigned as the Fmoc CH2 and CH carbons, respectively), as well as four aromatic 
signals between δ 121.9-144.3. The protonated molecular ion ([M + H]+) was assigned 
to the peak at m/z 895.6 in the ESIMS of 269 (Scheme 4.11).  
4.3.5 Synthesis of the [60]fullereno tetra and pentapeptides 272-275 
and their salts 276-279 
The protected fullerenyl peptoids 272-275 (Scheme 4.12) were successfully synthesised 
by coupling [60]fullerenyldihydropyrrole acid 198 with the presynthesised peptides 
269, 264, 270 and 271 under EDCI/HOBt peptide coupling conditions. In a typical 
example, the tetrapeptide 269 was added dropwise to a solution of acid 198 and HOBt 
in CH2Cl2, which was sonicated for 15 min. to aid solubility. EDCI was added at the 
same temperature and the reaction mixture was stirred for 4 h at room temperature. As 
the reaction progressed, the turbid solution transformed to a clear brown solution and 
upon workup, and the first-in-class [60]fullerenyl anchored tetrapeptide 272 was 
isolated. Synthesis of compound 273 was possible by coupling of the oxazole 
terminated tripeptide 264, and the tetrapeptide version of 270, with the extra glycine 
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amino acid in to the peptide chain producing 274. Coupling the acid 198 with peptide 
271, which contained two Boc protected lysines with an oxazole terminus, yielded 275. 
This reaction used CHCl3:CH2Cl2 (1:1) as a solvent due to better solubility of the diBoc 
protected lysine containing peptide whereas the synthesis of compounds 273 and 274 
only required CH2Cl2 as the single solvent (Scheme 4.12). 
To improve the solubility of the [60]fullerene based peptides for antibacterial testing, it 
was necessary to use them as dicationic salts, which were prepared using either TFA 
and/or 1 M HCl in diethyl ether. Peptides 273 and 274 were made as the HCl salts 277 
and 278, respectively, by treating them with TFA/CH2Cl2 (1:1) to deprotect the Pmc/Pbf 
and N-Boc functional groups. Then, after removing the solvents under reduced pressure, 
the residue was resuspended in a minimal volume of CH2Cl2 and treated with an excess 
1 M HCl in diethyl ether to obtain the targeted HCl salts. The peptides 272 and 275 
were made as their TFA salts 276 and 279 by treating them with TFA/CH2Cl2 (1:1) to 
deprotect the Pmc/Pbf and N-Boc groups (Scheme 4.12).  
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Scheme 4.12: Synthesis of C60 fullerenyl anchored amino acid oxazoles and iso pentyl esters. Reagents 
and conditions: (a) EDCI, HOBt, CH2Cl2, rt, 4 h; (b) TFA/ CH2Cl2 (1:1), rt, 16 h; (c) 1 M HCl.Et2O, 0-rt 
0.5 h. 
A broad singlet at δ 7.85 (-CHNH2) in the 
1
H NMR spectrum of 269 was no longer 
observed in the spectrum of 272 but a signal appeared at δ 4.28 (bs, 2H), assigned to the 
glycine methylene protons. This evidence indicated that the methylene, adjacent to the 
primary amine in precursor 269, experienced a downfield shift as a result of the newly 
installed amide bond. Additionally, a 
1
H NMR signal at δ 8.63 assigned to the acid –OH 
proton in [60]fullerenyldihydropyrrole acid 198 was not observed in compound 272.  
Further, the 
13
C NMR signal at δ 172.9 assigned to the new amide carbonyl group in 
272. The molecular structure of the product was verified by the appearance of the peak 
at m/z 1856.5916 in HRMS, that was assigned to the sodiated molecular formula ([M + 
Na]
+
, C118H83N9O11SNa) (Scheme 4.12).  
The salts 276-279 were characterised by HRMS, and additionally, compounds 276, 277 
and 278 returned 
1
H NMR spectra of good quality, but not the compound 279. 
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Unfortunately, due to the limited solubility of these salts, we were unable to obtain 
adequate 
13
C NMR spectra. 
The 
1
H NMR spectrum of the compound 276 lacked the prominent 9H peak at δ 1.42 
that was present in the spectrum of carbamate 272 and was assigned to the tert-butyl 
methyl protons. Furthermore, multiple diagnostic signals observed at δ 1.46, 2.08, 2.50, 
2.57 and 2.95 assigned to the Pbf protecting group of carbamate 272, were not observed 
in the 
1
H NMR spectrum of the final compound 276, indicating the successful removal 
of the Boc protecting group as well as Pbf group. HRMS analysis of compound 276 
showed a peak at m/z 1482.4717 that was assigned to the protonated molecular ion ([M 
+ H]+, C100H59N9O6).  
4.3.6 [60]Fullerenyl bispeptides 
Focus was then shifted to extending the carboxyl deprotection and coupling reactions, 
established on the mono-adducts (Section 4.3.1), to bisadducts (Scheme 4.13). 
Therefore, the synthesis of the tethered bisadduct 283 was performed using the 
previously reported procedures.
33,160
 Hydrolysis of ester group on the tethered bisadduct 
283 and subsequent amide coupling reaction with presynthesised peptide 262, was 
anticipated to give the first target bispeptide 285.  
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Scheme 4.13 Retrosynthetic analysis for the synthesis of [60]fullereno bispeptide of type 285 from the 
known diphenylfullerenyldihydropyrrole bisacid 284, and peptide 262. 
4.3.7 Regioisomerism  
In the formation of bis-methanofulleryl adducts, there are nine possible addition sites 
for functionalisation, assuming the reaction occurs across 6,6-fused bonds (Figure 
4.2).
161,162,163,164,165,166,167,168,169,170,171,172,173,174
  The basis for the positional algorithm is 
the contiguous numbering of carbon atoms of a [60]fullerene derivative in a spiral 
fashion.
171
 If the second addition occurs in the same hemisphere as the first, it is 
assigned the cis regiochemistry with the numbering scheme (cis-1, cis-2, cis-3) 
increasing as the second addend retreats from the first site of addition.  Trans 
regioisomers occur in the opposing hemisphere with the numbering scheme (trans-1, 
trans-2, trans-3, trans-4) increasing as the second addend approaches the first site of 
addition (Figure 4.2) (Table 4.1).   
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cis-1 32 4 CS 
cis-2 32 4 CS 
cis-3 30 0 C2 
e-face 60 0 CS 
e-edge 60 0 CS 
trans-1 8 0 D2h 
trans-2 30 0 C2 
trans-3 30 0 C2 
trans-4 32 4 CS 
Table 4.1: Summary of regioisomeric assignments for methanofullerene bisadducts, the number of 
observed fullerenyl 
13




4.3.8 Regioselective multifunctionalisation of [60]fullerene using 
tethered bis-N-(diphenylmethyleneglycinate) diesters 
4.3.8.1 Double Bingel reactions with bis-N-(diphenylmethylene 
glycinate) diesters 
The previously reported double Bingel reaction of 282
33,160
 with [60]fullerene was 
attempted using carbon tetrabromide (2.0 equiv.) and DBU (3.5 equiv.) (Scheme 4.14).  
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Purification and separation of the resulting products 283 and 286 was achieved by 
elution of the crude reaction mixture through two silica gel columns with 
CH2Cl2:petroleum spirit (90:10) as the eluent. Final recrystallizations of these 
regiosiomers yielded pure samples of 283 and 286 in 36% and 12%, yields, 
respectively.  The ESIMS spectrum of both 283 and 286 displayed a molecular ion at 
m/z 1298. 
 
Scheme 4.14 (a) DBU, CBr4, rt, toluene, C60, 6 h, 45%. 
The 
1
H NMR spectra of 283 and 286 revealed the loss of the methylene resonance (δ 
3.17) associated with the N-(diphenylmethyleneglycinate) ester (282) as a result of 
Bingel reaction.  Tether macrocyclisation induced the benzyl protons to become 
diastereotopic and these appeared as doublets [δ 5.06 and 5.71; J = 11.2 Hz for 283; δ 
5.32 and δ 5.41; J = 11.0 Hz for 286] in contrast to the singlet resonance (δ 5.09) of the 
starting material (282). 
The aromatic region of these bisfullerene derivatives exhibited a doubling up of 
resonances as a result of macrocyclisation.  As with the monosubstituted derivatives, the 
ortho protons (Ha) exhibit a characteristic downfield shift [(δ 7.92, 2H, d, J = 8.4 Hz 
and δ 8.04, 2H, d, J = 8.4 Hz for 283; δ 8.17, 2H, d, J = 7.6 Hz, δ 8.21, 2H, d, J = 7.6 
Hz for 286] compared to those corresponding protons in the starting material [282, (δ 
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7.64, 4H, dd, J = 8.4, 1.6 Hz)]. The 
13




4.3.8.2 Diester deprotection of 283 followed by amide coupling to 
synthesise [60]fullerenyl bispeptide 
We intended to synthesise fulleryl bispeptides by extension of the protocols of carboxyl 
deprotection and coupling reactions, established on the mono-adducts (Section 4.2.3), to 
bisadducts (Scheme 4.15). Therefore, a solution of 283 in 1,2-DCE was treated with 
(CH3)3SnOH at 80 
o
C for 24 h before being quenched with 5% HCl solution. The 
product bisacid 284 was then isolated as a brown solid. The previously reported
90
 BBr3 
mediated diester deprotection of 283 was also performed, but the former conditions 
((CH3)3SnOH) resulted in a better yield of 65% compared to that of 58% using BBr3.   
 
Scheme 4.15 (a) (CH3)3SnOH, DCE, 80 
o
C, 24 h, 65%. (b) BBr3, CH2Cl2, -10 
o
C - rt, 18 h, 58%. (c) 
pyridine/chloroform (1:2), EDCI, HOBt, 8 h, 50%. 
Analysis of the 
1
H NMR spectrum of bisacid 284 indicated the loss of the resonances 
attributed to the diastereotopic benzylic protons (δ 5.05 and 5.70). In addition, the 
aromatic region of the spectrum contained less peaks, notably the loss of the downfield 
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singlet (δ 7.18, 1H, s) assigned as the proton attached to C2 of the aromatic ring of the 
tether. In addition, the emergence of a broad singlet at δ 8.71, with a relative integration 
of 2H, indicated the presence of the carboxylic acid protons. ESIMS (+ve) analysis of 
compound 284 showed peaks at m/z 1195 (40%, [M+H]
+
) and 1200 (100%, [M+Li]
+
) 
which were assigned as the protonated molecular ion and the lithiated molecular ion, 
respectively.  
Attempts to synthesize the [60]fullerene bispeptoid 285 using the standard 
coupling reaction conditions developed in Section 4.2.5, failed, due to poor solubility of 
the bisadduct 284. No progress in the coupling reaction was observed even after longer 
reaction times and an increase in reaction temperature to 60 °C. Therefore, a change in 
solvent to a 1:2 ratio of pyridine/chloroform was used resulting in a 50% yield of the 
desired dipeptide 285 (Scheme 4.15). Unfortunately, attempted deprotection of 285 with 
TFA gave an insoluble product that could not be characterized. 
Confirmation of the structure of the bispeptide 285 was provided by analysis of 
its 
1
H NMR spectrum. The loss of the broad singlet at δ 8.71 (bs, 2H) corresponding to 
the carboxylic acid protons of 284 and the appearance of a broad 2H multiplet at δ 7.08, 
assigned to the amide protons of 285, indicating that the dipeptide had been formed. 
Furthermore, compound 285 showed a singlet (18H) at δ 1.28 ppm, assigned to the two 
Boc groups attached to the lysine side chains. The presence of a single peak for these 
two groups indicates that both peptide side chains are in an equivalent environment and 
this is consistent with the expected Cs symmetry of the trans-4 disubstituted [60]-
fullerene (Table 4.1).
175
 The presence of 30 sp
2
 resonances and 2 sp
3
 resonances (32 
signals in total) further confirms this symmetry. Analysis of the HRMS of 285 indicated 
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a peak at m/z 2884.1675, which was assigned to the sodiated species of 285, 
C174H164N16O20S2Na. 
4.3.9 Solubility and Antimicrobial Testing 
The solubilities of the dicationic salts 247, 276-279 in DMSO/H2O were determined 
(Table 4.2); they had relatively poor solubilities ranging from 70-350 μg/mL 
Table 4.2. Solubility of deprotected salts in DMSO/H2O 
Compound 
number 






















5% DMSO in 
H2O 
(70 μg/mL) 
As an initial screen for biological activity, the [60]fullerenyl peptides 243, 245, 272-275 
and 285 and the dicationic salts 247, 276-279 were subjected to in vitro antibacterial 
testing (Table 4.3) under the supervision of Prof. Thomas Riley at the University of 
Western Australia. These twelve [60]fullerene derivatives were tested using the broth 
microdilution method against Staphylococcus aureus NCTC 6571 and Escherichia coli 
ATCC 10418 with positive controls for E. coli NCTC 10418 being Kanamycin (4 
µg/mL) and chloramphenicol (2 µg/mL) while the positive controls used for S. aureus 
NCTC 6571 were Kanamycin (4 µg/mL) and Vancomycin (1 µg/mL). Unfortunately all 
fullerenyl-based compounds were inactive, even at higher concentrations, with 
minimum inhibitory concentrations (MICs) greater than 100 to 340 (µg/mL), which 
correlated well with their solubilities. 
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272 210 > 210 > 210 
273 340 > 340 > 340 
274 135 > 135 > 135 
275 135 > 135 > 135 
285 100 > 100 > 100 
243 315 > 315 > 315 
245 190 > 190 > 190 
276 165 > 165 > 165 
277 155 > 155 > 155 
278 100 > 100 > 100 
279 210 > 210 > 210 
247 210 > 210 > 210 
 
* Concentration may be an overestimation as compounds were not fully solubilised in DMSO at the 
highest test concentration, with the exception of compounds 247 and 279. 
4.3.10 Future directions and conclusions 
The synthesis of peptides anchored by [60]fullerenes was successful with a series 
of monosubstituted and disubstituted fullerene derivatives being realised. Although 
these derivatives did not show any substantial anti-bacterial activity, their synthesis has 
progressed the development of the important field of fullerenyl amino acids and peptide 
derivatives, in particular, their synthesis and isolation as peptide salts. This is 
highlighted by the modest solubility of the deprotected compounds in DMSO/water 
(Table 4.2) and the relative ease of purification of the protected fullerenyl peptides by 
column chromatography. Further, these fullerenyl amino acids have a more rigid, and 
thus more defined, tethered structure than most other fullerenyl peptides reported, which 
traditionally employ a flexible fullerene-peptide linkers. These more rigid properties 
could become increasingly important in the fields of medicinal chemistry or materials 
science. 
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This work can be applied to the potential synthesis of other bisadducts of the type 285, 
and trisadducts as well as their corresponding salts for the better aqueous solubility. 
 






Conclusions and Future Directions 
 This thesis has demonstrated the successful synthesis of [60]fullerenyl based  
peptides and oligomers (Chapters 2 and 3) that may have potential solar cell 
applications. We also demonstrated the synthesis and biological screening of dicationic 
peptoids (Chapter 4) as possible antibacterial agents. 
Chapter 2 has demonstrated the synthesis of the novel [60]fullerene monopeptide 201 
and dipeptide 204 (Figure 5.1). [60]Fullerenoproline acid  198 was coupled to lysine 
amine 200 to yield the monopeptide 201, which was deprotected to its amine salt 202 
using TFA and to its acid derivative 203 with Sn(CH3)3OH. An amide coupling reaction 
of the amine 202 and the acid 203 resulted in the dipeptide 204. Monopeptide 201 and 
the dipeptide 204 have been studied experimentally using spectroelectrochemical 
measurements with collaborators Prof. Timothy Clark and Prof. Dirk M. Guldi at the 
University of Erlangen-Nuremberg, Germany. The bis-fullerene-substituted peptide 204 
provided experimental support for density-functional theory (DFT) calculations which 
indicate that van der Waals fullerene dimers can form between adjacent fullerenes in 


















Figure 5.1: Structures of monopeptide 201 and dipeptide 204 
With the aim of preparing the tetrapeptide 207 (Figure 5.2), the dipeptide 204 was 
separately deprotected to the amine 205 and the acid 206. A range of amide coupling 
reaction conditions were employed to couple these two components. These reactions 
were not successful in providing a pure sample of the tetrapeptide 207. This material 
was difficult to purify and analyse because of its poor solubility properties.  
 
Figure 5.2: Structures of tetrapeptide 207 
An alternative synthesis of the tetrapeptide 207 was examined. The lysine tetrapeptide 
216 and its tetramine 217 (Figure 5.3) were successfully synthesised. Attempts to 
couple 217 with [60]fullerenoproline acid 198 to produce tetrapeptide 207 were also 
unsuccessful, possibly due to steric hindrance problems because of the sterically 
demanding fullerene groups.    






Figure 5.3: Structures of lysine tetrapeptide 216 and its tetramine 217 
Accordingly, it was postulated that the cyclic peptide tetrapeptide 220 (Figure 5.4) 
might help to solve these steric hindrance problems. Tetrapeptide 216 was successfully 
converted to the novel cyclic peptide 220 in three synthetic steps. However this route 
was not pursued because of the poor chemical yields and the difficulties with purifying 
220.  
 
Figure 5.4: Structures of cyclictetrapeptide 220  
 Chapter 3 reported an extension of [60]fullerenyl oligomers with the incorporation of 
spacers between the fullerenyl groups. Two types of amino acid spacers (L-lysine and 
L-phenylalanine) were introduced in to the oligomers (hexapeptide 227 and hexapeptide 
238, Figure 5.5). The synthesis of tripeptides with L-lysine spacers, 224, and L-
phenylalanine spacers 235 were achieved by coupling the acid 203 with the amine 213 
and the amine 202 with the acid 234, respectively. The previously used ester and N-Boc 





cleavage conditions were adopted to synthesise the corresponding acids (225 and 236) 
and amines (226 and 237) of 224 and 235 followed by amide couplings to provide the 
hexapeptides of 227 and 238. Currently, these molecules are under study to form 
supramolecular complexes between [60]fullerene and porphyrin, and photoinduced 




Figure 5.5: Structures of tripeptides 224 and 235, and hexapeptides 227 and 238 





Chapter 4 reported the synthesis and antibacterial screening of mono substituted 
[60]fullerenyl peptides (243, 245, 247, 272-279, Figure 5.6) and bis-[60]fullerenyl 
peptide (285). A range of tri, tetra and pentapeptides having an oxazole or isopentyl 
ester terminal group were synthesised. These peptides were then deprotected to form 
their HCl and TFA salts 247, 276-279. Antibacterial screening of these peptides (243, 
245, 247, 272-279 and 285) was performed at the University of Western Australia in 
Prof. Thomas Riley’s laboratory, unfortunately, none of these compounds showed 
significant activity.  















In future work, a cyclic peptide synthetic route leading to the synthesis of compound 
222 (Scheme 2.15, Chapter 2) followed by ring opening metathesis could be pursued 
depending on the availability of the starting material to achieve the tetrapeptide 207 in 
pure form.  
Density functional theory calculations indicate that van der Waals fullerene dimers and 
larger oligomers can form interstitial electron traps in which the electrons are even more 
strongly bound than in isolated fullerene radical anions. Spectroelectrochemical 
measurements on the bis-fullerene-substituted peptide 204 provide experimental 
support.  In the future, larger oligomers, including tetrapeptides 207, 227 and 238, could 
be studied for their spectroelectrochemical properties and these could possibly show 
better efficiencies as electron traps. 
Currently, studies on the formation of supramolecular complexes between our 
[60]fullerene-peptides (227 and 238) and porphyrin are going on in Prof. Fukuzumi’s 
laboratory at Osaka University, Japan. Based on the pending results, other spacers 
(Chapter 3) could be incorporated in to the [60]fullerene oligomer to which have less 
steric hindrance and are viable to synthesise in pure form to enhance the desired 
complexation and photoinduced charge separation properties. 






Scheme 5.1: Proposed synthetic strategy to achieve tetrapeptide 207 from the cyclic tetrapeptide 222. 
 
There is wide scope for the synthesis of a variety of peptides or peptidomimetic 
replacements to incorporate in to the [60]fullerene to form more water soluble peptoids 
(Chapter 4) of the type 286 and 287 (Figure 5.7), hopefully leading to increased 
antibacterial activities. Expansion of substitution on to the [60]fullerene to form tris 
adducts 288 can also be considered for the better solubility and biological activity.  






Figure 5.7: Structures of extended water soluble group incorporation in to the [60]fullerene mono, bis 
and tris peptides. 
 
Reductive ring opening of compounds 286, 287 and 288 followed by peptide coupling 
could provide ring-opened fullerenyl derivative 289, 290 and 291 (Scheme 5.2), which 
are consider to be true fullerenyl “capped” amino acids and could potentially provide 
better water solubilities and biological activities.  






Scheme 5.2: Proposed synthetic strategy of mono, bis and tris ring opened [60]fullerenyl “capped” 
peptides 289, 290 and 291.







6.1 General Experimental Procedures 
Reagents and solvents were purchased reagent-grade and used without further 
purification. Toluene and THF were distilled from sodium benzophenone ketyl under a 
nitrogen atmosphere. CH2Cl2 was stored over CaCl2 and distilled from CaH2. MeCN 
was distilled from potassium carbonate. [60]Fullerene was purchased from MER 
Corporation Tucson, Arizona AZ 85706, USA. All reactions were performed in 
standard glassware under an atmosphere of nitrogen unless otherwise specified. 
Microwave reactions were performed using a Discover CEM Focused Microwave 
Synthesis System in 10 mL closed vessels. Flash column chromatography was 
performed using silica 60 (230-400 mesh, 0.040-0.063 mm) purchased from Merck. 
Petroleum spirit refers to a hydrocarbon fraction with a boiling point of 40-60 
o
C. The 
mass spectra of a fullerenyl derivatives were run on a Thermo Finnigan LTQ (Waltham, 
MA) fitted with a conventional IonMax electrospray ionization source. Spectra were 
obtained by infusion of a standard solution in CHCl3/MeOH (2:1). Typical settings were 
spray voltages between 4 – 6 kV, capillary temperature 270 
o
C and sheath gas flow rates 
at 10 (arbitrary units). High resolution mass spectra were obtained using a QTOF mass 
spectrometer. 
1
H NMR spectra were acquired on a Varian Unity 300 or 500 
spectrometer at 300.1 and 499.9 MHz, respectively. 
13
C NMR spectra were acquired on 
Varian Unity 300 or 500 spectrometer at 75.4 and 125.0 MHz, respectively. Deuterated 
solvents CDCl3, CD3OD, (CD3)3SO were obtained commercially (Sigma-Aldrich or 





Cambridge) and were greater than 99.5 atom % d. All chemical shifts are reported 
relative to TMS (δ 0.00). 
1
H NMR spectral data are listed in the following order, chemical shift, multiplicity, 
integration, J value, and assignment. All fullerenyl carbon signals were reported as 
either a full resonance, (e.g. 148.0), or as a half-intensity peak denoted by a * or as an 
integer of a full resonance when there is peak overlap (e.g. 148.0, (2 x C)). When a 
reference is provided in the compound title it signifies that this reference procedure was 
used. Conversely, when a reference is provided with NMR spectroscopic data it 
signifies that our data is in agreement with those already reported using a different 
procedure. 
Melting points (m.p.) were determined using a Gallenkamp (Griffin) melting point 
apparatus. Temperatures are expressed in degrees Celsius (°C) and are uncorrected. 
Optical rotations were measured using a Jasco polarimeter with a 10 mm path length 
and a wavelength of 589 nm. Concentrations are expressed as c (10 mg/mL). Infrared 
(IR) spectra were recorded using neat samples on a Nicolet Avatar 360 FT-IR 
spectrometer fitted with a Smart Omni-Sampler germanium crystal accessory. 
Protocol 1: Peptide coupling 
To a solution of the acid in CH2Cl2 (10 mL/0.10 mmol) at rt was added EDCI (1.2 
equiv.), HOBt (1.2 equiv.), and the amine (1 equiv.). If the amine was a hydrochloride 
or TFA salt, Et3N (1.2 equiv.) was also added. After stirring for 3-6 h, the solvent was 
removed under reduced pressure, and then the resulting residue was subjected to silica 
gel column chromatography MeOH/CH2Cl2 (0.5:99.5-1:99 for peptides and 1:49-1:4 for 
C60 attached peptides) as the eluent to afford the coupled product.  
 





Protocol 2: N-Fmoc deprotection 
The Fmoc-protected amine was stirred in 1 equiv. of piperidine/acetonitrile (5 mL/0.10 
mmol) overnight at rt, unless otherwise stated. The solvent was removed under reduced 
pressure and the residue was subjected to column chromatography, using 
MeOH/CH2Cl2 (1:19) to yield the free amine.  
Protocol 3: N-Boc, Pbf and Pmc deprotection 
The N-Boc, Pbf or Pmc protected amine was stirred for 4 h (for Boc) or overnight (for 
Pbf and Pmc) in 1:1 CH2Cl2/TFA (6 mL/0.10 mmol) solution at rt. The solvent was 
removed under reduced pressure, and the residue was resuspended in a minimal volume 
of CH2Cl2. The solution was then treated with an excess amount of 1 M HCl/diethyl 
ether (2 mL/0.01 mmol) solution and the solvent evaporated. The product was obtained 
by precipitation from CH2Cl2, with hexane and/or diethyl ether. 
Protocol 4: Allyl and bis-1,3-benzyl ester hydrolysis 
To a solution of the ester in 1,2-dichloroethane (100 mL/0.10 mmol) at rt was added 
Sn(CH3)3OH (4 equiv.) and the solution was heated at 80 
o
C for 4 h, then further 
Sn(CH3)3OH (4 equiv.) was added at the same temperature and the reaction was 
continued for 4 h. The reaction mixture was evaporated under reduced pressure and the 
resulting residue was taken up in CH2Cl2 (15-20 mL). The organic layer was washed 
with 5% HCl (3 x 10-15 mL), brine (3 x 10 mL) dried (Mg2SO4) and evaporated under 

















(1.20 g, 2.56 mmol) in CH2Cl2 (50 mL) was added HOBt 
(0.415 g, 3.07 mmol) and EDCI (0.587 g, 3.07 mmol) and 
the mixture was stirred for 15 min before a solution of allyl 
alcohol (1.74 mL, 25.6 mmol) in CH2Cl2 (10 mL) was added dropwise. The resulting 
solution was stirred at rt for 14 h before the solvent was removed under reduced 
pressure. The crude residue was then subjected to flash silica gel chromatography, 
gradient elution with EtOAc/hexane (1:9 to 1:1) provided the title compound 199 as a 
colourless solid (0.954 g, 73%). m.p: 118-120 
°
C; 25]α[ D  -32.8 (c 4.16, CHCl3); IR (neat, 
cm
-1
): 3331 (w), 1722 (s), 1679 (s), 1530 (s);
 1
H NMR (500 MHz, CDCl3): δ 1.39-1.40 
(m, 2H, CHCH2CH2), 1.44 (s, 9H, Boc), 1.49-1.56 (m, 2H, CH2CH2NH), 1.62-1.70 (m, 
1H, CHCHHCH2), 1.80-1.84 (m, 1H, CHCHHCH2), 3.18-3.19 (m, 2H, CH2N (Lys)), 
4.21 (t, J = 6.3 Hz, 1H, CH (Fmoc)), 4.32 (bs, 1H, Lys-α-proton), 4.40 (d, J = 6.3 Hz, 
2H, OCH2 (Fmoc)), 4.61-4.64 (m, 2H, OCH2), 4.81 (bs, 1H, NHBoc), 5.04 (bs, 1H, 
NHFmoc), 5.25 (d, J = 10.5 Hz, 1H,  CH=CH(Z)H), 5.32 (d, J = 17.5 Hz, 1H,  
CH=CH(E)H), 5.89-5.90 (m, 1H, CH=CH2), 7.31 (t, J = 7.0 Hz, 2H, ArCH), 7.39 (t, J = 
7.5 Hz, 2H, ArCH), 7.59 (d, J = 7.5 Hz, 2H, ArCH), 7.76 (d, J = 7.5 Hz, 2H, ArCH); 
13
C NMR (CDCl3, 125 MHz): δ 22.8 (CHCH2CH2), 28.2 (C(CH3)3), 29.0 (CH2CH2NH), 
32.4 (CHCH2CH2), 39.8 (CH2NH), 47.2 (CH (Fmoc)), 53.2 (COCHNH), 65.8 
(CH2CH=CH2), 66.5 (CH2 (Fmoc)), 79.9 (C(CH3)3), 118.9 (CH=CH2), 120.3 (2 x 
ArCH), 125.1 (2 x ArCH), 128.4 (2 x ArCH), 129.7 (2 x ArCH), 131.5 (CH=CH2), 





141.3 (2 x ArC), 142.5 (2 x ArC), 156.2 (CO (Boc)); 162.1 (CONH), 172.3 (CO, ester); 
HRMS (ESI +ve) calcd for C29H36N2O6Na, 531.2471, found 531.2446. 
(S)-Allyl 6-amino-2-(tert-butoxycarbonyl)aminohexanoate (200) 






(0.52 g, 1.02 mmol) in acetonitrile (30 mL) was added piperidine 
(0.072 mL, 1.22 mmol) and the mixture was stirred at rt for 14 h before the solvent was 
removed under reduced pressure. The residue (0.292 g, 100%) was then taken through 





This compound was prepared via protocol 1 using 5,5-
diphenylfullerenyldihydropyrrole-2-carboxylic acid 198 
(0.180 g, 0.187 mmol) and (S)-allyl 6-amino-2-(tert-
butoxycarbonyl)aminohexanoate  200 (0.064 g, 0.224 mmol) 
to yield the title compound 201 as a brown solid (0.142 g, 
62%). 
1
H NMR (500 MHz, CDCl3): δ 1.23-1.25 (m, 2H, CHCH2CH2), 1.44 (s, 9H, 
Boc), 1.48-1.58 (m, 2H, CH2CH2NH), 1.68-1.82 (m, 2H, CHCH2CH2), 3.52-3.58 (m, 
2H, CH2N (Lys)), 4.36 (bs, 1H, Lys-α-proton), 4.58-4.64 (m, 2H, OCH2), 5.04 (bs, 1H, 
NHBoc), 5.28 (d, J = 10.0 Hz, 1H, CH=CH(Z)H), 5.30 (d, J = 17.0 Hz, 1H, 
CH=CH(E)H), 5.84-5.94 (m, 1H, CH=CH2), 7.42 (t, J = 7.5 Hz, 2H, ArCH), 7.53 (t, J = 
7.5 Hz, 4H, ArCH);  7.88 (bs, 1H, NH), 8.43 (d, J = 7.5 Hz, 4H, ArCH); 
13
C NMR 
(CDCl3, 125 MHz): δ 22.8 (CHCH2CH2), 28.2 (C(CH3)3), 29.0 (CH2CH2NH), 32.4 










), 95.3 (CPh2), 118.9 (CH=CH2), 128.4 (2 x ArCH), 129.7 
(ArCH), 131.5 (CH=CH2), 134.7 (ArC), [136.5, 139.0, 139.5, 140.8, 141.2, 141.7, 
141.76, 141.8, 142.3, 142.5, 142.6, 142.7, 142.9, 144.0, 144.3, 144.8, 145.0, 145.1, 
145.3 (2 x C), 145.4, 145.7, 145.9, 146.0, 146.3, 146.8*, 147.0*, 148.5, 149.1, 153.1 
(C60sp
2
)]; 155.3 (C=N), 161.2 (CO, Boc); 162.1 (CONH), 172.3 (CO, ester); HRMS 
(ESI +ve) calcd for C89H35N3O5Na, 1248.2474, found 1248.2494.  
(S)-6-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonylamino)-1-(allyloxy)-1-
oxohexan-2-aminium 2,2,2-trifluoroacetate (202) 
 This compound was prepared via protocol 3, using 201 
(0.10 g, 0.081 mmol) to afford the title compound 202 
(0.082 g, 90%) as a fine brown solid. 
1
H NMR (CDCl3, 
500 MHz): δ 1.25-1.28 (m, 2H, CHCH2CH2), 1.46-1.62 
(m, 2H, CH2CH2NH), 1.78-1.82 (m, 2H, CHCH2CH2), 
3.45-3.56 (m, 2H, CH2N (Lys)), 4.06 (bs, 1H, Lys-α-
proton), 4.62 (bs, 2H, OCH2), 5.25-5.38 (m, 2H, CH=CH2), 5.80-5.92 (m, 1H, 
CH=CH2), 7.40 (t, J = 7.5 Hz, 2H, ArCH), 7.51 (t, J = 7.5 Hz, 4H, ArCH), 7.84 (bs, 1H, 
NH), 8.02 (d, J = 7.5 Hz, 4H, ArCH); ESI-MS (+ve): m/z 1126 (100%, M+H
+
). This 
compound was not sufficiently soluble to generate an adequate 
13










carbonyl)aminohexanoic acid (203) 
 The titled compound was prepared via protocol 4 using 
201 (0.080 g, 0.065 mmol), 1,2-dichloroethane (80 mL) 
and (CH3)3SnOH (0.047 g, 0.260 mmol x 2) to yield the 
title 203  as a brown solid (0.068 g, 88%). 
1
H NMR (500 
MHz, CDCl3): δ 1.23-1.25 (m, 2H, CHCH2CH2), 1.45 (s, 
9H, Boc), 1.49-1.59 (m, 2H, CH2CH2NH), 1.66-1.82 (m, 
2H, CHCH2CH2), 3.50-3.60 (m, 2H, CH2N (Lys)), 4.38 (bs, 1H, Lys-α-proton), 5.02 
(bs, 1H, NHBoc), 7.40 (t, J = 7.5 Hz, 2H, ArCH), 7.56 (t, J = 7.5 Hz, 4H, ArCH);  7.88 
(bs, 1H, NH), 8.02 (d, J = 7.5 Hz, 4H, ArCH); HRMS (ESI +ve) calcd for 
C86H31N3O5Na, 1208.2161, found 1208.2145. This compound was not sufficiently 
soluble to generate an adequate 
13




This compound was prepared via protocol 
1, using 202 (0.056 g, 0.047 mmol) and 203 
(0.053 g, 0.047 mmol) 0.056 mmol) to yield 
the title compound as a brown solid (0.062 
g, 57%). 
1
H NMR (500 MHz, CDCl3): δ 
1.08-1.18 (m, 2H, CHCH2CH2), 1.20-1.30 
(m, 2H, CHCH2CH2), 1.45 (s, 9H, Boc), 1.48-1.58 (m, 4H, CH2CH2NH), 1.60-1.98 (m, 
4H, CHCH2CH2), 3.40-3.58 (m, 4H, CH2N (Lys)), 4.06 (bs, 1H, Lys-α-proton), 4.58-





4.68 (m, 3H, OCH2 and Lys-α-proton), 5.04 (bs, 1H, NHBoc), 5.28 (d, J = 10.5 Hz, 1H,  
CH=CH(Z)H), 5.30 (d, J = 17.0 Hz, 1H, CH=CH(E)H), 5.82-5.94 (m, 1H, CH=CH2), 
6.68 (bs, 1H, NH), 7.40 (t, J = 7.5 Hz, 4H, ArCH), 7.48-7.58 (m, 8H, ArCH);  7.80-7.98 
(m, 2H, 2 x NH), 8.08 (d, J = 7.5 Hz, 8H, ArCH); 
13
C NMR (CDCl3, 125 MHz): δ 22.8 
(CHCH2CH2), 23.0 (CHCH2CH2), 28.6 (C(CH3)3), 29.0 (CH2CH2NH), 29.2 
(CH2CH2NH), 32.4 (CHCH2CH2), 40.0 (2 x CH2NH), 52.1 (NHCHCO), 66.3 (OCH2), 




), 95.6 (CPh2), 119.3 (CH=CH2), 128.7 (2 
x ArCH), 130.0 (ArCH), 131.6 (CH=CH2), 135.0 (ArC), [136.6, 139.3, 139.8, 141.1, 
141.5, 142.01, 142.04, 142.1, 142.6, 142.7, 142.97, 143.0, 143.1, 144.3, 144.5, 145.0, 
145.3, 145.6, 145.7 (2 x C), 146.0, 146.2, 146.3*, 146.5*, 147.1, 147.3, 148.8, 149.4, 
149.42, 153.4 (C60sp
2
)],; 155.3 (C=N), 161.6 (CO, Boc), 161.7 (CONH), 162.7 




oxohexan-2-ammonium trifluoroacetate (205) 
This compound was prepared via 
protocol 3, using 204 (0.025 g, 0.010 
mmol) to afford the title compound 205 
(0.020 g, 86%) as a amorphous brown 
solid. 
1
H NMR (CDCl3, 500 MHz): δ 
1.21-1.35 (m, 4H, CHCH2CH2), 1.58-
1.90 (m, 8H, CH2CH2NH and CHCH2CH2), 3.35-3.58 (m, 6H, 2x CH2N (Lys), 2 x Lys-
α-proton), 4.60-4.62 (m, 2H, OCH2), 5.28 (d, J = 10.5 Hz, 1H,  CH=CH(Z)H), 5.30 (d, J 





= 17.0 Hz, 1H, CH=CH(E)H), 5.82-5.94 (m, 1H, CH=CH2), 7.38-7.58 (m, 4H, ArCH), 
7.60-7.68 (m, 8H, ArCH), 7.78-7.98 (m, 2H, NH), 8.02-8.06 (m, 8H, ArCH); HRMS 
(ESI +ve) calcd for C165H48N6O5, 2193.3794, found 2193.3764. This compound was not 
sufficiently soluble to generate an adequate 
13
C NMR spectrum. 
(S)-6-((5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl)amino)-2-((S)-6-((5,5-
diphenylfullerenyldihydropyrrole-2-carbonyl)amino)-2-((tert-
butoxycarbonyl)amino)hexanamido)hexanoic acid (206) 
 This compound was prepared via protocol 
4, using 204 (0.025 g, 0.010 mmol), 1,2-
dichloroethane (30 mL) and (CH3)3SnOH 
(0.008 g, 0.04 mmol x 2) to yield the title 
compound 206 (0.018 g, 75%) as a brown 
solid. 
1
H NMR (500 MHz, CDCl3): δ 1.21-
1.35 (m, 4H, CHCH2CH2), 1.44 (s, 9H, Boc), 1.58-1.90 (m, 8H, CH2CH2NH and 
CHCH2CH2), 3.35-3.38 (m, 4H, CH2N (Lys)), 4.08 (bs, 1H, NH), 4.38 (bs, 2H, Lys-α-
proton), 5.04 (bs, 1H, NHBoc), 7.41-7.42 (m, 4H, ArCH), 7.50-7.53 (m, 8H, ArCH);  
7.88 (bs, 1H, NH), 8.02-8.07 (m, 8H, ArCH); ESI-MS (+ve): m/z 2254 (50%, M+H
+
), 
2276 (100%, M+Na). This compound was not sufficiently soluble to generate an 
adequate 
13













This compound was prepared via protocol 1, using 205 (0.022 g, 0.010 mmol) and 206 







H NMR (500 MHz, CDCl3): δ 1.08-1.18 (m, 4H, CHCH2CH2), 1.22-1.38 (m, 4H, 
CHCH2CH2), 1.44 (s, 9H, Boc), 1.48-1.98 (m, 16H, CH2CH2NH and CHCH2CH2), 
3.20-3.64 (m, 8H, 4 x CH2N (Lys)), 4.02 (bs, 1H, Lys-α-proton), 4.12 (bs, 1H, Lys-α-
proton), 4.26 (bs, 1H, Lys-α-proton), 4.56-4.58 (m, 3H, OCH2 and Lys-α-proton), 4.80 
(bs, 1H, NH), 4.98 (bs, 2H, NH), 5.25 (d, J = 9.0 Hz, 1H, CH=CH(Z)H), 5.27 (d, J = 
17.0 Hz, 1H, CH=CH(E)H), 5.82-5.92 (m, 1H, CH=CH2), 7.32-7.37 (m, 8H, ArCH), 
7.48-7.50 (m, 16H, ArCH);  7.80-7.84 (m, 4H, 4 x NH), 8.01 (d, J = 7.5 Hz, 16H, 
ArCH); This compound was not sufficiently soluble to generate an adequate 
13
C NMR 
spectrum and not sufficiently soluble in MeOH to generate an adequate ESI-MS. 
 












yl)methoxy)carbonyl)-L-lysinate (500 mg, 1.22 
mmol) and Fmoc-(S)-Lys(Boc)-OH (573 mg, 
1.22 mmol) to yield the desired product 212 as a 
white foam (920 mg, 87%). IR (neat, cm
-1
): δ 
3302 (w), [1665, 1662, 1641, 1558 (s)], 1507, 1198, 1131 (m); 
1
H NMR (500 MHz, 
CDCl3): 1.29-1.39 (m, 4H, CHCH2CH2), 1.42 (s, 9H, Boc), 1.50-1.51 (m, 4H, 
CH2CH2NH), 1.62-1.68 (m, 2H, CHCH2CH2), 1.85-1.86 (m, 2H, CHCH2CH2), 3.16-
3.17 (bs, 4H, CH2N (Lys)), 4.12 (bs, 1H, Lys-α-proton), 4.18 (bs, 1H, Lys-α-proton), 
4.19-4.20 (m, 2H, 2 x CH (Fmoc)), 4.37 (d, J = 6.5 Hz, 2H, CH2CH (Fmoc)), 4.41 (d, J 
= 7.0 Hz, 2H, CH2CH (Fmoc)), 4.57-4.61 (m, 3H, CH2CH=CH2 and NH), 4.97 (bs, 1H, 
NH), 5.03 (bs, 1H, NH), 5.22 (d, J = 10.5 Hz, 1H,  CH=CH(Z)H), 5.29 (d, J = 17.5 Hz, 
1H, CH=CH(E)H), 5.82-5.90 (m, 1H, CH=CH2), 6.75 (bs, 1H, NH), 7.29 (t, J = 7.5 Hz, 
4H, ArCH), 7.38 (t, J = 7.5 Hz, 4H, ArCH), 7.57-7.60 (m, 4H, ArCH), 7.75 (d, J = 7.5 




dioxa-4,10,17-triazaicosan-12-ammonium trifluoroacetate (213) 
This compound was prepared via protocol 3, using 212 (150 mg, 0.174 mmol) to yield 
213 as a white foam (110 mg, 90%). IR (neat, cm
-1
): 3309 (w), [1667, 1662, 1635 (s)], 
1194 (m), 1135 (m); 
1
H NMR (500 MHz, CDCl3): δ 1.34-1.46 (m, 4H, CHCH2CH2), 





1.53 (m, 4H, CH2CH2NH), 1.59 (bs, 2H, 
CHCH2CH2), 1.74-1.77 (m, 2H, CHCH2CH2), 
3.12 (bs, 1H, Lys-α-proton), 3.18-3.20 (m, 4H, 
CH2N (Lys)), 3.43-3.44 (m, 2H, NH2), 4.12 (bs, 
1H, Lys-α-proton), 4.20 (t, J = 6.5 Hz, 2H, 
CH2CH (Fmoc)), 4.40 (d, J = 6.5 Hz, 4H, 2 x 
CH2CH (Fmoc)), 4.57 (bs, 1H, NH), 4.61 (d, J = 5.5 Hz, 2H, CH2CH=CH2), 4.86 (bs, 
2H, NH), 5.24 (d, J = 10.5 Hz, 1H,  CH=CH(Z)H), 5.32 (d, J = 17.0 Hz, 1H, 
CH=CH(E)H), 5.88-5.94 (m, 1H, CH=CH2), 7.30 (t, J = 7.5 Hz, 4H, ArCH), 7.39 (t, J = 
7.5 Hz, 4H, ArCH), 7.58 (d, J = 7.5 Hz, 4H, ArCH);  7.76 (d, J = 7.5 Hz, 4H, ArCH). 






 This compound was prepared via protocol 
1, using (S)-6-((((9H-fluoren-9-
yl)methoxy) carbonyl)amino)-2-(tert-
butoxycarbonyl) amino hexanoic acid 
(0.150 g, 0.320 mmol) and (9S,12S)-9-
((allyloxy)carbonyl)-1,20-di-(9H-fluoren-9-yl)-3,11,18-trioxo-2,19-dioxa-4,10,17-
triazaicosan-12-aminium 2,2,2-trifluoroacetate 213 (0.242 g, 0.320 mmol) to afford the 
title compound 214 as a white solid (0.325 g, 83%). m.p: 147-149 ºC;  25]α[ D  -44.6 (c 
3.18, CHCl3); IR (neat, cm
-1
): 3329 (w), [1719, 1679, 1532 (s)]; 
1
H NMR (500 MHz, 
DMSO-d6): δ 1.18-1.33 (m, 6H, CHCH2CH2), 1.30 (s, 9H, Boc), 1.40-1.48 (m, 6H, 





CH2CH2NH), 1.48-1.68 (m, 6H, CHCH2CH2), 2.88-2.89 (m, 6H, CH2N(Lys)), 3.92 (bs, 
1H, NH), 4.14-4.15 (m, 6H, 3 x CH2CH (Fmoc) and 3 x Lys-α-protons), 4.22 (bs, 6H, 3 
x CHCH2 (Fmoc)), 4.48 (bs, 2H OCH2), 5.13 (d, J = 10.5 Hz, 1H, CH=CH(Z)H), 5.22 
(d, J = 17.0 Hz, 1H, CH=CH(E)H), 5.78-5.82 (m, 1H, CH=CH2), 6.72 (bs, 1H, NH), 
6.81 (bs, 1H, NH), 7.18 (t, J = 7.0 Hz, 2H, ArCH), 7.26 (t, J = 7.0 Hz, 6H, ArCH);  7.35 
(t, J = 7.0 Hz, 6H, ArCH), 7.58 (bs, 1H, NH), 7.60-7.62 (m, 4H, ArCH),  7.67 (d, J = 
8.0 Hz, 1H), 7.82 (d, J = 7.0 Hz, 6H, ArCH), 8.22 (bs, 2H, NH); ESI-MS (+ve): m/z 
1231 (100%, M+Na
+
). This sample turned into a gum over a period of time, so without 
measuring the 
13




4,10,13,20-tetraazatricosan-15-ammonium trifluoroacetate (215) 
 This compound was prepared via 
protocol 3, using 214 (0.300 g, 0.248 
mmol) to afford the title compound 
215 (0.270 g, 98%) as a colourless 
solid initially which became a 
gummy mass. This material was taken for the next reaction by characterising only by 












 This compound was 





butoxycarbonyl)aminohexanoic acid 210 (0.105 g, 0.225 mmol) and 215 (0.250 g, 0.225 
mmol) to afford the title compound 216 as an off white solid (0.249 g, 70%). m.p: 136-
138 ºC; 25]α[ D  -37.2 (c 2.48, CHCl3); IR (neat, cm
-1
): 3330, 1718, 1680, 1537;  
1
H NMR 
(500 MHz, DMSO-d6): δ 1.12-1.30 (m, 8H, CHCH2CH2), 1.29 (s, 9H, Boc), 1.32-1.48 
(m, 8H, CH2CH2NH), 1.50-1.68 (m, 8H, CHCH2CH2), 2.88 (bs, 8H, CH2N(Lys)), 3.82 
(bs, 1H, NH), 4.12-4.14 (m, 8H, 4 x CH2CH (Fmoc), and 4 x Lys-α- protons), 4.16-4.22 
(m, 8H, 4 x CHCH2 (Fmoc)), 4.46 (bs, 2H CH2CH=CH2), 5.11 (d, J = 10.5 Hz, 1H, 
CH=CH(Z)H), 5.21 (d, 1H, J = 17.5 Hz, CH=CH(E)H), 5.78-5.82 (m, 1H, CH=CH2), 
6.82 (d, 1H, J = 7.5 Hz, NH), 6.81 (bs, 1H, NH), 7.17 (m, 4H, ArCH), 7.25 (t, J = 7.5 
Hz, 8H, ArCH);  7.33 (t, J = 7.5 Hz, 8H, ArCH), 7.55 (bs, 1H, NH), 7.60 (d, J = 7.0 Hz, 
6H, ArCH),  7.70 (bs, 2H, NH), 7.81 (d, J = 7.5 Hz, 6H, ArCH), 8.18 (bs, 2H, NH); 
13
C 
NMR (125 MHz, DMSO-d6): δ 22.5 (CHCH2CH2), 28.3 (C(CH3)3), 29.0 (CHCH2CH2), 
29.3 (CH2CH2NH), 31.6 (CHCH2CH2), 38.4 (4 x CH2NH (Lys)), 47.2 (CH2CH 
(Fmoc)), 55.0 (NHCHCO, Lys α carbon), 64.9 (CH2CH=CH2), 65.1 (CH2CH (Fmoc)), 
78.2 (C(CH3)3), 109.8, 117.9 (CH=CH2), 120.2 (8 x ArCH), 121.5 (8 x ArCH), 123.3 





(ArCH), 127.4 (8 x ArCH), 129.1 (8 x ArCH), 132.5 (CH=CH2), 137.5 (8 x ArC), 139.5 
(4 x ArC), 142.7 (4 x ArC), 152.8 (2 x CONH), 155.5 (CO, Boc), [158.2 (3 x CO), 
169.1, 171.8 (CONH)], 172.3 (CO, ester); HRMS (ESI +ve) calcd for C92H102N8O15Na, 
1581.7362, found 1581.7362. 
Allyl (6S,9S,12S,15S)-6,9,12,15-tetrakis(4-aminobutyl)-2,2-dimethyl-4,7,10,13-
tetraoxo-3-oxa-5,8,11,14-tetraazahexadecane-16-oate (217) 
This compound was 
prepared via protocol 2, 
using 216 (0.050 g, 0.032 
mmol) to afford a crude product (0.021 g, 100%), which was then taken through the 











This compound was prepared via protocol 3, using 216 (0.300 g, 0.248 mmol) to afford 
the title compound 218 (0.270 g, 98%) as a gummy mass. This material was carried 
forward to the subsequent reaction. ESI-MS (+ve): m/z 1459 (100%, M+H
+
). 








 This compound was 
prepared via protocol 1, 
using acrylic acid (0.051 g, 
0.684 mmol) and 218 (0.250 
g, 0.171 mmol) to afford the 
title compound 219 as an off 
white solid (0.194 g, 75%). 
1
H NMR (500 MHz, (CDCl3/CD3OD (1:1)): δ 1.26-1.30 (m, 
8H, CHCH2CH2), 1.32-1.48 (m, 8H, CH2CH2NH), 1.55-1.82 (m, 8H, CHCH2CH2), 
3.11-3.18 (bs, 8H, CH2N(Lys)), 3.60 (bs, 1H, NH), 4.17-4.23 (m, 8H, 4 x CH2CH 
(Fmoc) and 4 x Lys-α protons), 4.35 (bs, 2H, CHCH2 (Fmoc)), 4.47 (bs, 6H, CHCH2 
(Fmoc)), 4.56 (bs, 2H OCH2), 5.20-5.33 (m, 2H, CH=CH2), 5.63-5.65 (m, 1H, 
CH=CH2), 5.81-5.83 (m, 1H, CH=CHH), 6.06-6.20 (m, 1H, CH=CHH), 6.25-6.28 (m, 
1H, CH=CHH), 7.28-7.29 (m, 6H, ArCH), 7.36-7.37 (m, 8H, ArCH), 7.39 (d, J = 7.0 
Hz, 6H, ArCH),  7.58 (d, J = 7.5 Hz, 6H, ArCH), 7.74 (d, J = 7.5 Hz, 6H, ArCH); 
13
C 
NMR (126 MHz,CDCl3/CD3OD (1:1)): This compound was not sufficiently soluble to 
generate an adequate 
13

















A solution of 219 (0.110 g, 0.072 mmol) in CH2Cl2 (100 mL) was heated at reflux then 
Grubbs’ II catalyst (0.006 g, 0.0072 mmol) was added in one portion. The colour 
became pink then purple and then darkened to orange. The reaction was heated at reflux 
for 4 h, after which TLC analysis showed complete consumption of 219. The crude 
residue was then subjected to flash silica chromatography, elution with MeOH/CH2Cl2 
(1:25) provided the title compound 220 (0.021 g, 19%) as an off white solid. This 


















 This compound was prepared via 
protocol 1, using 203 (0.120 g, 
0.101 mmol) and 213 (0.076 g, 
0.101 mmol) to yield the title 
compound 224 as a brown solid 
(0.122 g, 62%). 
1
H NMR (500 
MHz, CDCl3): δ 1.34-1.47 (m, 6H, CHCH2CH2), 1.40 (s, 9H, Boc), 1.60-1.75 (m, 6H, 
CH2CH2NH), 1.80-1.86 (m, 6H, CHCH2CH2), 3.11-3.18 (m, 5H, 2 x CH2NHFmoc and 
Lys-α-proton), 3.47-3.48 (m, 2H, CH2N (Lys)), 4.08-4.20 (m, 3H, CHCH2 and CH2CH 
(Fmoc)), 4.37-4.43 (m, 5H, OCH2CH=CH2, CHCH2 (Fmoc), and Lys-α-proton), 4.54-
4.60 (m, 3H, CHCH2 and CH2CH (Fmoc), 5.07 (bs, 1H, NHBoc), 5.22-5.26 (m, 2H, 
CH=CH2), 5.82-5.88 (m, 1H, CH=CH2), 6.74-6.82 (m, 2H, NH), 7.28-7.30 (m, 4H, 
ArCH), 7.35-7.40 (m, 6H, ArCH);  7.50 (t, J = 7.5 Hz, 4H, ArCH (Fmoc)), 7.57 (t, J = 
7.5 Hz, 4H, ArCH (Fmoc)),  7.73 (d, J = 7.0 Hz, 4H, ArCH (Fmoc)), 8.05 (d, J = 7.5 
Hz, 4H, ArCH (Fmoc)); HRMS (ESI +ve) calcd for C131H79N7O11Na, 1948.5735, found 













trioxo-3-oxa-5,8,11-triazatridecane-13-oic acid (225) 
This compound was prepared 
via protocol 4, using 224 (0.060 
g, 0.031 mmol), 1,2-
dichloroethane (80 mL) and 
(CH3)3SnOH (0.024 g, 0.124 
mmol x 2) to yield 225 (0.045 g, 
77%) as a brown solid. 
1
H NMR (500 MHz, CDCl3): δ 1.25-1.48 (m, 6H, CHCH2CH2), 
1.39 (s, 9H, Boc), 1.70-1.74 (m, 6H, CH2CH2NH), 1.80-1.88 (m, 6H, CHCH2CH2), 
3.12-3.16 (m, 5H, 2 x CH2NHFmoc and Lys-α-proton), 3.47 (bs, 2H, CH2N (Lys)), 
4.06-4.22 (m, 3H, CHCH2 and CH2CH (Fmoc)), 4.36-4.58 (m, 4H, CHCH2, Lys-α-
proton and CH2CH (Fmoc)), 4.96-5.18 (m, 2H, NHBoc and Lys-α-proton), 6.60-6.78 
(m, 2H, NH), 7.28-7.29 (m, 4H, ArCH), 7.37-7.38 (m, 6H, ArCH);  7.50 (t, J = 7.0 Hz, 
4H, ArCH (Fmoc)), 7.58 (bs, 4H, ArCH (Fmoc)),  7.73 (d, J = 6.0 Hz, 4H, ArCH 
(Fmoc)), 8.05 (d, J = 8.0 Hz, 4H, ArCH (Fmoc)); HRMS (ESI +ve) calcd for 
C128H75N7O11Na, 1909.5455, found 1909.5359. This compound was not sufficiently 
soluble to generate an adequate 
13













This compound was prepared 
via protocol 3, using 225 
(0.060 g, 0.031 mmol) to 
afford the title compound 226 
(0.050 g, 89%) as a fine brown 
solid. 
1
H NMR (500 MHz, 
CDCl3): δ 1.22-1.38 (m, 6H, CHCH2CH2), 1.72-1.88 (m, 12H, CH2CH2NH and 
CHCH2CH2), 3.10-3.20 (m, 5H, 2 x CH2NFmoc (Lys) and Lys-α-proton), 3.40 (bs, 2H, 
CH2N (Lys)), 4.08-4.22 (m, 3H, CHCH2 (Fmoc) and CH2CH (Fmoc)), 4.34-4.60 (m, 
4H, CHCH2, Lys-α-proton and CH2CH (Fmoc)), 4.96-5.18 (m, 2H, NH and Lys-α-
proton), 5.70-5.90 (bs, 2H, NH), 7.29-7.38 (m, 10H, ArCH), 7.45-7.49 (m, 4H, ArCH), 
7.68-7.75 (m, 8H, ArCH),  8.01-8.04 (m, 4H, ArCH); HRMS (ESI +ve) calcd for 
C126H71N7O9, 1826.5392, found 1826.5789. This compound was not sufficiently soluble 
to generate an adequate 
13















This compound was prepared via protocol 1, using 225 (0.040 g, 0.021mmol) and 226 
(0.038 g, 0.021 mmol) to yield the title compound 227 as a brown solid (0.035 g, 44%). 
1
H NMR (500 MHz, CDCl3): δ 1.20-1.55 (m, 12H, CHCH2CH2), 1.39 (s, 9H, Boc), 
1.64-1.76 (m, 12H, CH2CH2NH), 1.80-1.90 (m, 12H, CHCH2CH2), 3.06-3.20 (m, 8H, 4 
x CH2NHFmoc), 3.40-3.48 (m, 4H, 2 x CH2N (Lys)), 3.67-3.69 (m, 1H, NH), 4.00 (bs, 
1H, NH), 4.17-4.20 (m, 4H, 4 x CH2CH (Fmoc)), 4.37-4.46 (m, 8H, 4 x CHCH2 
(Fmoc)), 4.50-4.62 (m, 8H, OCH2CH=CH2 and 6 x Lys-α-protons), 4.90 (bs, 1H, NH), 
5.03-5.06 (m, 3H, 3 x NH), 5.20-5.22 (m, 2H, CH=CH2), 5.81-5.86 (m, 1H, CH=CH2), 
6.83-6.84 (m, 2H, 2 x NH), 6.94-6.96 (m, 2H, 2 x NH), 7.29 (d, J = 6.5 Hz, 8H), 7.37 
(m, 12H);  7.49 (d, J = 7.0 Hz, 8H), 7.56 (d, J = 7.5 Hz, 8H),  7.74 (t, J = 7.0 Hz, 8H), 
8.05 (d, J = 8.0 Hz, 8H), 8.11-8.12 (bs, 2H, NH); This compound was not sufficiently 
soluble to generate an adequate 
13
C NMR spectrum and not sufficiently soluble in 
MeOH to generate an adequate ESI-MS. 





Attempted preparation of Allyl (6S,9S,12S,15S)-6,9,12,15-tetrakis(4-(5,5-
diphenylfullerenyldihydropyrrole-2-carboxamido)butyl)-2,2-dimethyl-4,7,10,13-
tetraoxo-3-oxa-5,8,11,14-tetraazahexadecane-16-oate (207) 
To a suspension of 198 (0.118 g, 0.124 mmol) in pyridine/CHCl3 (90 mL) was added 
HOBt (0.020 g, 0.148 mmol) and EDCI (0.028 g, 0.148 mmol) and the mixture was 
stirred for 15 min before a solution of 217 (0.021 g, 0.031 mmol) in pyridine/CHCl3 (25 
mL) was added dropwise. The resulting solution was stirred at rt for 8 h before the 





under reduced pressure. The crude residue was then subjected to flash silica gel 
chromatography with gradient elution with MeOH/CHCl3 (1:49 to 1:19). This resulted 
in the isolation of three different products (10 mg, 14 mg and 56 mg), none of them 
were the desired product and these could not be characterised by 
1
H NMR spectroscopy 





 This compound was prepared via protocol 1, using (((9H-fluoren-9-
yl)methoxy)carbonyl)-L-phenylalanine 231 (0.220 g, 0.568 mmol) and tert-butyl L-
phenylalaninate 232 (0.125 g, 0.568 mmol) to afford the title compound 233 as a 





colourless solid (0.310 g, 92%). 
1
H NMR (500 
MHz, CDCl3): δ 1.36 (s, 9H, C(CH3)3), 3.01 (d, J 
= 6.0 Hz, 2H, CH2Ph), 3.05 (bs, 2H, CH2Ph), 4.17 
(t, J = 7.0 Hz, 1H, α-Phe proton), 4.28 (bs, 1H, 
(CH2CH (Fmoc)), 4.40-4.43 (m, 2H, CH2CH (Fmoc)), 4.63 (m, 1H, α-Phe proton), 5.34 
(bs, 1H, NH), 6.31 (bs, 1H, NH), 7.02 (d, J = 6.0 Hz, 2H, ArCH), 7.17-7.31 (m, 10H, 
ArCH), 7.39 (t, J = 7.5 Hz, 2H, ArCH), 7.52 (t, J = 8.5 Hz, 2H, ArCH), 7.75 (d, J = 7.0 
Hz, 2H, ArCH); 
13
C NMR (125 MHz, CDCl3): δ 28.1 (C(CH3)3), 38.0 (CH2Ph), 38.2 
(CH2Ph), 47.3 (CH2CH (Fmoc)), 53.9 (CHCH2Ph), 56.1 (CHCH2Ph), 67.2 (CH2 
(Fmoc)), 82.5 (C(CH3)3)), [120.2, 125.0, 127.3, 127.6, 128.6, 128.9, 129.5, 129.6 
(ArCH)], [136.0, 136.3, 141.4, 143.8 (ArC)], 155.9 (C=O (Fmoc)), 170.0 (C=O), 170.2 
(C=O). HRMS (ESI +ve) calcd for C37H38N2O5 591.2859, found 591.2865. 
(S)-3-(Phenyl)-2-((S)-3-(phenyl)-2-(9H-fluoren-9-yl)methoxycarbonylamino 
propanamido)propanoic acid 234 
 This compound was prepared via protocol 3, using 233 
(0.250 g, 0.423 mmol) to afford the title compound 234 
(0.205 g, 90%) as a fine colourless solid. 
1
H NMR (500 
MHz, CDCl3): δ 3.00-3.02 (m, 2H, CH2Ph), 3.07 (bs, 2H, CH2Ph), 4.16 (t, J = 7.0 Hz, 
1H, α-Phe proton), 4.25 (bs, 1H, (CH (Fmoc)), 4.41-4.43 (m, 2H, CH2 (Fmoc)), 4.74 
(m, 1H, α-Phe proton), 5.37 (bs, 1H, NH), 6.35 (bs, 1H, NH), 7.02-7.05 (m, 2H, ArCH), 
7.20-7.32 (m, 10H, ArCH), 7.38 (t, J = 7.5 Hz, 2H, ArCH), 7.52 (t, J = 8.5 Hz, 2H, 
ArCH), 7.75 (d, J = 7.0 Hz, 2H, ArCH); HRMS (ESI +ve) calcd for C33H30N2O5 
535.2233, found 535.2238. 








 This compound was prepared 





234 (0.052 g, 0.097 mmol) and (S)-6-((5,5-diphenylfullerenyldihydropyrrole-2-
carbonyl)amino)-1-(allyloxy)-1-oxohexan-2-aminium 2,2,2-trifluoroacetate 202 (0.109 
g, 0.097 mmol) to afford the title compound 235 as a colourless solid (0.095 g, 60%). 
1
H NMR (500 MHz, CDCl3): δ 1.25-1.36 (m, 2H, CHCH2CH2), 150-1.52 (m, 2H, 
CH2CH2NH), 1.80-1.86 (m, 2H, CHCH2CH2), 2.95-3.01 (m, 4H, CH2N (Lys) and 
CH2Ph), 3.42-3.45 (m, 2H, CH2Ph), 4.06-4.11 (m, 1H, CH2CH (Fmoc)), 4.22-4.30 (m, 
2H, α-Phe proton), 4.39-4.59 (m, 5H, OCH2, CHCH2 (Fmoc), Lys-α-proton), 5.19-5.25 
(m, 2H, CH=CH2), 5.84-5.90 (m, 1H, CH=CH2), 6.57 (bs, 2H, NH), 7.05-7.28 (m, 20H, 
ArCH), 7.36-7.41 (m, 2H, ArCH);  7.45-7.48 (m, 2H, ArCH), 7.69-7.74 (m, 2H, ArCH),  
8.01-8.06 (m, 4H, ArCH); 
13
C NMR (CDCl3, 125 MHz): δ 22.8 (CHCH2CH2), 29.0 
(CH2CH2NH), 31.9 (CHCH2CH2), 37.8 (CH2Ph), 39.8 (CH2NH), 47.1 (CH2CH 
(Fmoc)), 52.3 (NHCHCO), 53.5 (CHCH2Ph), 54.6 (CHCH2Ph), 66.1 (CH2CH=CH2), 




), 95.5 (CPh2), 119.2 (CH=CH2), 
[120.1, 125.1, 125.5, 127.2, 127.3, 127.9, 128.5, 128.7, 128.9, 129.3, 129.9, 131.5 
(ArCH)], [134.8, 134.85 (ArC)], [136.2, 136.6, 139.2, 139.6, 141.0, 141.4, 141.9, 142.4, 







)], [142.6, 142.8(ArC)], [143.0, 144.2, 144.4, 144.9, 145.2, 145.3 (2 x C), 
145.33, 145.5, 145.6, 145.9, 146.1, 146.4* (1/2 x C), 146.9* (1/2 x C), 147.2, 148.6, 
149.2, 153.2 (2 x C) (C60sp
2
)], 153.3 (C=N), 161.4 (2 x CO), 162.4 (2 x CO), 171.3 
(CO, ester); HRMS (ESI +ve) calcd for C117H55N5O7,1641.4101, found 1641.4235. 
(5S,8S,11S)-5,8-Dibenzyl-11-(4-(5,5-diphenylfullerenyldihydropyrrole-2-
carboxamido) butyl)-1-(9H-fluoren-9-yl)-3,6,9-trioxo-2-oxa-4,7,10-triazadodecane-
12-oic acid (236) 
This compound was prepared 
via protocol 4, using 235 
(0.042 g, 0.025mmol), 1,2-
dichloroethane (40 mL) and 
(CH3)3SnOH (0.020 g, 0.100 
mmol) mL) to yield 236 




 This compound was prepared via 
protocol 2, using 235 (0.045 g, 0.027 
mmol) to afford the title compound 237 
(0.38 g, 99%) as a fine colourless solid. 
HRMS (ESI +ve) calcd for C102H45N5O5 
1419.3421, found 1419.3529. This 











This compound was prepared via protocol 1, using 236 (0.025 g, 0.015 mmol) and 237 
(0.021 g, 0.015 mmol) to yield the title compound 238 as a colourless solid (0.018 g, 40 
%). 
 1
H NMR (500 MHz, CDCl3): δ 1.21-1.39 (m, 4H, CHCH2CH2), 146-1.57 (m, 4H, 
CH2CH2NH), 1.80-1.88 (m, 4H, CHCH2CH2), 2.96-3.06 (m, 8H, 2 x CH2N (Lys) and 2 
x CH2Ph), 3.41-3.45 (m, 4H, 2 x CH2Ph), 4.04-4.15 (m, 1H, CH2CH (Fmoc)), 4.20-4.30 
(m, 4H, 4 x α-Phe proton), 4.37-4.61 (m, 6H, CH2CH=CH2, CH2 (Fmoc) and 2 x Lys-α-
proton), 5.17-5.25 (m, 2H, CH=CH2), 5.86-5.92 (m, 1H, CH=CH2), 6.60 (bs, 2H, NH), 
6.65 (bs, 2H, NH), 7.18-7.36 (m, 32H, ArCH), 7.36-7.41 (m, 4H, ArCH), 7.45-7.48 (m, 
8H, ArCH), 7.69-7.74 (m, 2H, ArCH),  8.01-8.06 (m, 2H, ArCH). This compound was 
not sufficiently soluble to generate an adequate 
13
C NMR spectrum and not sufficiently 
soluble in MeOH to generate an adequate ESI-MS. 
 
 








To a suspension of 
fullerenoprolineglycine-OH 242 (133 
mg, 0.131 mmol) in CH2Cl2 (100 mL) 
was added HBTU (59 mg, 0.157 
mmol) and Et3N (22 µL, 0.157 mmol) 
and the mixture was stirred for 15 min 
before a solution of 213 (100 mg, 0.131 mmol) in CH2Cl2 (15 mL) was added dropwise. 
The resulting solution was stirred at rt for 4 h, before the solvent was removed under 
reduced pressure. The crude residue was then subjected to flash silica gel 
chromatography, elution with MeOH/CH2Cl2 (1:99) provided the title compound 243 as 
a brown solid (155 mg, 67%). IR (neat, cm
-1
): 3303 (w), [1695, 1683, 1653, 1647 (s)], 
1246 (m), 1139; 
1
H NMR (500 MHz, CDCl3:CS2 (4:1)): δ 1.23-1.25 (m, 4H, 
CHCH2CH2), 142-1.49 (m, 4H, CH2CH2NH), 1.68-1.78 (m, 2H, CHCH2CH2), 1.85 (bs, 
2H, CHCH2CH2), 3.10-3.18 (m, 4H, 2 x CH2N (Lys)), 4.16-4.22 (m, 4H, 2 x CH 
(Fmoc) and 2 x Lys-α-proton), 4.36-4.40 (m, 5H, 2 x CH2CH (Fmoc) and NH), 4.51 
(bs, 2H, NHCH2CO (Gly)), 4.60 (bs, 2 x NH), 4.90-5.11 (m, 2H, CH2CH=CH2), 5.21 
(d, J = 10.5 Hz, 1H,  CH=CH(Z)H), 5.28 (d, J = 17.0 Hz, 1H,  CH=CH(E)H), 5.82-5.94 
(m, 1H, CH=CH2), 6.86 (bs, 1H, NH), 7.27-7.40 (m, 10H, ArCH), 7.47 (t, J = 7.5 Hz, 
4H, ArCH), 7.56 (bs, 4H, ArCH);  7.72 (d, J = 7.0 Hz, 4H, ArCH), 8.05 (d, J = 7.5 Hz, 
4H, ArCH), 8.57 (bs, 1H, NH); 
13
C NMR (125 MHz, CDCl3:CS2 (4:1)): δ 22.0 
(CHCH2CH2), 22.3 (CHCH2CH2), 29.3 (CH2CH2NH), 31.1 (CHCH2CH2), 31.5 





(CHCH2CH2), 38.6 (CH2NH (Lys)), 40.2 (CH2NH (Lys)), 43.0 (NHCH2CO), 47.2 
(CH2CH (Fmoc)), 52.3 (NHCHCO, Lys α carbon), 53.1 (NHCHCO, Lys α carbon), 
66.0 (CH2CH=CH2), 66.5 (CH2CH (Fmoc)), 66.9 (CH2CH (Fmoc)), 95.5 (NCPh2), 
118.9 (CH=CH2), [119.9, 125.0, 127.0, 127.6, 128.4, 129.7 (ArCH)], 131.4 (CH=CH2), 
134.7 (2 x ArC), [136.6, 139.1, 139.4, 140.8, 141.2, 141.3, 141.7, 142.3, 142.4 
(C60sp
2
)], 142.7 (2 x ArC), 142.9 (2 x ArC), 143.9 (4 x ArC), [144.0, 144.2 (2 x C), 
144.8, 145.0, 145.3 (2 x C), 145.4, 145.7, 145.9, 146.3* (1/2 x C), 146.8* (1/2 x C), 
147.0, 148.3, 148.9, 153.1 (2 x C) (C60sp
2
)], 156.7 (C=N), [156.8, 161.7, 165.7, 168.2, 
171.3, 171.7 (CO)]; Two C60sp
3
 signals were not observed due to poor signal to noise. 
MS (ESI +ve) m/z 1778.0 ([M+Na]
+
, 100%), HRMS (ESI +ve) calcd for 





This compound was prepared via 
protocol 4 using 243 (110 mg, 0.062 
mmol) to yield the desired carboxylic 
acid precursor of 244 as a brown solid 
(90 mg, 84%). This product was 
carried into the next reaction without 
any further purification, via protocol 1 using the acid 244 (75 mg, 0.043 mmol) and (S)-
isopentyl 2-amino-4-methylpentanoate (17 mg, 0.086 mmol) to yield the desired 
product 245 as a brown solid (52 mg, 62%). IR (neat, cm
-1
): 3305 (w), [1669, 1663, 





1647, 1632, 1558 (s)], 1515 (m), 1196, 1132 (m); 
1
H NMR (500 MHz, CDCl3): δ 0.80-
0.94 (m, 12H, 4 x CH3 (Leu and isopentyl)), 1.38-1.44 (m, 4H, CHCH2CH2), 1.51-1.57 
(m, 7H, 2 x CH2CH2NH, OCH2CH2 and CH(CH3)2 (Leu)), 1.66-1.71 (m, 4H, 
CHCH2CH2 (Lys)), 1.74-1.80 (m, 1H, CH(CH3)2 (isopentyl)), 1.87 (m, 2H, 
CH2CH(CH3)2 (Leu)), 3.44 (t, J = 6.0 Hz, 4H, 2 x CH2N (Lys)), 4.04 (t, J = 6.5 Hz, 2H, 
CO2CH2 (ester)), 4.11-4.17 (m, 4H, NHCH2CO and 2 x CHCH2 (Fmoc)), 4.19 (d, J = 
6.0 Hz, 2H, CHCH2 (Fmoc)), 4.35-4.40 (m, 4H, CHCH2 (Fmoc) and 2 x Lys-α-proton), 
4.49 (bs, 1H, Leu-α-proton), 5.08 (bs, 1H, NH), 5.19 (bs, 1H, NH), 6.50 (bs, 1H, NH), 
6.97 (bs, 1H, NH), 6.40 (bs, 1H, NH), 7.27-7.41 (m, 14H, ArCH), 7.57 (bs, 4H, ArCH),  
7.61 (d, J = 7.5 Hz, 4H, ArCH), 7.73-7.78 (m, 4H, ArCH), 8.05 (bs, 1H, NH); HRMS 
(ESI +ve) calcd for C130H79N7O10 1898.5967, found 1898.6011. This compound was not 
sufficiently soluble to generate an adequate 
13
C NMR spectrum. 
(S)-5-(2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl)aminoacetamido)-6-(S)-
6-ammonio-1-(S)-1-(isopentyloxy)-4-methyl-1-oxopentan-2-yl)amino-1-oxohexan-
2-ylamino-6-oxohexan-1-ammonium chloride (247) 
This compound was prepared via 
protocol 2, followed by protocol 3, 
using 245 (32 mg, 0.016 mmol) to yield 
247 as a brown solid (17 mg, 70%). IR 
(neat, cm
-1
): 3237 (w), 3064 (w), [1647, 
1635, 1558, 1539 (s)], 1507, 1185, 1155 (m). This compound was not sufficiently 
soluble to generate an adequate 
1
H NMR and 
13
C NMR spectrum. HRMS (ESI +ve) 
calcd for C100H59N7O6 1454.4604, found 1454.4750. 
 









This compound was prepared via protocol 





(250 mg, 0.410 mmol), Fmoc-(L)-
Lys(Boc)-OH (192 mg, 0.410  mmol) to 
yield the desired product 259 as a white foam (350 mg, 80%). IR (neat, cm
-1
): 3306 (w), 
[1668, 1662, 1647, 1635, 1558 (s)], 1190, 1132 (m); 
1
H NMR (500 MHz, CDCl3): δ 
0.84-0.88 (m, 12H, 4 x CH3 (Leu and isopentyl)), 1.40 (s, 9H, Boc), 1.43 (s, 6H, 
C(CH3)2, Pbf), 1.46-1.49 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.57-1.72 
(m, 6H, CHCH2CH2 (Lys), OCH2CH2 and CH2CH2NH (Lys)), 1.76 (bs, 1H, CH(CH3)2 
(Leu)), 1.92 (bs, 2H, CHCH2 (Leu)), 1.99 (bs, 1H, CH(CH3)2 (isopentyl)), 2.07 (s, 3H, 
CH3 (Pbf)), 2.50 (s, 3H, CH3 (Pbf)), 2.57 (s, 3H, CH3 (Pbf)), 2.92 (s, 2H, CH2 (Pbf)), 
3.06 (bs, 2H, CH2N (Arg)), 3.23 (bs, 2H, CH2N (Lys)), 4.05-4.10 (m, 2H, NH), 4.18 (t, 
J = 6.5 Hz, 2H, CO2CH2), 4.32-4.34 (m, 2H, CHCH2 (Fmoc) and Lys-α-proton), 4.43-
4.45 (m, 2H, CHCH2 (Fmoc)), 4.56-4.57 (m, 2H, Leu-α-proton and NH), 4.82 (bs, 1H, 
Arg-α-proton), 5.29 (bs, 1H, NH), 5.82 (bs, 1H, NH), 6.29 (bs, 2H, NH), 7.26-7.29 (m, 
2H, ArCH), 7.35-7.38 (m, 2H, ArCH), 7.57 (t, J = 6.5 Hz, 2H, ArCH), 7.73 (d, J = 7.5 
Hz, 2H, ArCH); 
13
C NMR (125 MHz, CDCl3): δ 12.8 (CH3, Pbf), 18.3 (CH3, Pbf), 19.6 
(CH3, Pbf), 21.9 (CHCH2CH2 (Lys)), 22.6 (2 x CH3 (Leu)), 22.7 (2 x CH3 (isopentyl)), 





22.8 (CHCH2CH2 (Arg)), 23.0 (CH(CH3)2 (isopentyl)), 25.0 (CH(CH3)2 (Leu)), 25.2 
(CHCH2CH2 (Lys)), 28.7 (C(CH3)3), 28.8 (C(CH3)2 (Pbf)), 29.6 (CHCH2CH2 (Arg)), 
29.8 (CH2CH2NH (Lys)), 37.5 (CH2CH(CH3)2 (isopentyl) and CH2CH2NH (Lys)), 40.3 
(CH2CH(CH3)2 (Leu)), 40.6 (NHCH2 (Lys)), 43.9 (NHCH2 (Arg)), 47.3 (CH2 (Pbf)), 
51.6 (CH2CH (Fmoc)), 52.7 (NHCHCO (Leu)), 53.7 (NHCHCO (Lys)), 55.5 
(NHCHCO (Arg)), 64.3 (OCH2 (isopentyl)), 67.4 (CH2CH (Fmoc)), 79.6 (OC(CH3)3), 
86.6 (OC (Pbf)), 117.7 (ArC), 120.2 (ArCH), 124.8 (ArC), [125.4, 125.5, 126.3 
(ArCH)], [128.0, 132.5, 133.1, 138.6, 141.4, 141.5, 143.9, 144.1 (ArC)], 156.6 (CO, 
Boc), 156.7 (C=N), 159.0 (ArC of Pbf), 171.9 (CO), 172.5 (CO), 173.4 (CO, ester); MS 
(ESI +ve) m/z 1060.0 ([M+H]
+






This compound was prepared via protocol 2 using 259 
(320 mg, 0.301 mmol) to yield the desired product 263 
as a white foam (195 mg, 77%). IR (neat, cm
-1
): 3300 
(w), [1668, 1662, 1647, 1558, 1507 (s)], 1194, 1131 
(m); 
1
H NMR (500 MHz, CDCl3): δ 0.90-0.91 (m, 12H, 
4 x CH3), 1.42 (s, 9H, Boc), 1.46 (s, 6H, C(CH3)2 Pbf), 
1.49-1.52 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.56-1.62 (m, 4H, 
CHCH2CH2 (Lys), and CH2CH2NH (Lys)), 1.64-1.75 (m, 2H, OCH2CH2), 1.80 (bs, 1H, 
CH(CH3)2 (Leu)), 1.96 (bs, 5H, CHCH2 (Leu),  CHCH2 (Arg) and CH(CH3)2 
(isopentyl)), 2.08 (s, 3H, CH3 (Pbf)), 2.51 (s, 3H, CH3 (Pbf)), 2.58 (s, 3H, CH3 (Pbf)), 
2.95 (s, 2H, CH2 (Pbf)), 3.06-3.09 (m, 2H, CH2N (Arg)), 3.24 (bs, 2H, CH2N (Lys)), 





3.40 (bs, 1H, NH), 4.10-4.14 (m, 2H, NH), 4.44-4.49 (m, 1H, Lys-α-proton), 4.52-4.53 
(m, 1H, Leu-α-proton), 4.78 (bs, 1H, NH), 6.17 (bs, 1H, NH), 6.29 (bs, 2H, NH2), 7.30 
(bs, 1H, NH), 7.90 (bs, 2H, NH), 
13
C NMR (125 MHz, CDCl3): δ 12.6 (CH3, Pbf), 18.0 
(CH3, Pbf), 19.4 (CH3, Pbf), 21.9 (CHCH2CH2 (Lys)), 22.6 (2 x CH3 (Leu)), 22.8 (2 x 
CH3 (isopentyl)), 23.0 (CHCH2CH2 (Arg)), 24.9 (CH(CH3)2 (isopentyl)), 25.1 
(CH(CH3)2 (Leu)), 25.2 (CHCH2CH2 (Lys)), 28.6 (C(CH3)3), 28.7 (C(CH3)2 (Pbf)), 29.9 
(CHCH2CH2 (Arg)), 30.1 (CH2CH2NH (Lys)), 34.6 (CH2CH(CH3)2 (isopentyl)), 37.3 
(CH2CH2NH (Lys)), 40.4 (CH2CH(CH3)2 (Leu)), 40.7 (NHCH2 (Lys)), 43.4 (NHCH2 
(Arg)), 51.3 (CH2 (Pbf)), 52.3 (NHCHCO (Leu)), 55.1 (NHCHCO (Arg)), 64.2 (OCH2 
(isopentyl)), 79.3 (OC(CH3)3), 86.5 (OC(Pbf), [117.6, 124.7, 132.4, 133.1, 138.5 
(ArC)]; 156.4 (CO, Boc), 156.5 (C=N), 158.9 (ArC, Pbf), 171.9 (CO), 173.3 (CO), 






This compound was prepared via 
protocol 1 using 263 (170 mg, 0.203 
mmol), Fmoc-Gly-OH (60 mg, 0.203 
mmol) to yield the desired product 266 
as a white foam (169 mg, 75%). IR 
(neat, cm
-1
): 3302 (w), [1671, 1660, 
1647, 1633, 1558, 1505 (s)], 1193, 1135 (m); 
1
H NMR (500 MHz, CDCl3): δ 0.85 (bs, 





12H, 4 x CH3 (Leu and isopentyl)), 1.38 (s, 9H, Boc), 1.42 (s, 6H, C(CH3)2 Pbf)), 1.46-
1.50 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.56-1.66 (m, 4H, CHCH2CH2 
(Lys), OCH2CH2)), 1.67-1.79 (m, 2H, CH2CH2NH (Lys)), 1.86 (bs, 1H, CH(CH3)2 
(Leu)), 1.91 (bs, 1H, 1H, CH(CH3)2 (isopentyl)), 1.95 (s, 3H, CH3 (Pbf)), 2.06 (s, 3H, 
CH3 (Pbf)), 2.57 (s, 3H, CH3 (Pbf)), 2.90 (s, 2H, CH2 (Pbf)), 3.06-3.08 (m, 2H, CH2N 
(Arg)), 3.19 (bs, 2H, CH2N (Lys)), 3.94-4.00 (m, 2H, NH), 4.01-4.09 (m, 2H, CHCH2 
(Leu)), 4.17 (t, J = 6.5 Hz, 1H, CHCH2 (Fmoc)), 4.33 (d, J = 7.0 Hz, 2H, CHCH2 
(Fmoc)), 4.46-4.47 (m, 2H, CH2 (Gly)), 4.58 (bs, 1H, Leu-α-proton), 5.01 (bs, 1H, Lys-
α-proton), 6.31 (bs, 4H, Arg-α-proton and 3 x NH), 7.23-7.25 (m, 3H,  2 x ArCH and 
NH), 7.34-7.37 (m, 2H, ArCH), 7.44 (bs, 2H, ArCH), 7.57 (d, J = 6.5 Hz, 2H, ArCH), 
7.73 (d, J = 8.0 Hz, 2H, ArCH). 
13
C NMR (125 MHz, CDCl3): δ 12.6 (CH3, Pbf), 18.3 
(CH3, Pbf), 19.4 (CH3, Pbf), 21.8 (CHCH2CH2 (Lys)), 22.4 (2 x CH3 (Leu)), 22.9 (2 x 
CH3 (isopentyl)), 22.95 (CHCH2CH2 (Arg)), 23.0 (CH(CH3)2 (isopentyl)), 25.2 
(CH(CH3)2 (Leu)), 25.25 (CHCH2CH2 (Lys)), 28.8 (C(CH3)3), 29.0 (C(CH3)2 Pbf), 29.5 
(CHCH2CH2 (Arg)), 29.8 (CH2CH2NH (Lys)), 31.7 (CHCH2 (Leu)), 37.6 (2 x CH2 
(CH2CH(CH3)2 (isopentyl) and CH2CH2NH (Lys)), 40.3 (CH2CH(CH3)2 (Leu)), 40.6 
(NHCH2 (Lys)), 43.9 (NHCH2 (Arg)), 44.4 (CH (Gly)), 47.3 (CH2 (Pbf)), 51.3 (CH2CH 
(Fmoc)), 52.7 (NHCHCO (Leu)), 53.7 (NHCHCO (Lys)), 55.9 (NHCHCO (Arg)), 64.3 
(OCH2 (isopentyl)), 67.4 (CH2CH (Fmoc)), 79.6 (OC(CH3)3), 86.6 (OC(CH3)2), 117.6 
(ArC), 121.9 (2 x ArCH), 124.9 (2 x ArCH), [125.4, 125.5, 128.0 (ArCH)], [132.5, 
133.1, 138.6, 141.4, 141.5, 143.9, 144.3 (ArC)], 156.6 (C=N), 156.7 (CO, Boc), 158.9 
(ArC), 172.0 (2 x CO), 172.9 (2 x CO), 173.7 (CO, ester); MS (ESI +ve) m/z 1017.6 
([M-Boc]
+
, 100%), 1117.6 ([M+H]
+
, 95%), 1139.6 ([M+Na]
+
, 22%). 








This compound was prepared via protocol 2 using 
266 (140 mg, 0.125 mmol) to yield the desired 
product 269 as a white foam (90 mg, 80%). IR 
(neat, cm
-1
): 3300 (w), [1666, 1662, 1647, 1635, 
1557, 1502 (s)], [1194, 1137 (m)]; 
1
H NMR (500 
MHz, CDCl3): δ 0.87-0.91 (m, 12H, 4 x CH3 (Leu 
and isopentyl)), 1.41 (s, 9H, Boc), 1.45 (s, 6H, C(CH3)2 Pbf), 1.48-1.52 (m, 4H, 
CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.56-1.61 (m, 4H, CHCH2CH2 (Lys), and 
CH2CH2NH (Lys)), 1.63-1.74 (m, 2H, OCH2CH2), 1.86-1.94 (m, 3H, CH(CH3)2 (Leu) 
and CHCH2 (Arg)), 1.96 (bs, 1H, CH(CH3)2 (isopentyl)), 2.02 (bs, 2H, CHCH2 (Leu) 
and ), 2.08 (s, 3H, CH3 (Pbf)), 2.51 (s, 3H, CH3 (Pbf)), 2.58 (s, 3H, CH3 (Pbf)), 2.95 (s, 
2H, CH2 (Pbf)), 3.06-3.08 (m, 2H, CH2N (Arg)), 3.22 (bs, 2H, CH2N (Lys)), 3.41 (m, 
2H, NH), 4.07-4.14 (m, 2H, CH2 (Gly)), 4.36 (bs, 1H, NH), 4.42-4.48 (m, 2H, Lys-α-
proton and Leu-α-proton), 4.91 (bs, 1H, NH), 6.40 (bs, 1H, NH), 6.35 (bs, 2H, NH2), 
7.36 (d, J = 7 Hz, 1H, NH), 7.45 (bs, 1H, NH), 7.85 (bs, 1H, NH). 
13
C NMR (125 MHz, 
CDCl3): δ 12.5 (CH3, Pbf), 18.0 (CH3, Pbf), 19.2 (CH3, Pbf), 21.8 (CHCH2CH2 (Lys)), 
22.4 (CH3 (Leu)), 22.8 (2 x CH3 (isopentyl)), 22.9 (CHCH2CH2 (Arg)), 24.8 (CH(CH3)2 
(isopentyl)), 25.0 (CH(CH3)2 (Leu)), 25.4 (CHCH2CH2 (Lys)), 28.4 (C(CH3)3), 28.6 
(C(CH3)2 Pbf), 29.6 (CH2CH(CH3)2 (isopentyl)), 29.7 (CHCH2CH2 (Arg)), 31.7 
(CH2CH2NH (Lys)), 37.2 (CH2CH2NH (Lys)), 40.2 (CH2CH(CH3)2 (Leu)), 40.6 
(NHCH2 (Lys)), 43.3 (NHCH2 (Arg)), 44.4 (NHCH2CO (Gly)), 51.2 (CH2 (Pbf)), 52.9 





(NHCHCO (Leu)), 53.7 (NHCHCO (Arg)), 64.0 (OCH2 (isopentyl)), 79.1 (OC(CH3)3), 
86.3 (OC(CH3)2 Pbf), [117.5, 124.5, 132.2, 133.0, 138.3 (ArC)], 156.4 (C=N), 156.7 
(CO, Boc), 158.7 (ArC), 171.7 (2 x CO), 172.2 (CO), 173.0 (CO, ester). MS (ESI +ve) 
m/z 895.6 ([M+H]
+







This compound was prepared via 
protocol 1, using 
[60]fullerenoproline acid 198 (75 
mg, 0.067 mmol) and amine 269 
(72 mg, 0.080 mmol) to yield the 
product 272 as a brown solid (65 
mg, 53%). IR (neat, cm
-1
): 3304 
(w), [1669, 1662, 1647, 1635, 1558, 1507 (s)], [1194, 1135 (m)]; 
1
H NMR (500 MHz, 
CDCl3)  0.87-0.90 (m, 12H, 4 x CH3 (Leu and isopentyl)), 0.95-1.05 (m, 2H, 
CHCH2CH2 (Lys)), 1.42 (s, 9H, Boc), 1.46 (s, 6H, C(CH3)2 Pbf), 1.48-1.57 (m, 4H, 
CHCH2CH2 (Arg) and CHCH2CH2 (Lys)), 1.63-1.66 (m, 6H, CH2CH2NH (Lys), 
OCH2CH2 and CHCH2 (Arg)), 1.85-1.86 (m, 4H, CH(CH3)2 (isopentyl), CHCH2 (Leu) 
and CH(CH3)2 (Leu)), 2.08 (s, 3H, CH3 (Pbf)), 2.50 (s, 3H, CH3 (Pbf)), 2.57 (s, 3H, CH3 
(Pbf)), 2.95 (s, 2H, CH2 (Pbf)), 3.05 (bs, 2H, CH2N (Arg)), 3.16 (bs, 2H, CH2N (Lys)), 
3.35 (m, 2H, NH), 3.62-3.76 (m, 2H, OCH2), 4.07-4.09 (m, 2H, Lys-α-proton and Leu-
α-proton), 4.28 (s, 2H, CH2 (Gly)), 4.34-4.44 (m, 3H, Arg-α-proton and 2 x NH), 5.33 





(bs, 1H, NH), 7.39-7.42 (m, 3H, 2 x ArCH, NH), 7.50-7.52 (m, 4H, ArCH), 7.81-7.83 
(bs, 2H, NH), 8.08-8.10 (m, 4H, ArCH); 
13
C NMR (125 MHz, CDCl3): δ 12.2 (CH3, 
Pbf), 17.7 (CH3, Pbf), 19.0 (CH3, Pbf), 21.2 (CHCH2CH2 (Lys)), 22.1 (CH3 (Leu)), 22.2 
(CH3 (Leu)), 22.8 (2 x CH3 (isopentyl)), 22.9 (CHCH2CH2 (Arg)), 24.6 (CH(CH3)2 
(isopentyl)), 24.8 (CHCH2CH2 (Lys)), 25.0 (CH(CH3)2 (Leu)), 28.3 (C(CH3)), 28.6 
(C(CH3)2 Pbf)), 29.2 (CH2CH(CH3)2 (isopentyl)), 29.6 (CHCH2CH2 (Arg)), 31.7 
(CH2CH2NH (Lys)), 37.0 (CH2CH2NH (Lys)), 40.2 (CH2CH(CH3)2 (Leu)), 40.3, 40.6 
(NHCH2 (Lys)), 42.5 (NHCH2 (Arg)), 43.0 (NHCH2CO (Gly)), 50.9 (CH2 (Pbf)), 51.0 
(NHCHCO (Leu)), 52.4, 53.3 (NHCHCO (Arg)), 53.9, 63.9 (OCH2 (isopentyl)), 66.3, 




), 86.3, 95.4 (NCPh2), [117.3, 124.3 
(ArC)], 128.3 (ArCH), 129.6  (ArCH), [132.2, 132.8 (ArC)], 134.6 (ArCH)]; 136.5, 
138.2 (ArC), [139.0, 139.3, 139.3 (C60sp
2
)]; 140.8 (ArCH), [141.2, 141.6, 141.7, 141.8, 
142.3, 142.34, 142.6, 142.65, 142.8, 144.0, 144.1, 144.7, 144.9, 145.1, 145.13, 145.2, 
145.3, 145.7, 145.8, 145.89, 146.2, 146.8*  (1/2 x C), 146.9*  (1/2 x C), 148.2, 148.9, 
153.1 (C60sp
2
)], 156.7 (CO, Boc), 158.5 (2 x C=N), 161.8 (ArC, Pbf), [162.0, 169.2, 
172.0, 172.4, 172.9 (CO)]. MS (ESI +ve) m/z 1857 ([M+Na]
+
, 100%), 1835 ([M+H]
+
, 
60%). HRMS (ESI +ve) calcd for C118H83N9O11SNa 1856.5830, found 1856.5916. 
1-(R)-4-(S)-2-(2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl 
aminoacetamido)-6-ammoniohexanamido)-5-(R)-1-(isopentyloxy)-4-methyl-1-
oxopentan-2-yl)amino-5-oxopentylguanidinium 2,2,2-trifluoroacetate (276) 
This compound was prepared via protocol 3, using 272 (30 mg, 0.016 mmol) to yield 
276 as a brown solid (17 mg, 70%). IR (neat, cm
-1
): 3291 (w), [1734, 1669, 1647, 1635, 
1558 (s)], [1186, 1158, 1146 (m)]; 
1
H NMR (500 MHz, CDCl3:CD3OD)  0.83-0.89 (m, 
12H, 4 x CH3 (Leu and isopentyl)), 1.24-1.28 (m, 2H, CHCH2CH2 (Lys)), 1.42-1.54 (m, 





7H, CHCH2CH2 (Arg), CHCH2CH2 
(Lys) and CHCH2 (Leu) and 
CH(CH3)2 (Leu)), 1.62-1.68 (m, 5H, 
CH2CH2NH (Lys), OCH2CH2 and 
CH(CH3)2 (isopentyl)), 1.70-1.79 (m, 
2H,),  2.80 (bs, 2H, CH2N (Lys)), 
3.10-3.12 (m, 2H, CH2N (Arg)), 3.26 (s, 2H, CH2 (Gly)), 3.55 (bs, 1H, NH), 4.00-4.02 
(m, 2H, OCH2), 4.12-4.20 (m, 2H, Lys-α-proton and Leu-α-proton), 4.40-4.60 (bs, 2H, 
Arg-α-proton and NH), 7.36 (t, 2H, J = 6.5 Hz, ArCH), 7.47 (t, 4H, J = 7.5 Hz, ArCH), 
7.79-7.80 (bs, 1H, NH), 8.03 (d, 4H, J = 8.0 Hz, ArCH), 8.12 (bs, 1H, NH), 8.28 (bs, 
1H, NH), 9.10 (bs, 1H, NH). This compound was not sufficiently soluble to generate an 
adequate 
13






This compound was prepared via protocol 
1 using amine 256 (350 mg, 0.552  mmol) 
and Fmoc-(D)-Lys(Boc)-OH (258 mg, 
0.552 mmol) to yield the desired product 
260 as a white foam (515 mg, 86%). 
1
H 
NMR (500 MHz, CDCl3): δ 0.84-0.87 (m, 
6H, 2 x CH3 (Leu)), 1.28 (s, 6H, 2 x CH3 (Pmc)), 1.39 (s, 9H, Boc), 1.46-1.65 (m, 7H, 





CHCH2CH2 (Lys), CHCH2CH2 (Arg), CH(CH3)2 (Leu) and CH2CH2NH (Lys)), 1.75-
1.78 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.96 (bs, 1H, 
NH), 2.05 (s, 3H, CH3 (Pmc)), 2.08 (s, 3H, CH3 (Pmc)), 2.54 (s, 3H, CH3 (Pmc)), 2.59-
2.60 (m, 4H, 2 x CH2 (Pmc)), 3.05 (bs, 2H, CH2N (Arg)), 3.20-3.26 (m, 2H, CH2N 
(Lys)), 3.80 (s, 3H, OCH3), 4.12-4.17 (m, 2H, CH2 (Fmoc)), 4.25-4.32 (m, 2H, Lys-α-
proton and Arg-α-proton), 4.54-4.55 (m, 1H, CH (Fmoc)), 4.83 (bs, 1H, NH), 5.14-5.18 
(m, 1H, α-CH to oxazole), 5.92 (bs, 1H, NH), 6.19 (bs, 1H, NH), 6.32 (bs, 2H, NH), 
7.26-7.28 (m, 2H, ArCH), 7.36 (t, J = 7.5 Hz, 2H, ArCH), 7.54 (t, J = 8.5 Hz, 2H, 
ArCH), 7.72 (d, J = 7.5 Hz, 2H, ArCH), 8.04 (s, 1H, oxazole); 
13
C NMR (125 MHz, 
CDCl3): δ 12.3 (CH3, Pmc), 17.7 (CH3, Pmc), 18.7 (CH3, Pmc), 21.6 (CHCH2CH2 
(Lys)), 22.8 (CHCH2CH2 (Arg)), 22.9 (2 x CH3 (Leu)), 24.8 (CH(CH3)2 (Leu)), 26.9 
(CHCH2 (Lys)), 27.0 (C(CH3)2 (Pmc)), 27.2 (CH2 (Pmc)), 28.6 (C(CH3)3), 29.8 
(CHCH2CH2 (Arg) and (CH2CH2NH (Lys)), 33.0 (CH2 (Pmc)), 40.5 (NHCH2 (Lys)), 
41.8 (NHCH2 (Arg)), 46.5 (CHCH2 (Leu)), 47.2 (CH2CH (Fmoc)), 51.8 (OCH3 ester), 
52.3 (NHCH (Leu)), 53.6 (NHCHCO (Lys)), 55.2 (NHCHCO (Arg)), 67.3 (CH2 
(Fmoc)), 73.8 (OC(CH3)2), 79.4 (OC(CH3)3), 118.1 (ArC), 120.1 (ArCH), 124.2 (ArC), 
[125.3, 127.3, 127.9 (ArCH)], [132.9, 133.6, 135.0, 135.6 (ArC)], 141.4 (CH, oxazole), 
143.9 (ArC), 144.3 (ArC), [153.8, 156.5 (CO)], 156.55 (C=N), 162.4 (ArC), [165.7, 














This compound was prepared via protocol 2 using 
260 (450 mg, 0.415 mmol) to yield the desired 
product 264 as a white foam (298  mg, 84%). 
1
H 
NMR (500 MHz, CDCl3): δ 0.87-0.90 (m, 6H, 2 x 
CH3 (Leu)), 1.25-1.28 (m, 2H, CHCH2CH2 (Lys)), 
1.29 (s, 6H, 2 x CH3 (Pmc)), 1.32-1.37 (m, 2H, 
CHCH2CH2 (Arg)), 1.41 (s, 9H, Boc), 1.45-1.56 (m, 3H, CH2CH2NH (Lys) and 
CH(CH3)2 (Leu)), 1.78-1.80 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and CHCH2CH2 
(Arg)), 2.09 (s, 3H, CH3 (Pmc)), 2.55-2.62 (m, 10H, 2 x CH3 (Pmc) and 2 x CH2 
(Pmc)), 3.01-3.07 (m, 4H, CH2N (Arg) and CH2N (Lys)), 3.20-3.26 (bs, 2H, NH2), 3.80 
(s, 3H, OCH3), 3.88 (bs, 1H, Lys-α-proton), 4.55 (bs, 1H, Arg-α-proton), 4.65 (bs, 1H, 
NH), 5.14-5.21 (m, 1H, α-CH to oxazole), 6.21 (bs, 1H, NH), 6.36 (bs, 2H, NH), 7.86 
(bs, 1H, NH), 8.15 (s, 1H, oxazole); 
13
C NMR (125 MHz, CDCl3): δ 12.2 (CH3, Pmc), 
17.5 (CH3, Pmc), 18.5 (CH3, Pmc), 21.5 (CHCH2CH2 (Lys)), 21.8 (CHCH2CH2 (Arg)), 
22.7 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 25.3 (CHCH2 (Lys)), 26.8 (C(CH3)2 
(Pmc)), 28.5 (C(CH3)3), 29.6 (CH2 (Pmc)), 31.0 (CHCH2CH2 (Arg)), 32.9 (CH2CH2NH 
(Lys) and CH2 (Pmc)), 40.3 (NHCH2 (Lys)), 41.9 (NHCH2 (Arg)), 46.0 (CHCH2 (Leu)), 
52.2 (OCH3 ester), 52.3 (NHCH (Leu)), 55.2 (NHCHCO (Lys)), 58.5 (NHCHCO 
(Arg)), 73.6 (OC(CH3)2), 79.6 (OC(CH3)3), [118.0, 124.0, 132.8, 133.6, 134.9, 135.5, 
137.4 (ArC)], 144.2 (CH, oxazole), 153.6 (C=N), 156.5 (CO), 162.1 (ArC), [166.0, 
170.8, 171.3 (CO)]. MS (ESI +ve) m/z 863.0 ([M+H]
+
, 100%). 









This compound was prepared via protocol 
1, using [60]fullerenoproline acid 198 (95 
mg, 0.099 mmol) and amine 264 (102 
mg, 0.118 mmol) to yield the product as a 
white brown (98 mg, 55%). IR (neat, cm
-
1
): 3309 (w), [1685, 1647, 1635, 1558, 
1507 (s)], 1195 (m), 1136; 
1
H NMR (500 MHz, CDCl3): δ 0.84-0.87 (m, 6H, 2 x CH3 
(Leu)), 1.29 (s, 6H, 2 x CH3 (Pmc)), 1.39 (s, 9H, Boc), 1.42-1.58 (m, 6H, CHCH2CH2 
(Lys), CHCH2CH2 (Arg) and CH2CH2NH (Lys)), 1.66-1.71 (m, 2H, CHCH2CH2 (Lys)), 
1.76-1.96 (m, 5H, CHCH2 (Leu), CHCH2CH2 (Arg) and CH(CH3)2 (Leu)), 1.99 (s, 3H 
CH3 (Pmc)), 2.07 (s, 3H, CH3 (Pmc)), 2.54-2.58 (m, 7H, CH3, 2 x CH2 (Pmc)), 3.07 (bs, 
2H, CH2N (Arg)), 3.25-3.62 (m, 2H, CH2N (Lys)), 3.20-3.26 (bs, 2H, NH), 3.80 (s, 3H, 
OCH3), 4.60 (bs, 1H, Lys-α-proton), 4.66-4.68 (m, 1H, Arg-α-proton), 4.80 (bs, 1H, 
NH), 5.12 (bs, 1H, α-CH to oxazole), 6.18 (bs, 1H, NH), 6.33 (bs, 2H, NH), 7.37-7.41 
(m, 2H, ArCH), 7.46-7.52 (m, 4H, ArCH), 7.60 (d, J = 7.0 Hz, NH), 8.05 (t, 4H, J = 8.5 
Hz, 4H, ArCH), 8.08 (s, 1H, oxazole), 8.37 (bs, 1H, NH); 
13
C NMR (125 MHz, CDCl3): 
δ 12.3 (CH3, Pmc), 17.7 (CH3, Pmc), 18.7 (CH3, Pmc), 21.5 (CHCH2CH2 (Lys)), 21.7 
(CHCH2CH2 (Arg)), 22.9 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 26.9 (C(CH3)2 (Pmc) 
and CHCH2 (Lys)), 28.5 (C(CH3)3), 29.6 (CH2 (Pmc)), 32.9 (CHCH2CH2 (Arg)) and 
CH2CH2NH (Lys)), 40.2 (NHCH2 (Lys)), 41.8 (NHCH2 (Arg)), 46.7 (CHCH2 (Leu)), 





52.3 (OCH3 ester), 54.2 (NHCH (Leu)), 55.2 (NHCHCO (Lys)), 58.5 (NHCHCO 
(Arg)), 73.7 (OC(CH3)2), 82.2 (OC(CH3)3), 95.8 (NCPh2), 118.3 (ArC (Pmc)), 124.1 
(ArC (Pmc)), [128.5, 128.6, 129.9 (ArCH)], 133.0 (ArC), [134.9, 135.6 (C60sp
2
)], 
[136.7, 138.2 (ArC, Pmc)], [139.3, 139.5 (C60sp
2
)], [139.8, 140.8 (ArC)], 141.0 (CH, 
oxazole ), [141.3, 141.8, 141.9, 142.0, 142.5, 142.8, 142.9, 143.0, 143.08, 144.2, 144.3, 
144.4, 145.0, 145.2, 145.3, 145.5, 145.6, 145.9, 146.4* (1/2 x C), 146.5* (1/2 x C), 
147.0, 147.2, 148.3, 148.6, 149.0, 153.4, (C60sp
2
)], 153.7 (C=N), 156.5 (CO, Boc),  
157.8 (C=N), [161.5, 161.9 (CO)], 162.3 (ArC), 171.7 (2 x CO)]. Two C60sp
3
 signals 
were not observed due to poor signal to noise. HRMS (ESI +ve) calcd for 
C116H75N9O11SNa 1824.5204, found 1824.5183. 
1-(S)-4-(R)-2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonylamino-6-
ammoniohexanamido)-5-(S)-1-(4-(methoxycarbonyloxazol-2-yl)-3-
methylbutylamino)-5-oxopentyl)guanidinium chloride (277) 
This compound was prepared via protocol 3, 
using 273 (60 mg, 0.033 mmol) to yield 277 as 
a brown solid (25 mg, 53%). IR (neat, cm
-1
): 
3336 (w), [1647, 1635, 1507 (s)], 1162 (m);  
1
H NMR (500 MHz, DMSO-d6):  0.77-0.86 
(m, 6H, 2 x CH3 (Leu)), 1.22-1.66 (m, 6H, CHCH2CH2 (Lys), CHCH2CH2 (Arg) and 
CH2CH2NH (Lys))), 1.67-1.79 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.85-
1.88 (m, 3H, CHCH2 (Leu) and CH(CH3)2 (Leu)), 2.73 (bs, 2H, NH2), 3.05 (bs, 2H, 
CH2N (Arg)), 3.34-3.62 (m, 2H, CH2N (Lys)), 3.75 (s, 3H, OCH3), 4.17 (bs, 1H, Lys-α-
proton), 4.36 (t, 1H, J = 6.5 Hz, NH), 4.45 (bs, 1H, Arg-α-proton), 4.62 (t, 1H, J = 7.5 
Hz, NH), 4.97-4.98 (m, 1H, α-CH to oxazole), 7.41-7.45 (m, 2H, ArCH), 7.53-7.58 (m, 





4H, ArCH), 8.06-8.10 (m, 4H, ArCH), 8.17 (d, 1H, J = 7.5 Hz, NH), 8.38 (d, 1H, J = 
8.0 Hz, NH), 8.43 (d, 1H, J = 8.0 Hz, NH), 8.56 (d, 1H, J = 8.0 Hz, NH), 8.68 (s, 1H, 
oxazole), 9.50-9.55 (m, 2H, NH2 (Arg)). This compound was not sufficiently soluble to 
generate an adequate 
13
C NMR spectrum. HRMS (ESI +ve) calcd for C97H49N9O6 





This compound was prepared via 
protocol 1 using 264 (136  mg, 0.157 
mmol) and Fmoc-Gly-OH (47 mg, 
0.157 mmol) to yield the desired 
product 267 as a white foam (128  
mg, 71%). 
1
H NMR (500 MHz, 
CDCl3): δ 0.82 (d, J = 6.0 Hz, 6H, 2 x CH3 (Leu)), 1.26 (s, 6H, 2 x CH3 (Pmc)), 1.38 (s, 
9H, Boc), 1.43-1.66 (m, 7H, CHCH2CH2 (Lys), CHCH2CH2 (Arg), CH(CH3)2 (Leu) and 
CH2CH2NH (Lys)), 1.74-1.76 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and 
CHCH2CH2 (Arg)), 1.96 (bs, 1H, NH), 2.06 (s, 3H, CH3 (Pmc)), 2.53 (s, 3H, CH3 
(Pmc)), 2.55 (s, 3H, CH3 (Pmc)), 2.57-2.58 (m, 4H, 2 x CH2 (Pmc)), 3.01 (bs, 2H, 
CH2N (Arg)), 3.18-3.26 (m, 3H, CH2N (Lys) and NH), 3.70 (s, 3H, OCH3), 3.90-4.13 
(m, 3H, CH2 (Fmoc) and NH), 4.22 (bs, 2H, Lys-α-proton and Arg-α-proton), 4.53 (bs, 
2H, CH2 (Gly)), 4.54-4.55 (m, 1H, CH (Fmoc)), 4.83 (bs, 1H, NH), 5.14-5.18 (m, 1H, 
α-CH to oxazole), 5.92 (bs, 1H, NH), 6.19 (bs, 1H, NH), 6.32 (bs, 2H, NH), 7.26-7.28 





(m, 2H, ArCH), 7.36 (t, J = 7.5 Hz, 2H, ArCH), 7.54 (t, J = 8.5 Hz, 2H, ArCH), 7.72 
(d, J = 7.5 Hz, 2H, ArCH), 8.04 (s, 1H, oxazole); 
13
C NMR (125 MHz, CDCl3): δ 12.3 
(CH3, Pmc), 17.7 (CH3, Pmc), 18.7 (CH3, Pmc), 21.6 (CHCH2CH2 (Lys)), 22.8 
(CHCH2CH2 (Arg)), 22.88 (2 x CH3 (Leu)), 24.8 (CH(CH3)2 (Leu)), 26.9 (CHCH2 
(Lys)), 26.98 (C(CH3)2 (Pmc)), 27.2 (CH2 (Pmc)), 28.6 (C(CH3)3), 29.8 (CHCH2CH2 
(Arg) and (CH2CH2NH (Lys)), 33.0 (CH2 (Pmc)), 40.5 (NHCH2 (Lys)), 41.8 (NHCH2 
(Arg)), 44.2 (CH2 (Gly)), 46.5 (CHCH2 (Leu)), 47.2 (CH2CH (Fmoc)), 52.3 (NHCH 
(Leu)), 53.6 (NHCHCO (Lys)), 55.2 (NHCHCO (Arg)), 67.3 (CH2, (Fmoc)), 73.8 
(OC(CH3)2), 79.4 (OC(CH3)3), 118.1 (ArC), 120.1 (ArCH), 124.2 (ArC), [125.3, 127.3, 
127.9 (ArCH)], [132.9, 133.6, 135.0, 135.6 (ArC)], 141.4 (CH, oxazole), 143.9 (ArC), 
144.3 (ArC), [153.8, 156.5 (CO)], 156.6 (C=N), 165.7 (ArC), 170.6 (2 x CO), 171.8 






This compound was prepared via protocol 2 
using 267 (120 mg, 0.105 mmol) to yield the 
desired product 270 as a white foam (85 mg, 
88%). IR (neat, cm
-1
): 3303 (w), 3064, [1683, 
1647, 1558, 1507 (s)], 1141 (m), 1106; 
1
H 
NMR (500 MHz, CDCl3): δ 0.82 (d, J = 6.0 Hz, 
6H, 2 x CH3), 1.25 (s, 6H, 2 x CH3 (Pmc)), 1.39 (s, 9H, Boc), 1.41-1.68 (m, 7H, 
CHCH2CH2 (Lys), CHCH2CH2 (Arg), CH2CH2NH (Lys) and CH(CH3)2 (Leu)), 1.74-
1.76 (m, 6H, CHCH2 (Leu), CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.96 (bs, 1H, 





NH), 2.08 (s, 3H, CH3 (Pmc)), 2.51 (s, 3H, CH3 (Pmc)), 2.56 (s, 3H, CH3 (Pmc)), 2.57-
2.58 (m, 4H, 2 x CH2 (Pmc)), 3.01 (bs, 2H, CH2N (Arg)), 3.18-3.26 (m, 3H, CH2N 
(Lys) and NH), 3.80 (s, 3H, OCH3), 3.90-4.13 (m, 3H, CH2 (Gly) and Lys-α-proton), 
4.22 (bs, 2H, NH2), 4.53 (bs, 2H, Arg-α-proton and NH), 4.83 (1H, NH), 5.14-5.18 (m, 
1H, α-CH to oxazole), 5.92 (bs, 1H, NH), 6.19 (bs, 1H, NH), 6.32 (bs, 2H, NH), 8.04 (s, 
1H, oxazole); 
13
C NMR (125 MHz, CDCl3): δ 12.3 (CH3, Pmc), 17.7 (CH3, Pmc), 18.7 
(CH3, Pmc), 21.6 (CHCH2CH2 (Lys)), 21.9 (CHCH2CH2 (Arg)), 22.8 (2 x CH3 (Leu)), 
24.8 (CH(CH3)2 (Leu)), 26.9 (CHCH2 (Lys)), 26.98 (C(CH3)2 (Pmc)), 28.6 (C(CH3)3), 
29.8 (CH2 (Pmc)), 33.0 (CHCH2CH2 (Arg)), 33.1 (CH2CH2NH (Lys) and CH2 (Pmc)), 
40.5 (NHCH2 (Lys)), 41.8 (NHCH2 (Arg)), 42.3 (CH2 (Gly)), 46.5 (CHCH2 (Leu)), 52.3 
(OCH3 ester), 53.6 (NHCH (Leu)), 55.2 (NHCHCO (Lys) and (NHCHCO (Arg)), 73.8 
(OC(CH3)2), 79.4 (OC(CH3)3), [118.1, 124.2, 125.3, 132.9, 133.6, 135.0, 135.6 (ArC)], 








This compound was prepared via 
protocol 1 using 270 (75 mg, 
0.0816 mmol) and fullerenoproline 
acid 198 (65 mg, 0.0679 mmol) to 
yield the desired product 274 as a 
brown solid (64 mg, 51%). IR (neat, 







): 3285 (w), [1685, 1635, 1653, 1507 (s)], [1253, 1164, 1100 (m)]; 
1
H NMR (500 
MHz, CDCl3): δ 0.86-0.90 (m, 6H, 2 x CH3 (Leu)), 1.30 (s, 6H, 2 x CH3 (Pmc)), 1.41 (s, 
9H, Boc), 1.45-1.51 (m, 4H, CHCH2CH2 (Lys) and CHCH2CH2 (Arg)), 1.62-1.68 (m, 
4H, CH2CH2NH (Lys) and CHCH2CH2 (Lys)), 1.79 (t, J = 6.5 Hz, 2H, CHCH2 (Leu)), 
1.78-1.88 (m, 3H, CHCH2CH2 (Arg) and CH(CH3)2 (Leu)), 2.08 (s, 3H, CH3, (Pmc)), 
2.54 (s, 3H, CH3, (Pmc)), 2.56 (s,  3H, CH3, (Pmc)), 2.61 (t, J = 6.5 Hz, 2H, CH2 
(Pmc)),  3.02 (bs, 2H, CH2N (Arg)), 3.14-3.18 (m, 2H, CH2N (Lys)), 3.83 (s, 3H, 
OCH3), 4.30 (d, J = 8.0 Hz, 2H (Gly)), 4.37-4.41 (m, 3H, Lys-α-proton, Arg-α-proton 
and NH), 5.16-5.17 (m, 1H, α-CH to oxazole), 7.38 (t, J = 6.5 Hz, 2H, ArCH), 7.45-
7.50 (m, 4H, ArCH), 7.75 (bs, 1H, NH), 7.84 (bs, 1H, NH),  8.05 (t, J = 7.5 Hz, 4H, 
ArCH), 8.13 (s, 1H, oxazole), 8.90 (bs, 1H, NH); 
13
C NMR (125 MHz, CDCl3): δ 12.1 
(CH3, Pmc), 17.5 (CH3, Pmc), 18.5 (CH3, Pmc), 21.4 (CHCH2CH2 (Lys)), 21.7 
(CHCH2CH2 (Arg)), 22.7 (2 x CH3 (Leu)), 24.6 (CH(CH3)2 (Leu)), 25.5 CHCH2 (Lys)), 
26.8 (C(CH3)2 (Pmc)), 28.4 (C(CH3)3), 29.6 (CH2 (Pmc)), 32.8 (CHCH2CH2 (Arg)) and 
CH2CH2NH (Lys)), 40.2 (NHCH2 (Lys)), 41.8 (NHCH2 (Arg)), 44.4 (CH2 (Gly)), 46.0 
(CHCH2 (Leu)), 52.3 (OCH3 ester), 52.5 (NHCH (Leu) and (NHCHCO (Lys)), 58.7 





95.6 (NCPh2), [117.9  124.0 (ArC (Pmc)], 128.4 (ArCH), 129.8 (2 x ArCH), [132.8, 
133.5, 134.7 (ArC)], [134.9, 135.5, 135.6, 136.6 (C60sp
2
)], [139.1, 139.5, 140.9 (ArC)], 
141.3 (ArCH, oxazole), [141.8, 141.9, 142.4, 142.5, 142.7, 142.8, 143.0, 143.1, 144.2, 
144.3, 144.9, 145.1, 145.3, 145.4, 145.5, 145.6, 145.8, 146.0, 146.1, 146.38* (1/2 x C), 
146.4* (1/2 x C), 146.9, 147.1, 148.3, 149.5, 153.6, (C60sp
2
)], 155.9 (C=N), 156.5 (CO, 
Boc), 157.8 (C=N), 162.0 (ArC, oxazole), [163.9 (CO), 167.3 (2 x CO), 171.5 (2 x CO). 
HRMS (ESI +ve) calcd for C118H78N10O12SNa 1881.5419, found 1881.5436.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   







yl-3-methylbutylamino)-5-oxopentylguanidinium chloride (278) 
This compound was prepared via protocol 
3, using 274 (35 mg, 0.0188 mmol) to 
yield 278 as a brown solid (13 mg, 46%). 
IR (neat, cm
-1
): 3305 (w), [1675, 1655, 
1651, 1507 (s)], [1258, 1162, 1107 (m)]; 
1
H NMR (500 MHz, CDCl3:CD3OD (4:1)):  0.84-0.88 (m, 6H, 2 x CH3 (Leu)), 1.24-
1.28 (m, 2H, CHCH2CH2 (Lys)), 1.56-1.79 (m, 7H, CHCH2CH2 (Arg), CH2CH2NH 
(Lys), CHCH2CH2 (Lys) and CH(CH3)2 (Leu)), 1.83-1.87 (m, 6H, CHCH2CH2 (Arg), 
CHCH2 (Leu) and CH2NH2 (Lys)), 2.10 (s, 1H, NH), 2.65 (bs, 1H, NH), 2.88 (bs, 2H, 
CH2N (Lys)), 2.93 (bs, 1H, NH), 3.08 (bs, 2H, CH2N (Arg)), 3.30 (s, 3H, OCH3), 3.40-
3.41 (m, 2H, NH2), 3.80 (s, 2H (Gly)), 4.19 (d, 1H, J = 7.5 Hz, NH), 4.34-4.40 (m, 3H, 
Lys-α-proton, Arg-α-proton and α-CH to oxazole), 7.40 (t, 2H, J = 7.5 Hz, ArCH), 7.51 
(m, 4H, ArCH), 7.85 (s, 1H, NH), 8.11-8.15 (m, 4H, ArCH), 8.41 (s, 1H, oxazole); This 
compound was not sufficiently soluble to generate an adequate 
13
C NMR spectrum. 












This compound was prepared via protocol 1 
using 257 (150 mg, 0.340 mmol) and Fmoc-
(D)-Lys(Boc)-OH (159  mg, 0.340 mmol) to 
yield the desired product 261 as a white foam 
(220 mg, 72%). 
1
H NMR (500 MHz, CDCl3): δ 
0.91-0.94 (m, 6H, 2 x CH3 (Leu)), 1.34-1.49 (m, 
7H, 2 x CHCH2CH2 (Lys), CH(CH3)2 (Leu) and CH2CH2NH (Lys)), 1.41 (s, 9H, Boc), 
1.42 (s, 9H, Boc), 1.65-1.69 (m, 2H, CH2CH2NH (Lys)), 1.75-1.78 (m, 2H, CHCH2 
(Leu)), 1.82-1.88 (m, 4H, 2 x CHCH2CH2 (Lys)), 3.04 (bs, 2H, CH2N (Lys)), 3.20 (bs, 
2H, CH2N (Lys)), 3.77 (s, 3H, OCH3), 4.18 (t, J = 7 Hz, 1H, CH, Fmoc), 4.36-4.37 (m, 
2H, CH2, Fmoc), 4.51 (bs, 1H, NH), 4.73 (bs, 1H, Lys-α-proton), 4.80 (bs, 1H, Lys-α-
proton), 5.20-5.29 (m, 1H, α-CH to oxazole), 5.95 (bs, 1H, NH), 7.08 (bs, 1H, NH), 
7.26-7.30 (m, 3H, 2 x ArCH, NH), 7.36-7.40 (m, 2H, ArCH), 7.51 (d, J = 7.5 Hz, 2H, 
ArCH), 7.57 (d, J = 7.5 Hz, 1H, NH), 7.74 (d, J = 7.5 Hz, 2H, ArCH), 8.00 (s, 1H, 
oxazole); 
13
C NMR (125 MHz, CDCl3): δ 21.6 (CHCH2CH2 (Lys)), 22.4 (CHCH2CH2 
(Lys)), 22.8 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 28.4 (2 x C(CH3)3), 29.4 (CHCH2 
(Lys)), 29.6 (CHCH2 (Lys)), 31.2 (2 x CH2CH2NH (Lys)), 39.5 (NHCH2 (Lys)), 40.1 
(NHCH2 (Lys)), 46.0 (CHCH2 (Leu)), 47.0 (CH2CH (Fmoc)), 52.0 (OCH3 ester), 52.9 
(NHCH (Leu)), 55.7 (2 x NHCHCO (Lys)), 67.2 (CH2, Fmoc), 79.2 (2 x OC(CH3)3), 
[119.9, 124.9, 125.0, 127.0 (ArCH)], 132.9 (ArC, oxazole), 141.2 (CH, oxazole), 141.3 





(ArC), 143.9 (ArC), 156.5 (2 x CO, Boc), 161.3 (ArC, oxazole), [166.0, 171.4 (2 x CO), 






This compound was prepared via protocol 2 using 261 (200 
mg, 0.224 mmol) to yield the desired product 265 as a white 
foam (128 mg, 85%). 
1
H NMR (500 MHz, CDCl3): δ 0.93-
0.95 (m, 6H, 2 x CH3 (Leu)), 1.34-1.39 (m, 4H, 2 x 
CHCH2CH2 (Lys)), 1.43 (s, 18H, 2 x Boc), 1.50-1.57 (m, 
5H, 2 x CH2CH2NH (Lys) and CH(CH3)2 (Leu)), 1.75-1.76 
(m, 6H, CHCH2 (Leu) and 2 x CHCH2CH2 (Lys)), 1.90-1.96 (m, 1H, NH), 3.11 (bs, 4H, 
2 x CH2N (Lys)), 3.48 (bs, 1H, Lys-α-proton), 3.87 (s, 3H, OCH3), 4.42-4.44 (m, 2H, 
NH2), 4.62-4.66 (m, 2H, Lys-α-proton and NH), 5.18-5.24 (m, 1H, α-CH to oxazole), 
7.18 (bs, 1H, NH), 7.82 (bs, 1H, NH), 8.12 (s, 1H, CH, oxazole); 
13
C NMR (125 MHz, 
CDCl3): δ 22.0 (CHCH2CH2 (Lys)), 22.9 (CHCH2CH2 (Lys)), 23.0 (2 x CH3 (Leu)), 
23.07 (CH(CH3)2 (Leu)), 25.0 (CHCH2 (Lys)), 28.6 (2 x C(CH3)3), 29.8 (CH2CH2NH 
(Lys)), 30.0 (CH2CH2NH (Lys), 40.3 (NHCH2 (Lys)), 42.7 (NHCH2 (Lys)), 46.1 
(CHCH2 (Leu)), 52.3 (NHCH (Leu)), 52.4 (NH2CHCO (Lys)), 55.1 (NHCHCO (Lys)), 
79.2 (2 x OC(CH3)3), 133.3 (ArC, oxazole), 144.1 (ArCH, oxazole), 156.2 (2 x CO, 













This compound was prepared via 
protocol 1 using 265 (65 mg, 0.0973 
mmol) and Fmoc-Gly-OH (30 mg, 
0.0973 mmol) to yield the desired 
product 268 as a white foam (76 mg, 
82%). 
1
H NMR (500 MHz, CDCl3): δ 
0.88-0.89 (m, 6H, 2 x CH3 (Leu)), 1.30-1.45 (m, 4H, 2 x CHCH2CH2 (Lys)), 1.41 (s, 
18H, 2 x Boc), 1.60-1.95 (m, 7H, CH(CH3)2 (Leu), 2 x CH2CH2NH (Lys) and CHCH2 
(Leu)), 2.61 (bs, 1H, NH), 3.05 (bs, 4H, 2 x CH2N (Lys)), 3.81 (s, 3H, OCH3), 4.05 (bs, 
2H, CH2 (Gly)), 4.18 (bs, 1H, CH, Fmoc), 4.22-4.37 (m, 2H, CH2, Fmoc), 4.55 (bs, 1H, 
NH), 4.62 (bs, 1H, Lys-α-proton), 4.90 (bs, 1H, Lys-α-proton), 5.08 (bs, 1H, NH), 5.20-
5.29 (m, 1H, α-CH to oxazole), 6.50 (bs, 1H, NH), 7.25 (t, J = 7.0 Hz, 2H, ArCH), 7.36 
(t, J = 7.5 Hz, 2H, ArCH), 7.73 (d, J = 7.5 Hz, 2H, ArCH), 7.77 (m, 3H, 2 x ArCH and 
NH), 8.09 (s, 1H, CH, oxazole); 
13
C NMR (125 MHz, CDCl3): δ 21.9 (CHCH2CH2 
(Lys)), 22.8 (CHCH2CH2 (Lys)), 22.9 (2 x CH3 (Leu)), 24.9 (CH(CH3)2 (Leu)), 28.6 (2 
x C(CH3)3), 29.8 (2 x CHCH2 (Lys)), 31.9 (2 x CH2CH2NH (Lys)), 40.1 (NHCH2 
(Lys)), 40.5 (NHCH2 (Lys)), 42.6 (CH2 (Gly)), 44.7 (CHCH2 (Leu)), 47.2 (CH2CH 
(Fmoc)), 52.3 (OCH3 ester), 53.1 (NHCH (Leu)), 54.2 (2 x NHCHCO (Lys)), 67.3 
(OCH2, Fmoc), 79.2 (2 x OC(CH3)3), [120.1, 125.3, 127.2, 127.9 (ArCH)], 133.1 (ArC, 
oxazole), 141.4 (CH, oxazole), 143.9 (ArC), 144.1 (ArC), 156.6 (2 x CO, Boc), 161.7 












This compound was prepared via protocol 2 using 268 
(60 mg, 0.0633 mmol) to yield the desired product 271 
as a white foam (39 mg, 86%). 
1
H NMR (500 MHz, 
CDCl3): δ 0.91-0.95 (m, 6H, CH(CH3)2 (Leu)), 1.24-
1.58 (m, 9H, 2 x CHCH2CH2 (Lys), 2 x CH2CH2NH 
(Lys) and CH(CH3)2 (Leu)), 1.42 (s, 18H, 2 x Boc), 
1.60-1.68 (m, 2H, CHCH2 (Leu)), 1.75-1.80 (m, 2H, CHCH2CH2 (Lys)), 1.82-1.88 (m, 
2H, CHCH2CH2 (Lys)), 1.90-1.96 (m, 1H, NH), 2.22-2.40 (bs, 2H, NH2), 3.07 (t, J = 
6.0 Hz, 4H, CH2N (Lys)), 3.36-3.45 (m, 2H, (CH2 (Gly)), 3.87 (s, 3H, OCH3), 4.30-4.35 
(m, 1H, Lys-α-proton), 4.48-4.55 (m, 1H, Lys-α-proton), 4.85-4.95 (m, 1H, NH), 5.20-
5.38 (m, 1H, α-CH to oxazole), 7.28 (bs, 1H, NH), 7.48 (bs, 1H, NH), 7.88 (bs, 1H, 
NH), 8.15 (s, 1H, CH, oxazole); 
13
C NMR (125 MHz, CDCl3): δ 21.7 (CHCH2CH2 
(Lys)), 22.7 (CHCH2CH2 (Lys)), 22.8 (2 x CH3 (Leu)), 24.7 (CH(CH3)2 (Leu)), 28.4 (2 
x C(CH3)3), 29.4 (CH2CH2NH (Lys)), 29.6 (CH2CH2NH (Lys), 31.1 (CHCH2 (Lys)), 
31.3 (CHCH2 (Lys)), 40.0 (NHCH2 (Lys)), 40.1 (NHCH2 (Lys)), 44.6 (CHCH2 (Leu)), 
45.9 (CH2 (Gly)), 52.1 (NHCH (Leu)), 52.7 (NHCHCO (Lys)), 53.8 (NHCHCO (Lys)), 
79.0 (2 x OC(CH3)3), 132.9 (ArC, oxazole), 143.9 (CH, oxazole), 156.2 (2 x CO, Boc), 
161.5 (ArC, oxazole), [165.9, 171.4, 172.0, 174.1 (CO)]. MS (ESI +ve) m/z 726.0 
([M+H]+, 100%). 









 To a suspension of acid 198 (46 mg, 
0.048 mmol) in CH2Cl2/CHCl3 (1:1), 
(100 mL) was added HOBt (7.7 mg, 
0.057 mmol) and EDCI (11 mg, 0.057 
mmol) and the mixture was stirred for 15 
min before a solution of 271 (35 g, 0.048 
mmol) and triethylamine (8.0 µL, 0.057 mmol) in CH2Cl2 (10 mL) was added dropwise. 
The resulting solution was stirred at rt for a further 4 h before the solvent was removed 
under reduced pressure. The crude residue was then subjected to flash silica gel 
chromatography, elution with MeOH/CH2Cl2 (1:49) provided the title compound 275 as 
a brown solid (52 mg, 65%). IR (neat, cm
-1
): 3321 (w), [1695, 1647, 1635 (s)], [1363, 
1248, 1153 (m)]; 
1
H NMR (500 MHz, CDCl3 + CD3OD (9:1)): δ 0.91-0.94 (m, 6H, 
CH(CH3)2 (Leu)), 1.34-1.51 (m, 8H, 2 x CHCH2CH2 (Lys) and 2 x CH2CH2NH (Lys)), 
1.42 (s, 18H, 2 x Boc), 1.58-1.76 (m, 4H, 2 x CHCH2CH2 (Lys)), 1.79-1.88 (m, 2H, 
CHCH2 (Leu)), 1.95 (bs, 1H, CH(CH3)2 (Leu)), 3.07 (bs, 4H, CH2N (Lys)), 3.37 (s, 2H, 
(CH2 (Gly))), 3.83 (s, 3H, OCH3), 4.20-4.32 (m, 1H, NH), 4.34 (bs, 2H, Lys-α-proton 
and NH), 4.50 (bs, 1H, Lys-α-proton), 5.18-5.20 (m, 1H, α-CH to oxazole), 5.26 (bs, 
1H, NH), 5.34 (bs, 1H, NH), 7.34, (s, 1H, CH, oxazole), 7.39-7.43 (m, 2H, ArCH), 
7.48-7.52 (m, 4H, ArCH), 7.69 (d, J = 7.0 Hz, 1H, NH), 7.92 (d, J = 7.5 Hz, 1H, NH), 
8.03 (d, J = 8 Hz, 4H, ArCH), 8.08 (bs, 1H, NH); 
13
C NMR (125 MHz, CDCl3 + 





CD3OD (9:1)): δ 21.5 (CHCH2CH2 (Lys)), 22.9 (2 x CH3 (Leu)), 24.8 (CH(CH3)2 
(Leu)), 28.4 (2 x C(CH3)3), 29.5 (CH2CH2NH (Lys) and (CHCH2 (Lys)), 42.6 (NHCH2 
(Lys)), 46.0 (CHCH2 (Leu)), 48.6 (CH2 (Gly)), 48.8 (NHCH2 (Lys)), 49.0 (NHCH 
(Leu)), 49.7 (NHCHCO (Lys)), 52.3 (NHCHCO (Lys)), 95.7 (CPh2), [128.5, 128.6, 
129.9 (ArCH)], 134.7, (ArC, oxazole), [134.9, 136.7, 139.2, 139.3, 139.5, 139.6, 140.9, 
141.0, 141.4, 141.9 (C60sp
2
)], 142.0 (CH, oxazole), 142.5 (ArC), [142.6, 142.9, 143.1, 
143.2, 144.2, 144.4, 144.9, 145.0, 145.2, 145.3, 145.5, 145.6, 145.9, 146.1, 146.5, 
147.0* (1/2 x C), 147.2* (1/2 x C), 148.4, 149.1 (C60sp
2
)], 153.2 (C=N), 153.3 (2 x CO, 
Boc), 161.6 (ArC, oxazole), [166.2 (2 x CO), 171.0 (2 x CO), 171.2 (CO, ester). Two 
C60sp
3
 signals and Boc tert-carbons were not observed due to poor signal to noise. 
HRMS (ESI +ve) calcd for C109H68N8O11 1665.5085, found 1665.5359. 
(R)-5-(2-(5,5-Diphenylfullerenyldihydropyrrole-2-carbonyl)-aminoacetamido)-6-
(R)-6-ammonio-1-(S)-1-(4-(methoxycarbonyloxazol-2-yl)-3-methylbutylamino-1-
oxohexan-2-yl)amino-6-oxohexan-1-aminium 2,2,2-trifluoroacetate (279) 
This compound was prepared via 
protocol 3, using 275 (35 mg, 0.0210 
mmol) to yield 279 as a brown solid (17 
mg, 56%). IR (neat, m
-1
): 3309 (w), 
[1685, 1647, 1558 (s)], [1457, 1193, 
1135 (m)]; HRMS (ESI +ve) calcd for 
C99H52N8O7 1465.4037, found 1465.4045. This compound was not sufficiently soluble 
to generate an adequate 
1
H NMR and 
13
C NMR spectrum. 








This compound was prepared via protocol 
1 using 254 (220 mg, 0.353 mmol) and 
Fmoc-(S)-Lys(Boc)-OH (165 mg, 0.353 
mmol) to yield the desired product 258 as 
a white foam (300 mg, 79%). 
1
H NMR 
(500 MHz, CDCl3): δ 0.84-0.88 (m, 12H, 
4 x CH3 (Leu and isopentyl)), 1.40 (s, 9H, Boc), 1.43 (s, 6H, C(CH3)2, (Pmc)), 1.46-1.49 
(m, 4H, CHCH2CH2 (Arg) and CHCH2CH2 (Lys)), 1.57-1.72 (m, 6H, CH2CH2NH 
(Lys), OCH2CH2 and CHCH2 (Arg)), 1.76 (bs, 1H, CH(CH3)2 (isopentyl)), 1.92 (m, 2H, 
CHCH2 (Leu)), 1.99 (bs, 1H, CH(CH3)2 (Leu)), 2.07 (s, 3H, CH3, (Pmc)), 2.50 (s, 3H, 
CH3, (Pmc)), 2.57 (s, 3H, CH3, (Pmc)), 2.92 (m, 4H, CH2, (Pmc)), 3.06 (bs, 2H, CH2N 
(Arg)), 3.23 (bs, 2H, CH2N (Lys)), 4.05-4.10 (m, 2H, Lys-α-proton and CHCH2 
(Fmoc)), 4.16-4.20 (m, 2H, CO2CH2), 4.32-4.34 (m, 2H, CHCH2 (Fmoc)), 4.43-4.45 
(m, 1H, Arg-α-proton), 4.56-4.57 (m, 1H, Leu-α-proton), 4.82 (bs, 1H, NH), 5.29 (s, 
1H, NH), 5.82 (bs, 1H, NH), 6.29 (bs, 2H, NH), 7.26-7.29 (m, 3H, 2 x ArCH, NH), 
7.35-7.38 (m, 2H, ArCH), 7.56-7.58 (m, 2H, ArCH), 7.73 (d, J = 7.5 Hz, 2H, ArCH); 
13
C NMR (125 MHz, CDCl3): δ 12.8 (CH3, Pmc), 18.3 (CH3, Pmc), 19.6 (CH3, Pmc), 
21.9 (CHCH2CH2 (Lys)), 22.6 (2 x CH3 (isopentyl)), 22.7 (2 x CH3 (Leu)), 22.8 (2 x 
CH3 (isopentyl)), 23.0 (CHCH2CH2 (Arg) and (CH(CH3)2 (isopentyl)), 25.0 (CH(CH3)2 
(Leu)), 25.2 (CHCH2CH2 (Lys)), 28.7 (C(CH3)3), 28.8 (2 x CH3 (Pmc) and (CH2 
(Pmc)), 29.6 (CHCH2CH2 (Arg)), 29.8 (CH2CH2NH (Lys)), 31.7 (CH2 (Pmc)), 37.5 





(CH2CH(CH3)2 (isopentyl)), 40.3 (CH2CH(CH3)2 (Leu)), 40.6 (NHCH2 (Lys)), 43.9 
(NHCH2 (Arg)), 51.6 (CH2CH (Fmoc)), 52.7 (NHCHCO (Leu)), 53.7 (NHCHCO 
(Lys)), 55.5 (NHCHCO (Arg)), 64.3 (OCH2 (isopentyl)), 67.4 (CH2CH (Fmoc)), 79.6 
(OC(CH3)3), 86.6 (OC(CH3)2), 117.7 (ArC, Pmc), 120.2 (ArCH), 124.8 (ArC, Pmc), 
[125.4, 125.5, 128.0 (ArCH)], [132.5, 138.6, 141.4, 141.5 (ArC, Pmc)], [143.9, 144.1 
(ArC)], 156.6 (CO, Boc), [159.0, 171.9, 172.5 (CO)], 173.4 (CO, ester); MS (ESI +ve) 




This compound was prepared via protocol 2 using 258 
(275 mg, 0.256 mmol) to yield the desired product 262 
as a white foam (185 mg, 85%). This compound was 
carried through the subsequent reaction without any 
further purification. 
 
trans-4-Bis-(5,5-diphenylfullerenyldihydropyrrole-2-carboxylic acid) (284) 
To a solution of the bis ester 283 (0.128 g, 0.098 mmol) in 1,2-
dichloroethane (80 mL) at rt was added (CH3)3SnOH (0.077 g, 
0.392 mmol) and the solution was heated at 80 
o
C for 4 h, then 
(CH3)3SnOH (0.077 g, 0.392 mmol) was added at the same 
temperature and the reaction was continued for 4 h. The reaction 
mixture was evaporated under reduced pressure and the resulting residue was taken in 





CH2Cl2 (100 mL). The organic layer was washed with 5% HCl (3 x 50 mL), brine (3 x 
50 mL), dried (Mg2SO4) and evaporated under reduced pressure to yield 284 (0.109 g, 
93%) as a brown solid. 
1
H NMR (500 MHz, CDCl3): 7.28-7.29 (m, 1H, ArCH), 7.39 
(t, 2H, J = 7.2 Hz, ArCH), 7.46 (t, 1H, J = 7.2 Hz, ArCH), 7.56 (t, 2H, J = 7.2 Hz, 
ArCH), 7.94 (d, 2H, J = 7.2 Hz, ArCH), 8.08 (d, 2H, J = 7.2 Hz, ArCH), 8.71 (bs, 1H, 
CO2H). ESI-MS (+ve): m/z 1195 (40%, [M+H]
+







To a suspension of bis[60]fullerenoproline 
acid 284 (96 mg, 0.080 mmol) in 
CHCl3/pyridine (2:1) (90 mL) was added 
HOBt (27 mg, 0.200 mmol) and EDCI (45 
mg, 0.240 mmol) and the mixture was 
stirred for 15 min before a solution of 262 
(171 mg, 0.200 mmol) in CHCl3/pyridine 
(2:1) (15 mL) was added dropwise. The 
resulting solution was stirred at rt for a further 4 h, before the solvent was removed 
under reduced pressure. The crude residue was then subjected to flash silica gel 
chromatography, elution with MeOH/CH2Cl2 (1:49) provided the title compound 285 as 
a brown solid (0.115 g, 50%). IR (neat, cm
-1
): 3277 (w), [1685, 1647, 1635, 1558 (s)], 
[1260, 1187, 1156 (m)]; 
1
H NMR (500 MHz, CDCl3): δ 0.79-0.90 (m, 24H, 8 x CH3 
(Leu and isopentyl)), 1.23-1.25 (m, 4H, 2 x CHCH2CH2 (Lys)), 1.28 (s, 18H, 6 x CH3 (2 





x Boc)), 1.30-1.38 (m, 12H, 4 x CH3 (Pmc)), 1.42-1.48 (m, 14H, 2 x CHCH2CH2 (Arg), 
2 x CH2CH2NH (Lys), 2 x OCH2CH2 and 2 x CH(CH3)2 (isopentyl)), 1.55-1.68 (m, 
10H, 2 x CHCH2 (Arg), 2 x CHCH2CH2 (Lys) and 2 x CH(CH3)2 (Leu)), 1.77 (t, J = 6.5 
Hz, 4H, 2 x CHCH2 (Leu)), 2.05 (m, 4H, 2 x CH2 (Pmc)), 2.07 (s, 6H, 2 x CH3, (Pmc)), 
2.31 (t, J = 7.5 Hz, 4H, 2 x CH2 (Pmc)), 2.52-2.59 (m, 12H, 4 x CH3, (Pmc)), 3.01-3.08 
(m, 4H, CH2N, (Lys)), 4.00-4.10 (m, 4H, 2 x OCH2), 4.53-4.56 (m, 6H, 2 x Leu-α-
proton and CH2N (Arg)), 4.65-4.68 (m, 2H, 2 x Lys-α-proton), 5.38 (bs, 4H, NH), 5.50-
5.58 (m, 2H, 2 x Arg-α-proton)), 6.24 (bs, 4H, NH), 7.08-7.16 (m, 2H, NH), 7.33-7.37 
(m, 6H, ArCH), 7.44-7.46 (m, 2H, ArCH), 7.51-7.54 (m, 4H, ArCH), 7.80-7.90 (m, 4H, 
ArCH), 8.02-8.05 (m, 4H, ArCH); 
13
C NMR (125 MHz, CDCl3): δ 12.1 (CH3, Pmc), 
14.1 (CH3, Pmc), 17.5 (CH3, Pmc), 18.5 (CH3, Pmc), 19.7 (CH3, Pmc), 21.5 
(CHCH2CH2 (Lys)), 21.6 (CHCH2CH2 (Lys)), 22.5 (2 x CH3 (isopentyl)), 22.6 (2 x CH3 
(isopentyl)), 22.7 (4 x CH3 (Leu)), 23.2 (CHCH2CH2 (Arg)), 24.8 (CH(CH3)2 
(isopentyl)), 24.9 (CH(CH3)2 (Leu)), 25.0 (CH(CH3)2 (Leu)), 25.1 (CHCH2CH2 (Lys)), 
26.8 (CHCH2CH2 (Lys)), 28.4 (C(CH3)3), 28.5 (C(CH3)3), 29.3 (CH2 (Pmc)), 29.7 (CH2 
(Pmc)), 30.0 (CHCH2CH2 (Arg)), 30.1 (CHCH2CH2 (Arg)), 31.9 (CH2CH2NH (Lys)), 
32.8 (CH2 (Pmc)), 37.1 (CH2CH(CH3)2 (isopentyl)), 37.14 (CH2CH(CH3)2 (isopentyl)), 
40.5 (CH2CH(CH3)2 (Leu) and (NHCH2 (Lys)), 51.0 (NHCHCO (Leu)), 52.8 
(NHCHCO (Leu)), 54.3 (NHCHCO (Lys) and (NHCHCO (Arg)), 62.9 (OCH2 
(isopentyl)), 64.0 (OCH2 (isopentyl)), 73.6 (2 x C(CH3)2), 79.2 (2 x C(CH3)3), [82.2*, 
83.4*, (C60sp
3
)], 96.2 (CPh2), [117.9, 121.0, 124.0, 128.2 (ArC, Pmc)], [128.4, 129.7, 
129.8, 130.0 (ArCH)], [134.9, 135.5 (ArC, Pmc)], [136.6, 139.0, 139.4, 140.7, 140.9, 
141.2, 141.5, 141.7, (C60sp
2
)], [141.8, 141.9, 1 (ArC)], [142.39* (1/2 x C), 142.4, 142.6, 
142.7, 142.9, 143.9, 144.2, 144.8, 145.1, 145.3, 145.39, 145.4* (1/2 x C), 145.9, 146.0, 
146.3, 146.9, 147.0, 147.5, 148.4* (1/2 x C), 148.8, 149.0, 150* (1/2 x C) (C60sp
2
)], 





153.2 (C=N), 153.3 (C=N), [153.5, 156.3 (CO, Boc), 160.8, 161.5, 162.0, 171.2, 171.4, 
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